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A provisional patent application has been filed at the South African Patent office based on some of the 
work presented in this thesis. The details of the patent are as follows: 
 
Title of Invention: Screening Method and Apparatus for Drug Efflux 
Displacement. 
Official application number:  2016/07824 
Full names of Inventors:  Jared Stuart Mackenzie  
Alissa Barbara Myrick 
Frederick Kiguli Balagaddé 
Summary of the invention: 
	
The invention provides a screening method to detect substrate displacement molecules. Instead of 
using efflux inhibitors to block the function of efflux pumps, the method and apparatus of the 
invention is configured to find non-toxic molecules that share substrate specificity with the efflux 
pumps. These molecules are selected for extrusion in preference to the drug molecules either because 
they have a higher affinity for the pump or they are present at much higher concentrations within the 
biological cell. In this way, there is no selection pressure for mutation as antibiotics are allowed to 
accumulate within the cells to active levels, thereby increasing treatment efficacy.  
The process is preferably implemented on a microfluidic device (microchemostat) that is configured 
to be automated, allowing the process to run for extended periods of time, typically hundreds of hours. 
In such an implementation, individual efflux pumps can be studied in isolation, thereby ensuring 
pump results are isolated and not confounded. Individual pumps are studied using a bioengineering 
approach. Uncharacterised efflux pumps are isolated from a host biological cell and inserted into E. 






Background: The Mycobacterium tuberculosis (M. tuberculosis) efflux system, estimated to 
comprise over 80 putative efflux pumps, represents a new frontier in the efforts to impede the ever-
worsening spread of drug-resistant forms of Tuberculosis. By extruding specific drug molecules from 
within microbial cells, efflux pumps not only create low levels of resistance but can also facilitate 
progressive acquisition of chromosomal mutations that may confer higher levels of resistance.	
However, the field must confront the challenge of functional redundancy, which obscures the possible 
contributions of efflux pumps to drug resistance development.  
Materials and Methods: To overcome the challenges of functional redundancy, we present a new 
bioengineering approach that involves expression of M. tuberculosis efflux pumps in transporter-
deficient E. coli cells combined with high-resolution measurements of cellular changes using a 
microchemostat device. 
Results and Discussion: Cells expressing the M. tuberculosis tap-like efflux pump Rv1258 had 
increased tolerance to growth-inhibiting compounds including streptomycin, gentamicin and ethidium 
bromide. Rv1258 expression engendered two alternating phenotypes in E. coli with distinct 
implications for drug tolerance. The first comprised of normal-sized, actively dividing cells with 
vibrant efflux activity, which can contribute to antibiotic resistance by extruding drug compounds. 
The second was characterized by arrested cell division and a filamentous cell phenotype, which are 
both phenotypes associated with the development of drug resistance in pathogenic bacteria. We 
present a new approach to characterizing efflux pumps, which can overcome the challenge of 
functional redundancy and will be generally applicable for understanding the interrelatedness among 
the transporters comprising the M. tuberculosis efflux system and elucidating its putative role in the 
evolution of drug resistance. Although the approach of engineering the expression of a single pump in 
E. coli does not require a microchemostat, characterization using the microchemostat was essential to 





This dissertation is presented in the following order: 
Chapter 1: Introduction 
This chapter provides a brief overview of the HIV/TB epidemic and discusses TB disease. The 
various treatment regimens are also introduced, as well as the problem of drug resistance and the 
mechanisms associated with it. 
 
Chapter 2:  Current Developments for TB Diagnostics 
Chapter 2 outlines the challenges associated with TB diagnosis, and outlines the phenotypic and 
genotypic methods currently in use. 
 
Chapter 3:  Microfluidics 
This chapter is a detailed description of the field of microfluidics and its application in diagnostics. It 
discusses the various types of microfluidic approaches and provides a number of examples that have 
been used previously for the study of cellular biology. 
 
Chapter 4:  The Microchemostat 
This chapter follows on from chapter 3 and introduces the microchemostat and the chemostat 
approach to continuous cell cultures. It provides a detailed description of the theory behind the 
chemostat, including benefits and drawbacks to its use. In addition to this, this chapter introduces the 
microchemostat as a solution to some of the drawbacks of conventional chemostats and the 
technology through which this study was made possible. 
 
Chapter 5:  A Microchemostat for the Study of M. tuberculosis Multidrug Efflux Pumps 
Chapter 5 provides the rationale behind the project and outlines the research aims and objectives for 
the study. 
 
Chapter 6:  Microchemostat Characterization of Tap, a Putative Multidrug Efflux Pump 
Present in Mycobacterium tuberculosis. 
This chapter consists of a manuscript submitted to the journal PLoS ONE that is currently under peer 
review. All information presented in this chapter (and manuscript) is presented in further detail 




Chapter 7:  Materials and Methods 
All activities undertaken throughout the study are discussed in this chapter. A description of all 
equipment, reagents and software is given, including the fabrication protocols for all microfluidic 
chips.  
 
Chapter 8:  Results 
This chapter describes in detail how the microchemostat and E.coli expression systems were used to 
detect two distinct phenotypes associated with drug tolerance during expression of a multi-drug 
M.tuberculosis efflux pump that were not detectable using conventional methods.  
 
Chapter 9:  Discussion 
This final chapter discusses the results obtained and the role of the microchemostat in obtaining these 
results. In particular, I explore the implications of the two phenotypes associated with drug tolerance 












1.1 The HIV/AIDS Pandemic 
	
In a few years, HIV/AIDS will eclipse the influenza pandemic of 1918 (also known as the Spanish 
Flu), to become “the deadliest emerging disease in recorded history”1. Since its discovery in 1983, 
HIV has been responsible for 35 million deaths worldwide, a number four times the number of deaths 
caused by World-War 1 2,3. This has created profound social and economic disruption in the disease-
ravaged countries of sub-Saharan Africa. 
 
The human immunodeficiency virus (HIV), the etiological agent of HIV/AIDS disease, is a retrovirus 
that can cripple the immune system through the destruction and gradual depletion of immune cells 
such as CD4+ T cells and macrophages4. Treatment of HIV with highly active antiretroviral therapy 
(HAART) has led to the conversion of the disease from the virtual death sentence it was at the 
beginning of the outbreak to a manageable chronic illness, leading to a 36% decrease in HIV related 
deaths since 20102. HAART involves the use of multiple antiretroviral drugs that target various steps 
of the HIV viral replication cycle to help suppress viral replication and accordingly, decrease the 
depletion of immune cells which in turn helps decrease the disease burden5. However, if left 
untreated, the HIV infection can progress to acquired immunodeficiency syndrome (AIDS), a 
condition associated with the progressive failure of the immune system that leaves the patient 
vulnerable to opportunistic infections and illness.  
 
Opportunistic infections are responsible for the majority of AIDS-related deaths and are caused by 
organisms that would normally present with mild or no disease implications in healthy, 
immunocompetent individuals6. The most common of these infections include herpes simplex virus, 
Pneumocystis carinii pneumonia (pneumonia), Toxoplasma gondii (Toxoplasmosis), and 
Mycobacterium tuberculosis. Mycobacterium tuberculosis (M. tuberculosis), the etiological agent of 
tuberculosis disease (TB), which was first described by Robert Koch in 18827, is regarded as the most 
important of these opportunistic infections and remains one of the deadliest curable infections the 







1.2 The HIV-Associated Tuberculosis Epidemic 
	
HIV and M. tuberculosis infections are very closely related (Figure 1). Studies have shown that the 
risk of contracting active TB disease is 28 times greater when patients are infected with HIV9. African 
countries in particular have been hard hit by the HIV-TB epidemic (Figure 2). It is estimated that of 
the people living in Southern Africa with TB, 60-80% of these are coinfected with HIV10. The 
statistics below show the stark reality of the problem faced by developing countries around the world.  
 
 
Figure 1| A schematic depicting the relationship between TB risk and CD4 cell count decline due to 
HIV infection. As the CD4 cell count decreases, the patient’s immune system becomes compromised 
and is susceptible to opportunistic infections such as tuberculosis. This risk is reduced when the CD4 






Figure 2| The estimated HIV prevalence in new and relapse TB cases around the world. The Southern 
African region has the highest prevalence, reaching levels greater than 50% in some cases. Adapted 
from reference 12. 
 
1.3 Mycobacterium Tuberculosis, a Brief Introduction 
	
“If anything kills 10 million people in the coming decades, it probably won’t be a missile – it will be a 
microbe.” – Quoting billionaire philanthropist and founder of Microsoft corporation, Bill Gates, as he 
summarized the potential devastating effects posed by infectious diseases. 
 
Tuberculosis has been described by thought leaders in the field as the world’s oldest and deadliest 
disease that has plagued mankind for most of human history13. Some have hypothesized that the genus 
Mycobacterium  has been around for approximately 150 million years14. A study conducted by 
Gutierrez and colleagues at the Institut Pasteur located in Paris, France, found that an ancestor of 





Tuberculosis spread rapidly during the industrial revolution in Europe, fuelled by the change in 
environmental conditions16. With no treatment options available, it spread uncontrolled across Europe 
for the next 400 years, eventually reaching sub-Saharan Africa 16. 
 
In the early and mid 19th centuary, mortality rates due to TB began to decline slowly and continued to 
decline due to a number of factors including access to antibiotics and improved living conditions13. 
However, with the advent of the HIV/AIDS epidemic in the 1980s, TB had returned with full force by 
the early 1990s, leading to the World Health Organization (WHO)  declaring it a global emergency in 
1993 in an attempt to increase public and political awareness17,18. 
 
1.4 The Impact of Tuberculosis in South Africa  
	
In 2013, the World Health Organization classified South Africa as having the third highest TB 
incidence globally, with an incidence rate that had increased by 400% since 200020. It is the leading 
cause of death in South Africa with 13 of every 100 deaths attributed to the disease19. TB infection is 
widespread throughout South Africa. Most cases of active TB are located in the province of 
KwaZulu-Natal (31%). This is followed by the Eastern Cape (14%), Western Cape (14%) and 
Gauteng (13%)21.  
 
South Africa is faced with an HIV-TB syndemic, where the high rate of HIV infection is fuelling the 
TB epidemic. In 2007 an eye opening statistic was released showing that South Africa had 17% of the 
global HIV burden, with only 0.7% of the world's population22. The World Health Organization 
estimates that of the people living in South Africa with TB, 60% of these are coinfected with HIV.  
 
The TB burden is also partly attributed to conditions of poverty that favour transmission of the 
disease. Many of the poorer communities within South Africa reside in informal settlements and make 
use of public transportation in the form of taxis and buses23. These are often poorly ventilated and 
encourage TB transmission as passengers are forced to sit in close proximity to each other with sub-
optimal airflow, particularly in the winter months23.   
 
Often, the long distances required to travel to health care facilities also pose a major barrier to 
receiving diagnosis and treatment of the disease23. Many of these health care facilities are in the form 
of small crowded clinics where uninfected patients often wait in close proximity to TB patients in 
unventilated waiting rooms. This can increase the risk of transmission, as well as the risk of 






1.5 Tuberculosis, The Disease 
	
Tuberculosis disease can be divided into latent and active disease states. Patients who are latently 
infected present with no symptoms and more importantly, they are not infectious and are therefore 
unable to spread the disease and are thus considered to be disease free for all practical purposes24. In 
this case, the tubercular mycobacteria remain dormant, benign and controlled within the body. This 
type of TB infection can only be detected through performing a tuberculin skin test or a blood test. 
The tuberculin skin test consists of an intradermal injection that contains a small concentration of M. 
tuberculosis antigen. If the patient has previously been exposed to the bacteria, they will develop an 
induration at the site of injection within 48 to 72 hours. 
 
One third of the world’s population is said to be infected with TB. However, although the vast 
majority (~75%) of these infections are latent, with no symptoms, they remain a concern due to their 
potential to reactivate and form active tuberculosis20.   
 
Patients’ presenting with latent TB infection can progress to active TB disease due to a number of 
reasons. The most common of these include a weakened immune system that is often observed in HIV 
patients or the elderly. Studies have shown that only 5 to 10% of infected patients will advance to 
active TB disease in their lifetime24,25. Patients with active tuberculosis present with a number of 
symptoms that include weight loss, fever, loss of appetite, fatigue and a persistent cough24. These 
patients are considered infectious and may be able to spread the disease to others. Currently, there are 
two threats to the management of TB — the HIV epidemic (as discussed previously), and the 
development of drug resistance26.  
 
1.6 The Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis 
	
Prior to the availability of anti- TB drugs, several treatment options were tried and tested with varying 
success. These included simple measures such as exposure to fresh air and sunlight, to more extreme 
measures such as the removal of ribs to collapse the chest wall27-29. However, many of these were 
abandoned after the introduction of antibiotics. 
 
Drug resistant strains of M. tuberculosis were first recognized soon after introduction of the first anti-
TB drug in the 1940s. Streptomycin was discovered by the laboratory of Selman Waksman, who 
accepted the Nobel Prize in 1952 and boldly claimed that it would lead to the elimination of “The 
great white plague” (Tuberculosis) 30. However, within months, streptomycin resistant strains of M. 
tuberculosis were discovered30. This prompted the development of drug combination regimens in an 




the directly observed treatment short course strategy, or DOTS. This involves the use of a 
combination of drugs that are taken under the supervision of a health practitioner in order to help 
improve adherence and decrease the spread of TB31. 
 
Drug combinations offer a promising strategy for improving treatment efficacy and controlling 
resistance. Generally, when multiple antibiotics are combined into a single regimen, the effects may 
be synergistic or antagonistic. Synergistic combinations of drugs have been shown to reduce side 
effects, increase drug potency and help minimize the rate of evolution of multidrug resistant 
bacteria32-34.  
 
Today there are five groups of drugs that can be used for the treatment of TB, with the first new drug 
in 40 years, Bedaquiline, approved in 2012 (Table 1) 35,36.  Rifapentine was approved in 1998; 
however Bedaquiline is the first new drug with a novel mechanism of action to be approved in over 
four decades37.  
 







1.7 The Management of Drug-Susceptible Tuberculosis 
	
The activity of anti TB drugs is believed to occur in two phases—an early bactericidal phase and a 
later sterilizing phase39. During the bactericidal phase, drugs predominately kill actively growing M. 
tuberculosis. The sterilizing phase also begins early in the treatment regimen; however it continues for 
much longer than the first phase and is necessary to kill semi-dormant organisms39. A high level of 
early bactericidal activity seems to be associated with the ability to prevent the emergence of drug 
resistance, while a high level of sterilizing activity is necessary to shorten the duration of treatment39.  
 
Standard tuberculosis treatment normally takes 6 to 9 months to achieve complete killing and to 
ensure that there is no reoccurrence of infection40. The reason for this long treatment time is not 
completely understood. However, studies have shown that antibiotics can effectively kill the majority 
of bacilli during the first 14 days of treatment41,42. This lengthy treatment regimen is likely due to the 
presence of persister cells that form a subpopulation of phenotypically drug tolerant cells. Persisters 
are non-growing, dormant cells that do not grow in the presence of antibiotics but are	able to regrow 
and form a population of cells that have the same susceptibility as the original population when the 
drug is withdrawn8. They are not affected by the majority of antibiotics as the pathways targeted by 
these drugs are inactive in dormant cells8. This long treatment duration associated with TB can lead to 
poor patient adherence and reduced patient follow-up, which in turn can increase the risk of 
developing multidrug-resistant and extensively drug–resistant strains43. 
 
High cure rates for drug susceptible M. tuberculosis can be achieved with treatment regimens 
consisting of the first line drugs isoniazid (INH), rifampicin (RIF), pyrazinamide (PZA), and 
ethambutol (EMB) (Figure 3). The standard regimen for susceptible M. tuberculosis includes a two-
month “intensive” phase, where INH, RIF, PZA, and EMB are administered, followed by a four 
month “continuation” phase with only INH and RIF administered. Below I provide a brief discussion 
of each drug and its mechanism of action. 
 
1.7.1 Isoniazid (INH) 
 
Isoniazid (isonicotic acid hydrazide), one of the most effective and commonly used anti-TB drugs,  
has a high level of early bactericidal activity but only limited sterilizing activity39. As a result, there is 
limited activity against non-replicating bacteria or bacteria that grow under anaerobic conditions43. 
 
For many years, the mode of action for INH was unknown. Studies have since revealed that it is able 
to inhibit cell wall synthesis. INH is a prodrug that enters the bacteria through passive diffusion and is 




a range of free radicals that are toxic to the mycobacteria by damaging a variety of cellular 
components. Once activated, its primary target is InhA, a protein involved in the synthesis of mycolic 
acids that are essential for cell wall formation44. 
 
Resistance to INH normally occurs through mutations in the katG or inhA protein coding regions, 
with mutations in katG being the primary mechanism of resistance44,45. Although resistance may also 
arise due to mutations in several other genes such as ndh, kasA and the oxyR-ahpC intergenic region44, 
studies have shown that 75% of the cases are due to mutations in katG and inhA46.  For this reason, the 
majority of genetic drug susceptibility tests focus on detecting mutations in the katG gene, suggesting 
that as high as 25% of INH resistant cases may be missed by these tests44. 
 
1.7.2 Rifampicin (RIF) 
 
Although rifamycin was first discovered in 1957, problems with absorption delayed the practical 
usefulness of the drug in clinical practice. In 1965, a hydrazone of a rifamycin B derivate, rifampicin, 
was discovered and found to be highly bactericidal and easily absorbed. The FDA eventually 
approved the drug for TB treatment in 197147. 
 
The primary mechanism of action for RIF is through the binding of the β-subunit of ribonucleic acid 
polymerase (RpoB). This leads to the inhibition of transcription (RNA synthesis) and the subsequent 
death of the organism48. Significantly, RIF is able to target actively growing, as well as slowly 
metabolizing (non-growing) bacilli, which make it vital for shortening treatment duration49. 
Therefore, together with INH, rifampicin is one of the most potent drugs used in the treatment of TB. 
 
Drug resistance to RIF normally occurs through mutations in the rpoB region, leading to decreased 
drug affinity and subsequent resistance44. Studies have shown that almost all RIF-resistant strains also 
present with resistance to other drugs, in particular, INH, thereby making it a good molecular marker 
for the detection of multi-drug resistance44,50. 
 
1.7.3 Pyrazinamide (PZA) 
 
Pyrazinamide has been shown to have considerable sterilizing activity and is vital for shortening the 
TB treatment duration to 6 months39,51. This is due to its ability to target a persistent population of 





Despite its vital role in the current treatment regimen and its discovery over 50 years ago, its method 
of action is still poorly understood52. PZA is an analog of nicotinamide, and is a prodrug that becomes 
activated by pyrazinamidase (PZase) once it enters the cell through passive diffusion53. This leads to 
the formation of pyrazinoic acid (POA). POA is pumped to the outside of the cell through the action 
of a weak efflux pump, where it becomes protonated54. Under acidic conditions, these protonated 
POA molecules are able to diffuse through the membrane back into the cell where they accumulate, 
thereby affecting the proton gradient, reducing membrane potential, and causing cellular damage54. 
The target of POA in M. tuberculosis remains unknown; however it has been shown to bind to 
ribosomal protein S1 (RspA), leading to the inhibition of trans-translation51. 
 
Pyrazinamide resistance mainly occurs through loss of PZase activity due to mutations in the pncA 
gene that encodes this enzyme52. However, mutations in the rspA gene that encodes for RspA, can 
also confer PZA resistance. Resistant strains have been found that contain no mutations in pncA or its 
promoter, suggesting alternate mechanisms of resistance such as enhanced efflux. 
 
1.7.4 Ethambutol (EMB) 
 
Ethambutol was first used as a TB drug in 1966 and has been shown to be effective against actively 
growing bacilli53. It mainly acts through interfering with cell wall biosynthesis, in particular the 
synthesis of arabinogalactan55. EMB targets Arabinosyltransferase, the enzyme involved in 
arabinogalactan synthesis.  
 
EMB resistance in M. tuberculosis has been shown to be associated with mutations in the embCAB 
10kbp operon. A study conducted by Telenti et al. showed that 50% of EMB resistant clinical isolates 
presented with mutations in codon 306 of embB56. However, this mutation has also been observed in 
EMB susceptible isolates. The observation that there are many EMB resistant clinical isolates that do 




















Figure 3| The various mechanisms of action for the most potent TB drugs used as the first line of 
treatment for patients. Adapted from reference 57. 
	
1.8 Combating Drug-Resistant Tuberculosis 
	
The first anti-TB drug, streptomycin, was introduced into clinical practice in the 1940s. Although it 
was the miracle drug of the time, resistance was observed within months of its inception by Marjorie 
Pyle in 194758. Since this discovery, countless clinical M. tuberculosis isolates have been found to 
have resistance to many of the drugs used in TB treatment. As previously discussed, this resulted in a 
transition from monotherapy to the use of drug combination regimens in an effort to eliminate 
resistance.  
 
A number of other solutions have been proposed to resolve the problem of monotherapy resistance. 
One of the most popular for HIV infected individuals include pre-exposure prophylaxis through the 
use of INH59. A previous study showed that a 6-12 month course of INH can provide up to 90% 
protection from M. tuberculosis infection60. This study made the World Health Organization take 
notice of the potential benefits of pre-exposure prophylaxis and in 1998 caused them to recommend 
the use of INH as a form of preventative therapy59. However, continued exposure to INH could in fact 





Drug resistance represents a significant global health problem that threatens the progress made over 
the last 50 years in TB care worldwide.  A patient can either present with primary resistance (infection 
with an already resistant strain), or develop acquired resistance (resistance due to poor adherence)61. 
This resistance may be to a number of different drugs and can lead to the disease being classified as 
either multidrug resistant tuberculosis (MDR- TB) or extensively drug resistant tuberculosis (XDR-
TB).   
 
1.8.1 Multidrug Resistant Tuberculosis (MDR-TB) 
	
Multidrug resistant TB is caused by M. tuberculosis isolates resistant to RIF and INH, the two most 
potent anti-TB drugs. In 2014, an estimated 5% of the people who contracted TB presented with 
MDR-TB, with an estimated 190 000 deaths worldwide caused by the disease 62,63.  
 
The cure rate for this disease is incredibly poor, with statistics showing that half of MDR patients will 
die due to the illness62. This form of TB is notoriously difficult to treat and normally takes 2 years or 
longer to achieve a cure. The treatment regimen relies on the use of second-line drugs (such as 
fluoroquinolones and injectable aminoglycosides) that are less effective, more toxic, and far more 
costly64. The standard MDR-TB regimen consists of 8 months of pyrazinamide, kanamycin, ofloxacin, 
prothiomide and cycloserine followed by 12 months of ofloxacin, prothiomide and cycloserine65. 
Recently, Bedaquiline has also been approved as part of combination therapy in adults for the 
treatment of MDR-TB37.  
 
1.8.2 Extensively Drug-Resistant Tuberculosis (XDR-TB) 
The acquisition of resistance to second-line drugs often used in the treatment of  MDR-TB defines 
extensively drug-resistant (XDR) TB66. More specifically, XDR-TB is defined as resistance to INH 
and RIF, as well as any fluoroquinolone and at least one of the injectable drugs (kanamycin, amikacin, 
capreomycin, streptomycin etc.)62. This form of resistance has emerged due to poor management of 
MDR-TB and cases have now been reported in more than 50% of countries worldwide62. It is 





Figure 4|	Survival rate of HIV infected XDR-TB patients after sputum collection at a clinic in Tugela 
Ferry, KwaZulu Natal, South Africa. Adapted from reference68. 
 
Substantial morbidity and mortality has been associated with co-infection of XDR-TB with HIV. The 
seriousness of this association became clear in 2006 during the Tugela Ferry outbreak in KwaZulu 
Natal, South Africa, where 52 of the 53 patients presenting with XDR-TB and HIV succumbed to 
their illness (Figure 4)67. Shockingly, the median time of death from sputum collection was shown to 
be only 16 days30,67.  
 
As with MDR-TB, treatment of XDR-TB is extremely expensive, toxic and less effective compared to 
treatment of susceptible TB. Despite these high costs, clinical outcomes remain poor, particularly in 
South Africa where the treatment success rate for XDR patients is less than 20%69. Treatment 
regimens are normally different for each patient based on results from drug susceptibility testing 
(DST) and may incorporate group 5 drugs in cases where resistance is found to all four second line 
drugs. Unfortunately, in many resource-limited countries, drug susceptibility testing is faced with 





1.8.3 Totally Drug-Resistant Tuberculosis (TDR-TB) 
	
XDR-TB is not where the problem ends. Ten years ago, the first cases of totally drug resistant (TDR) 
TB were reported in Italy where two patients were shown to be resistant to all drugs tested70. Totally 
drug resistant TB is defined as resistance to all first and second line drugs, making it almost 
impossible to treat71. This form of TB has now been found around the world, and its rising prevalence 
threatens to push us back into a pre-antibiotic era.  
 
The emergence of TDR-TB illustrates the rapid rate at which mycobacteria can develop resistance to 
drugs available in clinical practice. It is clear that the rate of development of new drugs is not keeping 
up with the development of resistance. In fact, resistance has already been found to Bedaquiline, the 
first new TB drug in over 40 years 72. As a result, the various mechanisms of resistance have now 
become an important research topic and need to be understood in order to restore drug efficacy. 
 
1.9 Mechanisms of Resistance 
	
Drug resistance in M. tuberculosis can occur through multiple mechanisms and is often due to 
multiple mechanisms acting simultaneously73. These mechanisms of resistance can be divided into 
acquired (or genetic) resistance and intrinsic (or epigenetic) resistance. 
 
1.9.1 Acquired Resistance 
 
Acquired resistance is the main form through which resistance develops and normally occurs through 
spontaneous mutations that can interfere with drug target binding, compromise prodrug activation, or 
cause overexpression of the target. The two most powerful anti-TB drugs, RIF and INH, have been 
rendered useless in countless TB isolates through a number of these mechanisms. 
 
The most common form of resistance to RIF normally occurs through mutations in the rpoB protein-
coding region of the genome, thereby interfering with drug target binding48. INH is a prodrug that 
enters the bacteria through passive diffusion and is subsequently activated by catalase-peroxidase 
(KatG). Following activation, its main target is inhA, a protein involved in the synthesis of mycolic 
acids44. Although mutations in KatG are the primary mechanisms of INH resistance, mutations can 
also develop in the promoter region of inhA, resulting in overexpression of inhA and subsequent 
resistance44,45. 
 
These spontaneous mutations can occur as a result of low adherence to treatment, inadequacy of the 




administered64. Low adherence is particularly common in resource-limited settings where patients 
often have to travel great distances in order to obtain medication.  
 
Acquired resistance is normally detected through the use of genetic tools such as the line probe assay 
(LPA), GeneExpert and DNA sequencing. I elaborate further on these tools in chapter 2. 
 
Although the presence of mutations accounts for the vast majority of resistant isolates, studies have 
shown that there is a high prevalence of drug-resistant clinical isolates that do not harbour mutations 
in known resistance genes—reaching 30% in some contexts66. For example, 75% of INH resistant 
cases have been found to be due to mutations in KatG and inhA, suggesting that 25% of these cases 
present with alternate mechanisms of resistance44. Similar findings have been seen for PZA, where 
resistant strains present with no mutations in the pncA gene or its promoter52. This is strong 
motivation for new areas of research into epigenetic determinants of drug resistance (intrinsic 
resistance). 
 
1.9.2 Intrinsic Resistance 
 
Intrinsic resistance is another form of resistance that is not acquired through spontaneous mutations, 
and instead makes use of physiological attributes that the bacteria naturally possess.  
 
A distinctive attribute of pathogenic mycobacteria is their slow growth rate. They have a relatively 
long doubling time of 18 to 24 hours depending on the growth conditions, a doubling time ~100 times 
slower than the fastest growing bacteria ever found, Clostridium perfringens that divides every 12 
minutes74-76. It has been speculated that this slow growth rate is associated with the pathogenesis of 
the mycobacteria, as non-pathogenic species generally grow at a much faster rate. Antimycobacterial 
drugs generally act by targeting cell division and as a result, a slow microbial growth rate may 
decrease their potency. The mechanisms behind this slow growth rate are currently unknown. 
However, studies suggest that mycobacteria present with limited RNA synthesis which may be able to 
explain their slow growth77,78. 
 
M. tuberculosis  is naturally resistant to many antimicrobials due to its unique, highly impermeable 
cell wall (Figure 5)79.  This cell wall is rich in mycolic acids that are linked to arabinogalactan 
(arabinan and galactan), ultimately forming the mycolyl arabinogalactanpeptidoglycan complex 
(mAGP)79,80. The outer part of the cell wall is fairly complex and is composed of free lipids, 
glycolipids and glycoproteins80. These glycoproteins are rich in fatty acids that, along with mycolic 




impermeable outer membrane, extreme hydrophobicity and acid-fastness. They also provide 
protection against harsh, stressful environments as well as a great variety of antimicrobial agents81. 
However, if antibiotics are able to overcome the obstacles posed by the cell wall, their potency can be 
















Figure 5| Schematic of the highly impermeable mycobacterial cell wall. Adapted from reference 82.  
 
Drug extrusion through the action of efflux pumps is another mechanism employed by bacteria to 
develop resistance or tolerance to many antimicrobials, even acting as a precursor to the development 
of spontaneous mutations79. As a result, efflux pumps have now come into focus as a key factor 
influencing the rate of the evolution of resistance to antibiotics. This thesis explores mycobacterial 







1.10 Efflux Pumps as Drug Resistance Mechanisms 
 
Efflux pumps are transport proteins that are known to be present in all organisms and are responsible 
for moving substances out of a cell83. In bacteria, the genes that encode these transport proteins can be 
found on the chromosome or on plasmids84. These pumps have a number of physiological functions 
that include extruding natural substrates such as spermidine in Bacillus subtilis and bile salts in 
Escherichia coli (E.coli)85,86. In this way, efflux pumps help to maintain homeostasis within the 
intracellular environment and enable microorganisms to adapt to biochemically hostile conditions87. 
Individual efflux pumps differ in terms of substrate specificity and energy coupling mechanisms, 
thereby making their characterization incredibly difficult88. Although information regarding their 
natural substrates is poor, studies have shown that efflux pumps are able to extrude antibiotics and 
other chemotherapeutic agents, thereby contributing to the problem of drug resistance89. 
 
Efflux mediated antimicrobial resistance was first described in E.coli in 1980 by the labs of Ian 
Chopra and Stuart Levy from the University of Bristol and the Tufts University School of Medicine 
respectively. These studies showed that an active efflux system was able to induce resistance to 
tetracycline90,91. Multi-drug efflux pumps are naturally found in wild-type bacterial cells but can be 
induced or upregulated through mutations or through the addition of antibiotics64.	 	Active efflux has 
been shown to infer an important survival advantage by reducing intracellular levels of antibiotics. 
This in turn can lead to bacterial survival under sub-lethal concentrations of antibiotics for a long 
period of time, providing favourable conditions for the development and accumulation of drug 
resistance mutations8,89.  This process may also be exacerbated by the presence of pumps with 
overlapping substrate specificities, allowing the drug to be extruded by multiple different pumps. 
 
Multidrug efflux systems have been classified into five superfamilies based on a number of factors 
that include the energy source used, the number of components of the pump and the substrate 
specificity (Figure 6). These families include the ATP-binding cassette family (ABC), major 
facilitator family (MFS), resistance-nodulation cell division family (RND), the small multidrug 
resistance family (SMR) and the multidrug and toxic compound efflux family (MATE)84,88.  All of 
these superfamilies can be found in prokaryotic microorganisms, whilst other families, such as the 
multidrug endosomal transporter family (MET), have only been found in eukaryotes75. Below I 






Figure 6| A schematic illustrating the five major efflux families found in microorganisms, including 
example transporters and their method of action. These transporters include Staphylococcus aureus 
NorA, Escherichia coli EmrE, Vibrio parahaemolyticus NorM, Escherichia coli AcrAB–TolC, and 
Lactococcus lactis LmrA. Adapted from reference 92. 
	
1.10.1 ATP-Binding Cassette Superfamily (ABC) 
 
The ABC superfamily of transporters are classified as primary transporters and are one of the largest 
and oldest families, consisting of 52 subfamilies that are divided into influx and efflux systems93. 
They are active transporters, capable of transporting both small molecules and 
macromolecules94. These include the transport of a wide range of substrates such as drugs, sugars, 
amino acids and peptides93. As their name suggests, this group primarily utilizes energy obtained 
through the hydrolysis of ATP for the efflux process, thereby explaining their classification as 
primary transporters95. ABC transporters are essential in humans for many physiological processes 
within the cell96. Mutations in the ABC genes have been shown to contribute to the development of a 
number of human genetic diseases that include cystic fibrosis, retinal degeneration, and cholesterol 
and bile transport defects96. 
 
1.10.2 Major Facilitator Superfamily (MFS) 
 
Unlike the ABC superfamily, the MFS family are classified as secondary transporters as they make 




transporters is typically made up of 400 amino acids that are arranged to allow either 12 or 14 
membrane spanning helices94,95. This group of secondary transporters are only able to transport small 
solutes such as simple sugars, amino acids and some drugs through the use of chemiosmotic ion 
gradients94. 
 
1.10.3 Resistance-Nodulation Cell Division Family (RND) 
 
The MFS and RND families are similar in that they both make use of proton motive force for the 
efflux process and are secondary transporters93. However, RND transporters are normally much 
larger, consisting of approximately 1000 amino acid residues, and they possess large periplasmic 
domains95. This group of efflux pumps consist of a transporter protein located in the cytoplasm, an 
accessory protein located in the periplasmic space, and an outer membrane channel to allow transport 
across the inner and outer membranes of gram negative bacteria84,97,98. One of the most well known 
RND transporter systems is the E. coli AcrABTolC system that has been extensively studied for its 
role in exporting xenobiotics through this hierarchical export system99. 
 
1.10.4 Small Multidrug Resistance Family (SMR) 
 
The SMR family, a group of secondary transporters, is the smallest family, normally comprising of 
100 to 140 amino acids and four alpha-helices95,100. Functionally, they are very similar to the MFS and 
RND families, relying on proton motive force for the efflux process95. This family has only been 
shown to transport lipophilic compounds. These primarily include quaternary ammonium compounds 
(QAC) and a number of antibiotics100.  However, not all SMR proteins are involved in drug efflux. 
For this reason, they have been divided into two classes based on their phenotype, namely small 
multidrug pumps (SMP) and suppressor of groEL mutation proteins (SUG)100. 
 
1.10.5 Multidrug and Toxic Compound Efflux Family (MATE) 
 
The MATE family are similar to MFS transporters in that they are composed of 450 amino acids and 
are secondary transporters95. They are also arranged into 12 helices, but do not appear to have any 
sequence similarity to MFS transporters. The first MATE transporter categorized in 1998 was NorM, 
a transporter capable of inducing resistance to norfloxacin, ethidium bromide (EtBr) and certain 
aminoglycosides101. This family utilizes the Na+ gradient as an energy source for efflux (Figure 6)92. 






1.11. The Tuberculosis Efflux System 
 
The M. tuberculosis efflux system is estimated to comprise over 80 putative primary and secondary 
transport proteins that must be explored for their respective substrate spectra, potential contribution to 
multidrug resistance and role in the basic biology of the bacterium102. While many of these transport 
systems have functional homology to proteins in other bacteria, their function and role in M. 
tuberculosis has not been elucidated103,104. As a result, mycobacterial transport proteins (or efflux 
pumps) have now come into focus as a key factor influencing the rate of the evolution of resistance to 
antibiotics105,106.  
 
The first mycobacterial efflux pump to be characterized was LfrA, a pump found in Mycobacterium 
smegmatis109. It was found that activation of this pump confers low level resistance to 
fluoroquinolones, ethidium bromide (EtBr) and acridine93,109. This identification triggered substantial 
interest towards the contribution of efflux pumps in TB drug resistance.  
 
Many studies have focused on the effect of efflux pumps on the first-line TB drugs in particular. 
Efflux action has been proposed to be responsible for tolerance to INH, one of the most potent anti-
TB drugs currently used89. This tolerance is said to be mediated by IniA, the isoniazid-induced 
protein110. The mmpl7 gene was also found to upregulate an RND transporter that can confer 
resistance to INH93.  
 
Studies have shown that efflux can induce cross resistance in TB, whereby treatment with one drug 
may induce resistance to another through upregulation of an efflux protein89,111. For example, a study 
conducted by Louw and colleagues showed that RIF treatment of an already RIF-resistant strain of M. 
tuberculosis can lead to resistance to ofloxacin106. This appeared to be induced through an efflux 
related mechanism as the effects could be reversed through the addition of an efflux pump inhibitor106.  
 
Some other important efflux pumps that have demonstrated a role in TB drug resistance include the 
P55 transporter shown to induce resistance to streptomycin and tetracycline, and the mmr protein of 
the SMR transporter family, shown to cause resistance to acriflavine, ethidium bromide and 
erythromycin93. 
 
TetV and Rv1258—an in vitro essential tap-like efflux pump—were both found to confer resistance 
to tetracycline, while the latter also conferred resistance to aminoglycosides112,113. Expression of 
Rv1258 was also found to be induced through the administration of rifampicin and ofloxacin87,93. The 




WhiB7 in response to sub-inhibitory concentrations of antibiotics114-116. Similar results were obtained 
in a study conducted by Jiang and colleagues at the Shanghai University of Traditional Chinese 
Medicine in 2008, who found that in an MDR TB isolate, Rv1258 expression was significantly 
increased in the presence of RIF or INH117.   
 
Rv1258 is a secondary transporter that belongs to the MFS family of efflux pumps. Apart from 
addition of rifampicin, ofloxacin or isoniazid, this efflux pump was also found to be induced 
following engulfment by macrophages118. Within the macrophage, Rv1258 acts as a virulence factor 
and has been shown to confer tolerance to RIF119,120. In the absence of antibiotics, it has been shown 
to play a role in the promotion of intracellular growth of M. tuberculosis119. As a result, Rv1258 
represents a particularly important multidrug efflux pump that not only contributes to drug resistance, 
but also promotes growth of the mycobacterium. These characteristics have brought about much 
interest surrounding this transporter. Therefore, the main focus of this thesis will be on the 
characterization of the Rv1258 efflux pump.  
 
Conventionally M. tuberculosis efflux pumps are studied through the use of efflux protein knockouts. 
However, the few experimental demonstrations published to date have underscored the daunting 
inadequacies of this approach, primarily due to the coexistence of multiple efflux pumps with 
overlapping substrate specificity and functional redundancy. Inactivation of a specific efflux pump 
may not yield the expected changes in resistance to an antibiotic drug known to be extruded by the 
pump due to compensatory overexpression by other efflux pumps with overlapping functionality107,108. 
In theory, all efflux pumps that can extrude the antibiotic would have to be inactivated simultaneously 
to obtain the desired effect. 
 
Intrinsic resistance is detected through phenotypic assays, whereby mycobacteria are grown in the 
presence of a drug. Culture based methods are the gold standard in today’s clinics and are vital for the 
early detection of disease. Reliable drug susceptibility tests are required to help prevent further spread 
of drug resistant strains within communities, and can prevent further acquisition of resistance through 







2. Current Developments for Tuberculosis Diagnostics 
	
Early diagnosis and detection of drug-resistant cases through drug susceptibility testing is essential for 
the management and global control of TB disease. Conversely, the absence of proper diagnostic 
systems can lead to low case detection rates, increased risk of transmission and the spread of drug-
resistant strains. 
 
There are several challenges to the timely diagnosis of TB, with studies showing that current case 
detection rates are very low. In 2005, a global target was set by the World Health Organization to 
identify 70% of new smear-positive TB cases121. However, 9 years later, this goal had not been met, 
when in 2014 it was reported that only 63% of new TB cases were diagnosed62. This suggests that 
there are close to 3.6 million people with undiagnosed and accordingly, untreated TB.  Even more 
worrying is the fact that a percentage of these may present with MDR or even XDR-TB. However, 
this is not where the problem ends. Even when all cases are diagnosed, drug resistant tests are not 
routinely carried out in most cases and it is only after treatment failure that drug resistant tests are 
performed. This fuels the spread of drug resistance and reinforces the need for rapid and reliable drug 
susceptibility tests. 
 
There are currently a number of methods used for the diagnosis of drug susceptible and drug resistant 
TB. These are generally categorized into phenotypic and genotypic testing methods or assays. 
Phenotypic assays are considered the gold standard, and normally involve growing the mycobacteria 
in liquid or solid media containing anti-mycobacterial drugs to determine their drug susceptibility122. 
However, as this method relies on mycobacterial growth, and given the long doubling time of M. 
tuberculosis of about 18 hours, the turnaround time of phenotypic tests can require as long as two 
months.  Genotypic methods involve the detection of known drug resistance associated mutations in 
the M. tuberculosis genome. These methods are often rapid and sufficiently accurate. However, they 
can be extremely expensive, and can only be used to detect resistance, but not susceptibility123. This is 
one major short-fall of these methods as often M. tuberculosis strains present with resistance whilst 
presenting with no mutations in the mycobacterial genome. For the purpose of providing a contextual 
background for this thesis, I shall briefly discuss a number of the most popular phenotypic and 





2.1 Phenotypic Methods for the Diagnosis of Tuberculosis 
 
2.1.1 Sputum Smear Microscopy 
 
Sputum smear microscopy is by far the most commonly used method in resource-limited settings. It 
relies on the detection of bacilli using simple lab equipment and can be performed quickly and at 
minimal cost to the patient124. This makes it highly attractive to developing countries where the TB 
burden is often the highest124. In order to detect mycobacteria from sputum, the most common 
methods include the use of the carbo fuchsin Zeihl-Neelsen stain or the auramine stain. 
 
In the 19th century, Robert Koch developed a number of ground-breaking techniques to diagnose 
bacterial infections. Several other researchers subsequently improved on his methods. These include 
Paul Ehrlich, who developed the haematoxylin stain in 1886, which was modified by a bacteriologist 
known as Franz Ziehl. Subsequently, a pathologist named Friedrich Neelsen changed the primary 
stain to fuchsin. By the 1980s, this method had become known as the Ziehl–Neelsen method125. 
 
Carbol fuchsin Zeihl-Neelsen staining is often used for identification of acid-fast bacilli124. This 
process involves the incubation of a sputum-smeared slide in the stain for 3 minutes, following which, 
the stain is rinsed and decolourized and a methylene blue solution is added. The mycobacteria are able 
to withstand the decolourization process and absorb the carbol fuchsin dye. This makes them appear 
red to purple when observed using a conventional light microscope (Figure 7)124.  
 
Mycobacteria can also be detected by fluorescence. Auramine, a fluorochrome dye, is added to the 
sputum sample, where it binds to the mycolic acid cell wall of the mycobacteria and is subsequently 
detected through the use of a fluorescent microscope (Figure 8)124. Auramine has a number of benefits 

















Figure 7| M. tuberculosis stained red/purple with the Zeihl-Neelsen stain and viewed under a 











Figure 8| M. tuberculosis stained with fluorescent auramine stain and viewed under a fluorescent 





The detection of M.tuberculosis through the use of sputum offers a number of challenges. The low 
sensitivity (60%) of this test suggests that a number of patients are going undiagnosed. This 
sensitivity is further decreased (43-51%) in HIV infected patients and paediatric TB patients, where 
obtaining adequate sputum samples is often challenging128. As a result, sputum smear microscopy is 
often paired with a chest X-ray when patients are presenting with TB like symptoms but sputum 
smear results are negative. 
 
2.1.2 The Culture Based Method 
 
Culture based methods are conventionally used following an initial diagnosis in order to determine 
drug susceptibility of the M. tuberculosis strain. This is one advantage over sputum smear microscopy 
which is unable to detect susceptibility. Conventionally, this method is divided into three different 
variations that all involve the culture of M tuberculosis in the presence of a drug at a certain 
concentration. The three variations include the proportion method, the absolute concentration method 
and the resistance ratio method. These were all first described in 1963 by a French microbiologist, 
Georges Canetti, who was also the first to report Mycobacterium canetti129. 
 
The proportion method is regarded as the most widely used culture based method and involves several 
dilutions of the culture which are inoculated onto drug free and drug containing media130. Growth of 
mycobacteria in the various dilutions is then compared. If a proportion greater than 1% of the TB 
population is able to grow in the presence of a drug, the strain is deemed resistant131.  
 
The absolute concentration method is similar to the proportion method in that mycobacteria are 
inoculated on agar plates both with and without drugs. However, a number of different drug 
concentrations are used in order to determine the concentration at which growth is inhibited. This 
concentration is compared to the minimum inhibitory concentration (MIC), and if greater, the strain is 
classified as resistant131. 
 
The resistance ratio method is distinguished from the previous two methods as it compares the 
resistance of a clinical strain to a laboratory strain such as H37Rv132. Each strain is grown in the 
presence of a drug and the MIC determined. The resistance ratio is then calculated by dividing the 
MIC of the clinical strain by that of the lab strain. If the ratio is 8 or more, the strain is considered 
resistant132. 
 
Culture based methods are the gold standard for drug susceptibility testing. They provide a number of 
advantages such as being more reliable than sputum smear microscopy, they are inexpensive, and no 




around time. The slow growth rate of M. tuberculosis means that results can only be obtained in three 
weeks to a month. For this reason, many researchers have adopted a number of alternate approaches 
to detect TB and drug resistant strains. 
 
2.1.3 The BACTEC MGIT-960 TB System 
 
One such alternative is the BACTEC MGIT-960 TB system (Figure 9). This system is a phenotypic, 
culture based system that is fully automated and does not rely on the formation of colonies in order to 
obtain a result. Instead, it relies on fluorometric technology that is able to detect oxygen consumption 
by the mycobacteria growing inside the mycobacteria growth indicator tubes (MGIT)133. This feature 
allows the test to be completed within 10 to 15 days133,134. 
 
This test is relatively simple and involves the use of a ruthenium pentahydrate oxygen sensor at the 
bottom of the MGIT tube that is able to fluoresce upon a reduction in the oxygen concentration133. As 
the mycobacteria grow and divide in liquid media, they use up oxygen which leads to fluorescence 
that can be detected under UV light. Drug susceptibility tests can be performed through the addition 
of specific drugs to the media within the MGIT tubes. The presence of fluorescence indicates that the 
mycobacteria are metabolically active, allowing the researcher to conclude that the strain is resistant. 
This system is essentially able to incubate and test up to 960 culture tubes, and as mentioned 
previously, it is fully automated providing a great advantage over conventional culture systems133. 
 
However, the use of this system does present with a number of limitations. The medium used in the 
MGIT tubes can facilitate growth of other bacterial species that may outcompete M.tuberculosis and 
yeild false positive results. The system itself is also very expensive, making it unsuitable for use in 
resource limited settings. The machine required to run the tests is priced at $63,900, while a set of 100 




















Figure 9| The BACTEC MGIT-960 TB system used for the detection of oxygen consumption by 
mycobacteria.  
	
2.2 Genotypic Methods for the Diagnosis of Tuberculosis 
 
Genotypic methods involve the detection of known drug resistance conferring mutations within the 
bacterial genome. Currently, a number of mutations conferring drug resistance have been described 
for many first-line and second-line TB drugs.  These methods are often rapid and very accurate, which 
makes their use more attractive compared to the phenotypic methods explained previously. However, 
they can be extremely expensive, and can only be used to detect resistance, but not susceptibility123. 
 
2.2.1 DNA Sequencing 
 
DNA sequencing is the gold standard genotypic method for identification of M. tuberculosis bacilli 
and drug resistance. Whole genome sequencing is able to simultaneously detect mutations known to 
be associated with drug resistance, as well as markers that can be used to monitor transmission136. It 
can also be used to detect new mutations that could be associated with drug resistance137. 
 
Conventionally, DNA sequencing of a specific genomic region works using the chain termination 
method. A primer is bound to a single stranded DNA, following which, DNA extension occurs 
through the action of a DNA polymerase enzyme. This extension process is eventually terminated by 
a dideoxynucleotide that interrupts the formation of a phosphodiester bond. Through this process, 





Sequencing often requires the culture of the sample in order to obtain adequate amounts of DNA. This 
can be a rate-limiting step, as cultures can take 3 weeks or longer to grow. However, studies have 
shown that sequencing can be performed on MGIT cultures that are no less than 3 days old136,138. This 
offers great hope for this technique. 
 
The main challenges associated with DNA sequencing are the high costs associated with its use, as 
well as the need for highly trained personnel. Whole genome sequencing can become very costly, 
reaching as high as ~R10 000 for a single genome. Many of the results obtained require someone who 
has been trained extensively in order to accurately interpret them. These challenges make it 
impractical for use in resource-limited settings where the TB burden is the highest. Until these 
challenges can be overcome, other methods need to be developed and utilized. 
 
2.2.2 The Line Probe Assay (LPA) 
 
The line probe assay offers great potential for the rapid diagnosis of drug susceptible and drug 
resistant TB. In 2008, the use of this assay was endorsed by the World Health Organization for the 
detection of drug resistance.  However, the recommendation was only for culture samples and acid 
fast bacilli positive samples139. 
 
This assay works through the use of isolated DNA or RNA obtained from culture isolates or directly 
from sputum samples. This is then amplified via multiplexed polymerase chain reaction and reverse 
hybridized onto a nitrocellulose strip that contains probes for various resistance associated mutations 
linked to first and second line TB drugs139. These nitrocellulose strips can then be interpreted using a 
template, with the entire process completed within a day139. However, according to WHO guidelines, 
in practice the average turnaround time for LPA results is normally between two to three days140. 
 
A number of different LPAs have been developed that are capable of detecting resistance to a number 
of drugs. The INNO-LiPA Rif TB line-probe assay (Innogenetics, Ghent, Belgium) was first 
developed by Rudi Rossau and colleagues and reported in 1998141. This assay was developed to detect 
RIF resistance through the presence of mutations in the rpoB region in the hopes of accelerating the 
diagnosis of MDR-TB and subsequently, the time to treatment141,142. 
 
The Genotype MTBDR assay (Hain Lifescience GmbH, Nehren, Germany) is an improved adaptation 
of the INNO-LiPA assay that also allows for the detection of INH resistance through the detection of 




MTBDRplus (Hain LifeScience GmbH, Germany) which also allows for the detection of mutations 
within the inhA region144. 
 
Although LPAs present with a number of advantages such as being able to perform tests directly on 
sputum, the ability to obtain fast results, and relatively low costs per test (~R40), they still have a few 
limitations. The assays are all fairly labour intensive, and they also require highly trained staff and 
dedicated lab space.  
 
2.2.3 GeneXpert MTB/RIF Assay 
 
In 2010, two years after the World Health Organization had endorsed the use of LPAs, it endorsed the 
use of GeneXpert for the rapid and accurate detection of pulmonary TB following extensive testing in 
six countries145,146. Following their recommendation, its use expanded significantly, with 8.5 times 
more cartrages being sold in 2014 compared to 201162. 
 
This system is a novel, microfluidics based diagnostic device that uses heminested PCR in real-time 
for the detection of M.tuberculosis (Figure 10)146,147. The test also employs the use of molecular 
beacons for the identification of RIF resistance through the detection of mutations in the rpoB region 
of the mycobacterial genome146. When there is nucleotide concordance between the beacons and 
target of interest (rpoB), the beacon emits a fluorescent signal. If there is no fluorescence, this 
suggests that there is a mutation present within the target region148. The detection of RIF resistance 
can be used as a marker for MDR-TB, as studies have shown that almost all RIF-resistant strains also 
present with resistance to other drugs, in particular, INH44,50. The entire process can be completed in 











Figure 10| An example of one of the GeneXpert machines from Cepheid. A sputum sample is 
processed within 2 hours using PCR. Resistance to rifampicin is determined by detecting mutations in 
the rpoB region of the M. tuberculosis  genome. Adapted from reference 149. 
 
The introduction of GeneXpert was said to revolutionize the TB industry as it has a number of 
advantages over previously used diagnostics. A significant contribution to its success is its fast 
turnaround time as mentioned above. Another benefit is the closed cartridge system that allows the 
device to be operated by minimally trained staff in a number of environments, even outside a 
conventional laboratory setting146. This closed system also decreases the biohazard risk, as well as the 
risk of cross contamination. In addition to these advantages, the assay has been shown to have high 
sensitivity (90%) for culture-positive TB, and is even able to detect smear negative TB, thereby 
providing a significant advantage over many other diagnostics145,146. 
 
Despite all these benefits there are a number of limitations that create a barrier to the scaling of 
GeneXpert technology in many countries. Although one of the major advantages of the system is the 
rapid turnaround time, many people only receive their results a few days later instead of the 2 hours 
that has been widely publicised. This is often not due to the test itself, but instead due to issues such 





The machine itself is also very costly, with a single machine costing US$17,000. The cartridges 
required for each test can cost US$10, a price not easily affordable for patients in many resource 
limited settings145. In many of these settings, a constant power source is not guaranteed, so the need 
for a sustained power supply is not a feasible one. Instead, a battery operated system would provide a 
better solution145. The normal operation of this assay also requires a number of conditions that may 
not be possible in many cases. These include an ambient air temperature of no higher than 30˚C, 
storage for cartridges under 28˚C, as well as annual calibration of the machines145. 
 
2.2.4 Emerging Diagnostic Technologies 
 
In order to keep up with the rapid rate of evolution, new diagnostic technologies need to be 
developed. One such technology is that developed by Brilliant Luthuli and colleagues in 2015 at the 
Africa Health Research institute (AHRI)150. This study describes the use of microfluidic technology in 
the form of a cell culture system to detect the presence of epigenetic and genetic drug resistance. This 
paper illustrates the power of up and coming technologies such as microfluidics that allow you to 
perform multiple tests at the same time, as well as detect a single division cycle, thereby shortening 









3.1 Introduction  
 
Microfluidics is defined as “the science and technology of systems that process or manipulate small 
(10–9 to 10–18 litres) amounts of fluids, using channels with dimensions of tens to hundreds of 
micrometres” 151. The field of microfluidics expanded rapidly following the end of the cold war in 
1991, where it was clear that chemical and biological weapons posed a major threat to national 
security. As a result, the US-based Defence Advanced Research Projects Agency (DARPA) supported 
a number of programmes aimed at developing microfluidic systems that could be used in the field to 
detect for chemical and biological threats151. This subsequently led to the rapid growth of microfluidic 
technology both in industrial and academic settings. 
 
3.2 Advantages of Microfluidics  
 
Microfluidics offers a number of benefits that make its use highly attractive in a wide range of fields 
that include molecular and cellular biology, biodefence, and microelectronics. These devices are 
highly customizable and new designs for specific applications can be constructed within a week. This 
provides precise control over experimental conditions via custom chip designs, thereby making this 
technology very flexible, tailoring to the needs of the researcher. As custom chip designs are possible, 
devices can be constructed that allow for multiple experiments in parallel.  This, along with the 
opportunity to automate the experiments through computer control, provides the opportunity to run 
high throughput studies152. 
 
In addition, there is minimal to zero need for the use of conventional lab equipment such as culture 
flasks that require large amounts of reagents and space. Instead, entire experiments can be conducted 
in chip-based microfluidic reactors at the nanoliter or microliter scale, thereby greatly reducing the 
amount of reagents needed, as well as the labour required153. The risk of contamination is also greatly 
reduced, as these reactors are closed environments. 
 
As mentioned previously, microfluidic devices also offer the ability to study small numbers of cells or 




aspect as it can allow for the detection of minority events that may be masked when using larger 
populations of cells. 
 
3.3 Microfluidic Developments 
 
There are currently a number of different types of microfluidics that are in use for a number of 
applications. Each type offers benefits and drawbacks that prevent usefulness in other applications. To 
provide context for this thesis, I shall briefly describe a few of the types that are in use below. 
 
3.3.1 Microfluidic Large-Scale Integration (MLSI) 
 
Microfluidic large-scale integration is the most commonly used type of microfluidics in research. Due 
to the many benefits this form of microfluidics offers, our lab at AHRI has embraced this technology 
to elucidate many unanswered biological questions. Therefore, many of the results presented in this 
thesis were obtained through experiments conducted with a microfluidic chip that is constructed based 
on the principles of MLSI. 
 
This platform emerged in 1993 along with the process of softlithography. However, this technology 
was expanded in 1999 to multilayer soft lithography by the lab of Stephen Quake through the use of 
PDMS and microfabricated valves that have become known as “Quake valves”154,155. 
 
This platform offers a number of advantages. For example, it enables the development of extremely 
complex microfluidic chips that can perform multiple steps on a single device (Figure 11). This is 
possible through the use of integrated microvalves154. A valve is normally created through the use of a 
glass substrate and two layers of PDMS layered on top of each other155. One of the PDMS layers 
contains the “flow channel” that contains the fluid, whilst the other PDMS layer is known as the 
“Control channel.” A valve is created when the control channel crosses a flow channel. Once the 
control channel is pressurized, it expands and pinches off the flow channel below it, thereby blocking 
the flow of liquid, essentially closing the valve (figure 12a,b). This system can also be used to create 
pumps for mixing, whereby several valves can be positioned alongside each other and then actuated in 
a peristaltic sequence (Figure 12d, e)155. As a result, multiple devices can be integrated onto a single 
chip, thereby significantly reducing space requirements. The valve system can also be automated 
which can lead to improved throughput154. However, the presence of valves often makes these chips 




























Figure 11|An example of a chip designed using the principles of microfluidic large-scale integration. 
This device contains 256 reaction chambers and 2056 microvalves that allow for complex fluidic 



























Figure 12| Valve operation in the multilayer PDMS based large-scale integration platform. The valve 
is open when no pressure is applied (a), and is closed when a pressure p is applied (b).  Multiple 
valves (c) can be positioned to create pumps (d) and (e) through peristaltic like action. Adapted from 
reference 155. 
 
One example of a device created according to these principles is a chip developed in 2002 by the lab 
of Stephen Quake for high throughput screening of cells with desired gene expression phenotypes 
(Figure 11)156. The unique attributes offered by microfluidics allowed this device to outperform all 
conventional techniques at the time. This chip is able to perform 144 parallel reactions whilst only 






3.3.2 Lateral Flow Microfluidics 
 
Lateral flow microfluidics was one of the first successfully commercialised type of microfluidics and 
has evolved significantly over the last 30 years. Devices based on this type normally work through the 
use of capillary forces, whilst the movement of liquid is controlled by the wettability and size of the 
substrate157. Conventionally, these are simple devices that, unlike MLSI, do not contain valves. 
Instead, all reagents are pre-stored on the device and the readout is typically in the form of a colour 
change that can be detected by eye within a few minutes (Figure 13). Today, this form of 
microfluidics is used for a number of applications such as at home pregnancy tests, glucometers for 
the detection of blood glucose levels, as well as devices for the detection of infectious agents such as 




















Figure 13| A lateral flow test for blood coagulation using a hand held device from Roche diagnostics 
(a). The blood flows into the device through capillary action where it rehydrates the coagulation 
chemistry.  A number of different electrodes are used to detect the presence of blood, as well as used 
as standards for calibration and analysis. A final result is obtained through optical or electrochemical 




3.3.3 Linear Actuated Microfluidics 
 
Linear actuated microfluidic devices are similar to lateral flow tests. However, fluid is transported 
through the use of mechanical displacement in the form of a plunger (e.g. syringe). The liquid 
normally moves in a linear fashion, with all reagents and buffers pre-stored on the device. An 
example of one such device is the i-STAT analyser (Figure 14), which is used to measure a number of 














Figure 14| The i-STAT analyser used for clinical blood tests (a). Blood is loaded onto a disposable 
cartridge that acts as the “plunger” in this case (b). This cartridge is then inserted into the device for 










3.3.4 Segmented Flow Microfluidics 
 
Segmented flow microfluidics involves “the separation of fluids or gas through the use of plugs or 
droplets that are confined to microfluidic compartments or channels”157. This form of microfluidics 
can also be combined with MLSI to create more complex devices. An example of this technology is 
droplet based microfluidics or digital microfluidics. Individual droplets can be used as compartments 
in which single cells can be trapped and then studied in isolation	 (Figure 15). This can provide the 
user with single cell information which may be very useful for a number of applications as well as 
provide high throughput through the generation of hundreds or even thousands of cell containing 
droplets157. To date, a few droplet-based systems have been commercialised. One such system is the 
QX200 Droplet digital PCR system from Bio-Rad used for absolute quantification of DNA or RNA. 




Figure 15| A droplet microfluidic device designed by the McCarroll lab at Harvard University for the 
study of single cell genomics. The cells, barcoded bead primers, and oil are all combined to form a 





3.3.5 Centrifugal Microfluidics 
 
Centrifugal microfluidics is one of the most rapidly expanding types of microfluidics and has even 
been adopted by some corporations for commercial use that include Panasonic, Roche, Samsung, 
Qiagen and Abaxis159. 
 
Normally, these devices are circular in shape, with all processes performed through the use of a 
rotating microstructured substrate (Figure 16). The device can be placed on a centrifuge like system 
and then spun at varying revolutions per minute, thereby exploiting a number of forces to facilitate 
liquid transport. These forces include centrifugal force, Euler force, Coriolis force and capillary force. 
Conventionally, the assays are performed in a sequence arranged from radially inward to radially 
outward positions with all reagents pre-loaded157.  
 
 
Figure 16| An example of a centrifugal microfluidic device developed by Qiagen for the processing 
and analysing of samples for a number of different tests. The rotation of the disk generates centrifugal 
forces which act to move the sample fluid though the different channels and compartments on the 




3.3.6 Paper Based Microfluidics 
 
The invention of paper based microfluidics has been attributed to the lab of George Whiteside; 
however, the technology was initially described in 1949 by Ralph Muller and colleagues155. 
 
This form of microfluidics is based on creating a hydrophilic-hydrophobic contrast on paper in order 
to create capillary like channels (Figure 17). This technology is rapidly expanding as it offers a 
number of attractive properties for use in the diagnostics field, particularly in the developing world. 
Paper is an easily available and portable cheap material that is compatible with many applications and 
is also easily disposable161. It allows for the transport of fluids through the use of capillary forces, and 
as a result does not require any external forces, thereby reducing the need for complicated equipment. 
However, paper based microfluidic systems are normally limited to simple assays and therefore may 













Figure 17| An example of a paper based microfluidic device created by the Wyss Institute at Harvard 
University for the detection of glucose (brown colour) and protein (blue colour) in 5µl of urine. 
Adapted from reference 162. 
	
3.4 Fabrication of Microfluidic Chips 
 
These devices can be created through the use of a number of different methods and materials. 
Conventionally, construction of a microfluidic device requires the use of a cleanroom in order to 




integrated circuit design151,157. A cleanroom is an area in which the temperature, humidity and amount 
of dust particles are highly regulated in order to provide optimal working conditions for the 
construction of devices such as microfluidic chips163. 
 
Over the years, a number of different substrates have been used for the development of microfluidic 
devices. Silicon was initially the most widely used substrate and contributed significantly to the rapid 
evolution of the technology164. However, the use of silicon requires a complicated fabrication process 
that can be very costly. This led to the widespread use of polymer materials such as polymethacrylate, 
polycarbonate and polydimethylsiloxane (PDMS)164. 
 
Polydimethylsiloxane or PDMS is now the most widely used substrate for the development of 
microfluidic chips (particularly those developed using the principles of MLSI) due to its 
biocompatibility, good optical transparency, permeability to air, and relatively low manufacturing 
costs164. PDMS based microfluidic chips are fabricated through photolithography and soft 
lithography. Initially, a silicon mould is developed through the process of photolithography that will 
have the pattern for the microfluidic chip etched onto the surface. This mould can then be used to 
develop the microfluidic chip through a number of steps involving the layering and curing of 
PDMS165. A more detailed description of this entire process can be found in appendix A. 
 
3.5 Microfluidic Applications in Cell Culture 
 
A major area of research that has leveraged the use of microfluidics is cell biology. Microfluidic 
devices have become useful tools for the study of eukaryotic cells and bacteria due to a number of 
reasons. They can be created to accommodate any cell type, with channels being constructed with 
similar dimensions to those of eukaryotic cells. This makes their visualisation easier and can offer 
single cell resolved measurements. Many microfluidic chips are also made from PDMS, a substrate 
that offers excellent optical transparency, low toxicity, and high permeability to oxygen and carbon 
dioxide, making them highly suited for the culture and study of a number of different cell types151. 
 
The ability to create custom chip designs offers enormous potential to create a microfluidic device for 
any assay. Since the inception of microfluidics, there have been a number of published examples of 
devices developed specifically for academic purposes that have provided researchers a significant 







3.5.1 A Microfluidic Device for Determining Drug Cytotoxicity 
	
Sugiura and colleagues from the Research Centre of Advanced Bionics in Japan developed a 
“pressure driven perfusion cell culture system” with an 8 x 5 array of microchambers (Figure 18)166. 
This microfluidic chip was developed from PDMS through the process of softlithography and was 
used to test the cytotoxicity of seven anticancer drugs on the HeLa cell line from a human cervical 
carcinoma. Drug containing medium was transferred into the culture chambers through the use of a 
micropipette connected to an external pressure source. Cytotoxicity tests were performed over 3 days 
with seven different drugs tested in parallel166. This device illustrates the opportunity provided by 
microfluidics for high throughput drug screening, and may become in indispensable tool in the future. 










Figure 18| A schematic representation of the perfusion culture chip illustrating the microchamber 
array used for determining drug cytotoxicity. Adapted from reference 166.  
	
3.5.2 The Microdialyser 
 
The microdialyser system was developed in 2015 by Luthuli and colleagues in the Bioengineering lab 
at AHRI. This device contains 120 microdialyser culture chambers that are able to operate 
independently from each other (Figure 19). Each chamber can be monitored through the use of 
automated optical microscopy that is able to provide the researcher with a real time, non-invasive 
measurement of cell density150.  In this study, the microdialyser was utilised for mycobacterial drug 







Figure 19| A Microdialyser chip with 120 microchambers that can operate independently. Food dyes 
have been used to visualise the individual channels and growth chambers. The coin is 10mm in 
diameter. (Image reproduced with permission from ref. 150). 
 
This microfluidic device is based on the Microfluidic Large Scale Integration platform and works 
using a microdialysis scheme. It contains multiple growth chambers with varying volumes, with the 
smallest being 200pL. Fresh nutrients are periodically introduced and waste removed through 
diffusion in these small chambers, thereby mimicking the exchange of factors across the macrophage 
membrane150. 
 
This device is able to provide real time, non-invasive measurements of cell density allowing for the 
detection of small changes in bacterial growth (Figure 20). The authors describe an epigenetic drug 
tolerant phenotype of M. smegmatis to rifampicin that was induced when cells were cultured in small 
reactors (~200pL). This effect was not observed in larger reactors. The study revealed that this 
tolerance appears to be induced through an efflux mechanism that only becomes active in space-





Figure 20| Typical growth curves of M. smegmatis Mc2155 in a 200pL growth chamber in a 
microdialyser. Medium is switched from nutrient rich to nutrient poor and vice versa. At 40 hours 
(point A), cultures 3 and 4 were switched to nutrient poor medium using microdialysis, which resulted 
in a decreased steady state cell density. At the same time, cultures 5 and 6 were switched to nutrient 
rich medium through microdialysis, resulting in faster growth. These cultures were all grown 
simultaneously on the same chip at 37˚C. Bottom panels (a to e) show micrographs of the cell density 








Figure 21| Growth dynamics of M. smegmatis cells with and without rifampicin in reactors of varying 
size.  The growth curves in the right most column represent the average cell density of the reactors on 
the left. In drug free medium (black curves), the cells grow as normal. Rifampicin (red curve) was 
able to suppress growth in all reactors, with the exception of the 200pL reactors where 5 out of 6 
cultures were able to grow in the presence of the drug. The cultures were grown simultaneously on the 
same chip at 37˚C. Adapted from reference 150. 
 
This device offers great promise for rapid cell culture-based drug susceptibility tests in the future, as it 
allows for multiple tests in parallel and can detect single mycobacterial cell division events. This 
removes the need to wait for the growth of an entire colony in order to confirm resistance. Therefore, 
the time to a result can be significantly decreased, with an answer being obtained in less than a day 
compared to a month as is common with conventional culture-based tests. For further information on 
this device, please see reference 150. 
 
3.5.3 The Microchemostat 
 
The microchemostat is a novel microfluidic bioreactor developed by Balagaddé and colleagues in 
2005 (Figure 22). This device functions in a similar manner to a conventional chemostat in that it 
allows for long-term culture and monitoring of bacteria167. However, it offers a number of other 
benefits over a conventional chemostat that make its use highly attractive in a research setting. For 




proportionately. This, in turn, effectively insulates the micro-cultures from rapid evolution and allows 
prolonged monitoring of genetically programmed behaviour167. This small reactor volume and the 
ability to monitor bacteria through optical microscopy also allows for single cell resolution. 
 
In this particular study, the microchemostat enabled researchers to observe the behaviour of bacterial 
populations over a long period of time (~100 hours). This elucidated unnatural behaviour induced by 
a synthetic circuit that included oscillations in cell density and changes in morphology167. For further 
information regarding this study, please see reference167. 
 
For this current study we have made use of the microchemostat to characterize a multidrug efflux 
pump in M.tuberculosis. For this reason, the operation of chemostats and the microchemostat will be 













Figure 22| The original microchemostat chip. This device contains six individual microchemostat 
reactors that operate in parallel. Various inputs have been loaded with food dyes in order to visualise 
the microchannels and reactors. The coin is 17.91mm in diameter (Image reproduced with permission 








chemostat (figure 3.2). The chip was fabricated out of silicone elastomer 
polydimethylsiloxane (PDMS) (General Electric RTV 615) using microfluidics large scale 
integration (MLSI) (4, 43, 47) as described in appendix B.  
 
 
Figure 3.2. Six microchemostats that operate in parallel on a single chip. Various inputs 
have been loaded with food dyes to visualize channels and subelements of the 







4. The Microchemostat  
4.1 The Conventional Chemostat 
 
A chemostat or continuous stirred tank reactor (CSTR) is a simple piece of laboratory equipment used 
to continuously culture microbial populations in steady state. By eliminating stationary growth, it 
allows for the study of microbial populations over an indefinitely long period of time168-171. 
 
The invention of the chemostat is attributed to Hungarian born physicist Leo Szilard. He initially 
became famous for his development of the first self-sustained nuclear reactor based on uranium 
fission in 1940. Following his invention it was realised that nuclear chain reactions could be used in 
bombs. This marked the advent of nuclear warfare. However, after the end of the Second World War 
Szilard realised the devastating effects his invention could have on the world, and subsequently 
changed careers in 1947 and became a Biologist. 
 
“We turned the switch, saw the flashes, watched for ten minutes, then switched everything off and 
went home. That night I knew the world was headed for sorrow.” 
— Leo Szilard 
 
Leveraging his experience as a physicist, he went on to develop a continuous microbial bioreactor 
based on binary fission in 1950 along with his colleague Aaron Novick. This invention they later 
called the chemostat168. 
 
4.1.1 Chemostat Operation 
 
Often referred to as a continuous culture device or a continuously stirred tank reactor (CSTR), the 
chemostat allows for active growth of bacterial populations over indefinitely long periods of time. 
This is achieved by continually substituting a fraction of the culture with fresh, sterile nutrients whilst 
removing waste products (a dilution). 
 
A conventional chemostat normally consists of a growth chamber where the bacteria are cultured, a 
reservoir that contains fresh, sterile medium, and an overflow that is used to maintain the volume in 




the displacement of a portion of the culture into the overflow. As a result, the displaced bacterial 
suspension leaves at the same rate at which fresh nutrients enter the growth chamber. This maintains a 
constant volume in the growth chamber whist replenishing nutrients and removing waste products. 
The growth chamber is kept well stirred and all parameters that affect growth (temperature, pH etc.) 
are kept constant168. 
Figure 23| Schematic of a conventional chemostat showing the medium reservoir that contains fresh 
sterile medium, the growth chamber containing the bacterial culture, and the overflow or waste. The 
culture is kept continuously mixed through the use of a mechanical mixer. 
 
Chemostats offer a significant advantage over the use of conventional batch culture systems such as 
culture flasks and test tubes170. In batch cultures, nutrients are not replenished and waste products are 
not removed. As a result, bacterial growth is restricted by the amount of nutrients present in the media 
and the amount of waste products produced.  In these closed systems, the bacterial growth rate 
changes over time as there is a constant pressure exerted by a decreasing nutrient concentration and an 
increasing waste product concentration. This ultimately slows down bacterial division. However, in a 
chemostat there is an indefinitely long steady state period of active growth as nutrients are being 
replenished, and waste products removed. This allows for long-term experimentation of microbes 






4.1.2 Chemostat Applications 
 
Over the years, chemostats have become an indispensable tool in research settings. The ability to 
allow for indefinite bacterial growth provides an ideal environment for the study of microbial 
metabolism, programmed cell behavior and other regulatory processes. It has also emerged as an 
important means of studying mutation rates and evolution in bacteria. This is hugely beneficial in the 
drug resistance field where acquisition of genetic mutations can lead to drastic changes in the 
phenotype of the bacteria. A study conducted in 2007 followed the growth and mutation of 
Acinetobacter baylyi over 2 weeks and 200 generations, a feat that would not be possible with 
conventional batch cultures172.  
 
The unique ability of chemostats to culture microbes indefinitely has been exploited for a number of 
commercial processes. In the pharmaceutical industry, chemostats are used to analyze the response of 
bacteria to antibiotics, as well as for the production of insulin through the use of genetically altered 
microorganisms. They also play a significant role in the production of fermented food such as cheese, 
and the fermenting of sugar to produce alcohol173. Governmental institutes have utilized chemostats as 
a model for the wastewater treatment process. A study conducted by Qu and Bhattacharya made use 
of a chemostat to study the toxicity and degradability of formaldehyde found in industrial 
wastewaters174. 
 
4.1.3 Theory of the Chemostat 
 
The normal operation of a chemostat is governed by a number of differential equations. These can be 
used to help explain its operation, as well as determine a number of factors related to bacterial growth 
that include growth rate, steady state cell density and the maximum number of cells possible within 
the reactor. 
 
As mentioned previously, in a conventional closed system a number of factors come into play that 
eventually stop the growth of the organism once it has reached a significantly large population size. 
These factors include decreased nutrient and oxygen concentration, as well as increased production of 
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However, this equation can be adjusted to incorporate the maximum number of microbes allowable 








where µ represents the specific growth rate.  
In a chemostat, nutrients are replenished and waste products are removed through the dilution process.  
As a result, the factors that would normally suppress growth are no longer present, leading to the 
maintenance of the population in a state of active growth. In this situation, let V represent the volume 
of the culture or growth chamber with units l3 that stand for length. The volumetric flow rate is 
denoted by v and contains the units l3/t, where t is time. Therefore, the standard growth equation in a 










This differential equation illustrates that the growth of cells in a chemostat is denoted by the growth of 
the organism (µ [1-n/Nmax]) less the amount that is removed during a dilution (n[v/V]).  This equation 









Within a chemostat, the bacterial population grows at a state of active growth and eventually reaches a 
steady state. During this state cells are replenished at the same rate at which they are lost through 
dilution, leading to a constant cell density. The cell density at steady state may be changed by altering 
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as a result of the cells being washed out (D) at the same rate that they are being replaced through 










4.1.4 Drawbacks of the Conventional Chemostat 
 
Although chemostats offer a number of benefits for the culture of bacteria in industry and academia, 
their use has not been widely adopted due to a number of reasons. Conventionally chemostats take up 
a lot of space and are difficult to maintain, often requiring frequent services (Figure 24).  Their large 
size also necessitates the need for large amounts of culture medium which can become extremely 













Figure 24| An example of a conventional chemostat used for the study of microbiota in the 
gastrointestinal tract. Adapted from reference 175. 
	
One of the most significant challenges with chemostat operation is the development of biofilms. 
Biofilms were first described in the 17th century by a dry-goods merchant and scientist named Antonie 
van Leeuwenhoek, the “father of microbiology,” who reported the presence of “animalcules” or 
microscopic animals in dental plaque through the use of one of his own microscopes176,177.  However, 
biofilms themselves were not completely described until 1978176. Biofilms are present in virtually all 
ecosystems and are defined as “matrix enclosed bacterial populations adherent to each other and/or to 
surfaces or interfaces”178. 
 
“...I observed certain animalcules, within whole bodies I saw so quick a motion as to exceed belief; 
they were about the size of a large grain of sand, and their bodies being transparent, that the internal 
motion could plainly be seen...” 





Biofilms interfere with chemostat operation by attaching to the growth chamber walls178,179. As a 
result, they are not removed through the dilution process and can therefore consume a significant 
proportion of the growth media. This essentially decreases the benefit associated with removing a 
portion of the culture, introducing characteristics similar to that seen in batch cultures. Biofilms are 
also phenotypically different from planktonic cells and therefore introduce heterogeneity into the 
population, a potentially confounding factor in many studies178. 
 
Furthermore, another challenge associated with chemostat operation is that of evolution. It has been 
shown that the variation in fitness of an organism increases with population size180-182. The number of 
mutations introduced into the bacterial genome is proportional to the number of cell division events 
within a unit time period180. This can ultimately lead to evolution of the population and possibly a 
change in the phenotype of the bacteria, rendering the experiment invalid. The ability of a chemostat 
to allow for constant active growth of large populations of cells leads to an increase in the number of 
cell division events and therefore makes the population susceptible to mutations and evolution. 
 
Another challenge with the use of chemostats is the quantification of the population within the growth 
chamber. Conventionally, bacterial colonies are counted using plates in order to obtain an estimate of 
the population. However, in a chemostat this can lead to inaccurate results as cultures are able to 
actively grow at varying rates during the dilution period. As a result, plating may not be the best 
method for determining the growth rate of a bacterial population growing within a chemostat. Other 
methods can be used such as the use of a haemocytometer, whereby the number of cells within a 
certain area of the counting chamber are used to make predictions based on the entire population. 
However, this method is manually performed and as a result prone to human error. A few other 
methods have been described such as the use of a Coulter counter. However, this can be very 
laborious and expensive and as a result is not practical in many settings. 
 
Due to these many considerable challenges associated with maintaining and operating continuous 
bioreactors, a microfluidic chemostat or microchemostat has been developed by Balagaddé and 
colleagues that is able to overcome many of these challenges, thereby providing an indispensable tool 
for the study of bacterial growth167. 
 
For this study, we have made use of the microchemostat to achieve high-resolution measurements of 








4.2 The Microchemostat 
 
Lab on a chip technology has being growing exponentially over the years with the process of 
miniaturization providing a number of benefits that have been explained previously in the 
microfluidics chapter. These include low reagent consumption, as well as the possibility for 
automation that can lead to increased speed, precision and reproducibility of experiments. 
 
4.2.1 Description of the Microchemostat 
 
The microchemostat is one such example that represents the epitome of lab on a chip technology. This 
microfluidic device has been developed based on the principles of MLSI and therefore makes use of 
microfabricated Quake valves in order to mimic the operation of a conventional chemostat. A more 
detailed description of the fabrication process can be found in appendix A. The current 
microchemostat chip that we are using at AHRI contains 14 independent microchemostat reactors on 
a single chip (Figure 25). These reactors can operate in parallel through automation, essentially 
allowing us to conduct 14 different experiments simultaneously.  
 
Each microchemostat reactor on the chip consists of a growth chamber (yellow reactor Figure 25b) 
that is 10µm high, 100µm wide and ~13mm in circumference. This small growth chamber volume 
allows for the growth of small populations of bacteria (~104 compared to ~109 in batch cultures). This 
essentially reduces the number of cell division events per unit time leading to a decreased mutation 
rate and decreased microbial evolution.  This chip also contains five input ports per microchemostat 
reactor for the introduction of media and other reagents, as well as 3 additional ports that can be used 
as input or waste ports (Figure 25b). 
 
4.2.2 Microchemostat Operation 
 
The operation of the microchemostat occurs in two different states that allow for the continuous 
culture of bacteria whilst minimizing biofilm formation. The first is the continuous culture state 
whereby the bacterial culture and media are mixed throughout the reactor through the use of a 
peristaltic pump (Figure 25b). During this phase, the culture is able to grow as normal whilst 
receiving fresh nutrients. The second state is the cleaning and dilution state. During this phase the 
mixing process is temporarily stopped. A portion of the reactor is then isolated through the use of 
valves, and a lysis buffer (Bacterial protein extraction reagent or BPER) is washed through the 




the reactor walls. This isolated section is then washed with sterile media to flush out the lysis buffer. 
Once this process is complete, the reactor is reopened and the continuous culture state begins again 
with the new media being mixed into the culture. This process is entirely automated and repeated 
cyclically, with a different chamber segment cleaned each time and is analogous to the dilution step in 
a conventional chemostat. Through these dilutions involving the use of a lysis buffer, biofilm 





Figure 25| The microchemostat chip containing 14 individual microchemostat reactors (a). Each 
microchemostat reactor (b) operates in parallel allowing for high throughput experiments. Various 
inputs have been loaded with food dyes in order to visualise the microchannels and reactors.  (Image 





4.2.3 Quantification of Bacterial Populations in the Microchemostat 
 
The microchemostat is fabricated from PDMS, a polymer material with excellent optical 
transparency. This allows for easy visualisation of bacteria within the 10µm high growth chamber 
through the use of a microscope. Bacterial populations can be quantified through the use of automated 
microscopy and image processing software such as Matlab. Images can be taken at a given location of 
known volume and the total number of cells within the reactor determined. As the entire process is 
automated, images can be taken every few minutes, allowing for high resolution measurements that 
can detect small changes in the bacterial growth rate. A motorized stage allows for the simultaneous 
documentation of cell number for all 14 microchemostat reactors. Fluorescence studies can be 
conducted using a ~3µm high imaging section that is incorporated along the growth loop. This smaller 
section was developed to enable visualisation of fluorescent cells within a single focal plane (Figure 
26). Quantification of the fluorescent cell number is achieved as mentioned previously. 
Figure 26| An enlarged view of the 3µm section (blue strips) along the growth loop used for the 
detection of fluorescence (a). A schematic showing a three dimensional view of the imaging section 
(b). A fluorescent image illustrating the improved image quality in the 3µm section compared to the 





In summary, the microchemostat is an extremely powerful tool for the study of cell biology. It 
provides all of the benefits of a conventional chemostat whilst addressing many of the limitations. 
Continuous cleaning of the reactors through the use of a lysis buffer prevents biofilm growth, thereby 
ensuring efficient functioning of the device.  The small reactor size provides a unique advantage to 
slow down microevolution, allowing for long-term experimentation without the risk of mutations and 
greatly reducing the amount of medium required for experimentation. Quantification of bacterial 
populations is achieved using an automated microscope and image processing software, allowing for 








5. A Microchemostat for the Study of M. tuberculosis Efflux Pumps 
 
This project was aimed at utilizing the microchemostat to develop a new way of studying M. 
tuberculosis efflux pumps over a long period of time in order to elucidate their potential role in the 
development of drug resistance. Individual M. tuberculosis efflux pumps were expressed in E.coli 
cells which have had their native transporters removed.  
 
5.1 E.coli Expression System for Efflux Pump Gene Expression 
 
Over the last 40 years, only one new TB drug has been discovered36. This slow rate of drug 
development illustrates how drug resistant M. tuberculosis strains are emerging at a rate that surpasses 
the rate of development of new antibiotics. It is therefore crucial to understand the mechanisms 
underlying resistance to the currently available antibiotics, with the hope of restoring efficacy to 
traditional antibiotics that have otherwise lost potency. 
 
The majority of drug resistance to M. tuberculosis has been attributed to mutations in specific gene 
targets of antibiotics such as rpoB (rifampicin), iniBAC (isoniazid) and gyrA (fluoroquinolones)183-185. 
However, a significant portion of clinically drug-resistant isolates lack the corresponding drug 
resistance mutations. This discrepancy has been attributed to the presence of active efflux systems 
which contribute to drug resistance by extruding antibiotics185. Studies have shown that treatment of 
resistant isolates with efflux pump inhibitors can re-sensitize drug resistant mycobacteria to 
isoniazid89,186.  In addition, studies on the evolution of isoniazid resistance in Mtb have shown that 
increased expression of efflux pumps is an important precursor to the development of genetic 
resistance to this drug110,187. Detailed knowledge of the molecular basis of efflux pumps is therefore 
required for the development of new antibiotics that are not extruded or of inhibitors that block efflux 
pumps and allow traditional antibiotics to remain effective.  
 
The conventional knockout approach for studying mycobacterial efflux pumps has many limitations, 
primarily due to the coexistence of multiple efflux pumps with overlapping substrate specificity and 
functional redundancy. Inactivation of a specific efflux pump may not yield the expected changes in 




overexpression by other efflux pumps with overlapping functionality 107,188.  Therefore, in order to 
obtain the desired effect, in theory all efflux pumps would need to be inactivated.  
 
Within the mycobacterial host, some efflux pumps are essential for growth, and therefore inhibiting 
their expression may kill the organism. At the same time, excessive expression of an efflux pump—to 
enhance and document its function—can also be deleterious to the host because of the direct, physical 
disruption of membrane integrity or the undesirable export of essential metabolites189. Furthermore, 
the M. tuberculosis genome contains 82 proteins that are secondary transporters capable of 
engendering intrinsic drug resistance via efflux mechanisms102. The sheer number of these pumps 
presents a monumental research challenge, which makes it difficult for scientists to assign a function 
to every single pump. 
 
In order to overcome the challenges of functional redundancy we have characterized E.coli strains 
constructed by Dr. Alissa Myrick from the Eric Ruben lab at Harvard University, who is now located 
at H3D at the University of Cape Town. In order to develop these strains, uncharacterized efflux 
pumps were isolated from M.tuberculosis and inserted into transporter-deficient E. coli cells in order 
to ‘program’ cellular behaviour190. This E. coli expression system insulates the inserted efflux pumps 
against interference from co-functional transporters that are normally encountered in the native host 
species, and allows researchers to more cleanly pinpoint antibiotic substrates extrudable by the pump 
than would be possible by working entirely within the native host environment. We have leveraged 
novel microchemostat technology to systematically monitor the dynamics of M. tuberculosis efflux 
pumps conditionally expressed in this E.coli system. With the use of the microchemostat we are able 
to resolve gene expression characteristics of individual cells, whilst monitoring the dynamics of each 




We hypothesize that the use of a heterologous system such as E. coli will provide the sorely needed 
breakthroughs required for systematic characterization of M.tuberculosis efflux pumps. By 
conditionally expressing an M.tuberculosis pump in E.coli strains that are deficient in transporter 
proteins and highly sensitive to drugs, we will characterize the pump in terms of substrate specificity, 
cognate inhibitors and efflux capacity. We will also leverage a novel microchemostat technology to 
systematically monitor the dynamics of the efflux pump conditionally expressed in transporter-









1. To implement the microchemostat system at UKZN. Implementation of the system involves 
the construction of the chips, microscope setup and development of Matlab scripts for image 
processing. 
2. To utilize the microchemostat to culture E.coli constructs whilst monitoring the effects of 
long-term efflux gene expression on bacterial growth in the absence of drugs. 
3. To characterize a multidrug TB efflux pump in terms of substrate specificity and to determine 
whether efflux gene expression is able to provide a survival advantage in the presence of 
these drugs. 
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Abstract 
The Mycobacterium tuberculosis efflux system, estimated to comprise over 80 putative efflux 
pumps, represents a new frontier in the efforts to impede the ever-worsening spread of drug-
resistant forms of Tuberculosis. However, the field will have to confront the challenge of 
functional redundancy, which obscures the possible contributions of efflux pumps to drug 
resistance development. We present a new bioengineering approach that involves expression 
of M. tuberculosis efflux pumps in transporter-deficient E. coli cells combined with high 
resolution measurements of cellular changes using a microchemostat device. Cells expressing 
the M. tuberculosis tap-like efflux pump Rv1258 had increased tolerance to growth-inhibiting 
compounds including streptomycin, gentamicin and ethidium bromide. Rv1258 expression 
engendered two alternating phenotypes in E. coli with distinct implications for drug 
tolerance. The first comprised of normal-sized, actively dividing cells with vibrant efflux 




second was characterized by arrested cell division and a filamentous cell phenotype, which 
are both phenotypes associated with the development of drug resistance in pathogenic 
bacteria. We present a new approach to characterizing efflux pumps, which can overcome the 
challenge of functional redundancy and will be generally applicable for understanding the 
interrelatedness among the transporters comprising the M. tuberculosis efflux system and 
elucidating its putative role in the evolution of drug resistance. Although the approach of 
engineering the expression of a single pump in E. coli does not require a microchemostat, 
characterization using the microchemostat was essential to revealing the alternating states of 
growth and dormancy. 
 
Introduction 
Over the last several years, the frequency and spectrum of multidrug-resistant 
infections due to Mycobacterium tuberculosis have increased resulting in higher rates of 
morbidity and mortality 191. The increasing frequency of drug resistance has mostly been 
attributed to microbial mechanisms typically associated with spontaneous mutations that 
interfere with drug-target binding, compromise prodrug activation, or cause overexpression 
of the target. However, the high prevalence of drug-resistant clinical isolates that do not 
harbor mutations in known resistance genes—reaching 30% in some contexts—is a strong 
motivation for new areas of research into epigenetic determinants of drug resistance 66. 
Bacterial transport systems such as the E. coli AcrABTolC system have been extensively 
studied for their role in exporting xenobiotics through a hierarchical export system 190.  M. 
tuberculosis does not have an analogous system to mediate resistance to dozens of antibiotic 
classes; however, the large number of primary and secondary transporters may contribute to 
the intrinsic resistance of mycobacteria, in addition to essential housekeeping functions.  
Mycobacterial transport proteins (or efflux pumps) have now come into focus as a key factor 
influencing the rate of the evolution of resistance to antibiotics 192,193.  
Studies primarily using single efflux protein knockouts have shown that by extruding 
specific drug molecules from within microbial cells, efflux pumps not only create low levels 
of resistance but can also facilitate progressive acquisition of chromosomal mutations that 
may confer higher levels of resistance 44,194-196. However, the few experimental 
demonstrations published to date have underscored the daunting inadequacies of this 
approach, primarily due to the coexistence of multiple efflux pumps in specific bacterial 




specific efflux pump may not yield the expected changes in resistance to an antibiotic drug 
known to be extruded by the pump due to compensatory overexpression by other efflux 
pumps with overlapping functionality 107,188. In theory, all efflux pumps that can extrude the 
antibiotic would have to be inactivated simultaneously to obtain the desired effect. The 
functional interplay between the efflux transporters is a key but poorly understood component 
of microbial efflux systems. 
We are developing bioengineering strategies for understanding microbial efflux 
systems that overcome the challenge of functional redundancy through isolating 
uncharacterized efflux pumps from native bacterial species and inserting them into 
transporter-deficient E. coli cells 190 in order to ‘program’ cellular behavior. The E. coli 
expression system insulates the inserted efflux pumps against interference from co-functional 
transporters that are normally encountered in the native host species, and allows researchers 
to more cleanly pinpoint antibiotic substrates extrudable by the pump than would be possible 
by working entirely within the native host environment. Attributes conferred to the E. coli 
cells by expression of the inserted efflux genes are then investigated using a 
microchemostat—a miniaturized 10 nanoliter bioreactor that enables automated culturing of 
small populations (102–104) of bacteria for hundreds of hours with single cell resolution 
monitoring using optical microscopy 197,198. By reducing the reactor volume by a factor of at 
least 105 when compared with conventional cell culture vessels, the microchemostat 
suppresses the total mutation rate proportionately. This, in turn, effectively insulates the 
micro-cultures from rapid evolution and allows prolonged monitoring of genetically 
programmed behavior.  
The M. tuberculosis efflux system represents an interesting challenge because M. 
tuberculosis is the causative agent of Tuberculosis—a respiratory disease which is a leading 
cause of death worldwide with increasing reports of multidrug-resistant isolates that present a 
major challenge to effective global control of the disease 199.  Its efflux system is estimated to 
comprise over 80 putative transport proteins that must be explored for their respective 
substrate spectra, potential contribution to multidrug resistance and role in the basic biology 
of the bacterium 102.  While many of these transport systems have functional homology to 





In the present work, we investigated Rv1258, an in vitro essential tap-like efflux 
pump found in Mycobacterium tuberculosis that has been associated with resistance to 
multiple antibiotics including rifampicin, streptomycin, tetracycline, and gentamicin 202-204. 
We inserted the Rv1258 gene into transporter-deficient E. coli cells and used the 
microchemostat system to perform high-resolution measurements of the perturbations in 
cellular behavior due to expression of the Rv1258 genes in the presence and absence of 
growth-inhibiting substrates of the pump. Nonlinear regression analysis of the 
microchemostat data (described in the methods section) yielded transitory phenotypic 
properties—including the instantaneous growth rate and cell filamentation rates, which were 
essential for quantifying the efflux attributes but not obtainable with conventional culturing 
platforms. 
In addition to increasing tolerance to growth-inhibiting compounds including 
streptomycin, gentamicin and ethidium bromide in E. coli cells, constitutive expression of the 
Rv1258 gene engendered two alternating phenotypes representing distinct implications for 
drug-tolerance: active and dormant efflux. During active efflux, the pump actively extruded 
substrates from within the cells, which were normal-sized and actively dividing. A decrease 
in the intracellular concentration of antibiotics is associated with antibiotic resistance 
development 44,194-196. Conversely, the dormant efflux phase was characterized by suppressed 
efflux activity, filamentous cell morphology and cell division arrest. Filamentation is a 
recurring phenotype in many pathogenic bacterial species, providing several survival 
advantages 205 and in some cases enhancing the development of antibiotic resistance 206,207. A 
non-dividing cell phenotype can also contribute to resistance to antibiotics that rely on active 
cell division to achieve rapid killing, which may include antibiotics that are not directly 
extruded by the efflux pumps 208,209. In this study we present a new approach to 
characterizing efflux gene expression dynamics and evaluating the specificity of drug 
substrates to specific efflux pumps, which can overcome the challenge of functional 
redundancy encountered in the native mycobacterial environment. We believe this approach 
will be generally applicable for understanding the interrelatedness among the efflux 
transporters comprising the M. tuberculosis efflux system and elucidating its putative role in 







Materials and Methods 
E. coli strains: The wild type E coli cells—BW25113 ΔemrE ΔmdfA—lacked two of the 
transporters responsible for multidrug resistance 99. Cloning of the Rv1258 tap-like efflux 
pump into arabinose inducible vector, pBAD-DEST49, was performed by standard Gateway 
cloning by amplifying complete genes minus the stop codon with attB and promoter regions 
modified within the primers (S1A Fig.).  The plasmid was maintained with 100µg/ml of 
ampicillin. The GFP plasmid (S1B Fig.) was cloned similarly and was maintained using 
100µg/ml of chloramphenicol. 
 
Microchemostat cultures, medium and growth conditions: Luria Bertani (LB) medium 
(Sigma Aldrich) used in the microchemostat and off-chip cultures contained tryptone (10g/L), 
yeast extract (5g/L), NaCl (5g/L), inert binding agents (2.2g/L) and bovine serum albumin 
(10g/L) as an anti- cell adhesion adjuvant. Pre-cultures for microchemostat experiments were 
prepared by inoculating 10 ml of sterile medium with 100µl of glycerol stock cultures and 
shaking at 120 rpm for 4 hours at 37˚C in a bench top incubator (Scientific Orbital Shaking, 
model 260). The pre-cultures were then used to seed microchemostat reactors. The pBAD-
DEST49 plasmid was maintained with 100µg/ml of ampicillin (Sigma-Aldrich). The 
heterologous efflux pump, under control of a synthetic promoter was inducible with 
arabinose (Sigma-Aldrich) at concentrations ranging from 0.0002% to 0.0008% (v/V). All the 
microchemostat chip experiments were performed on a heated stage to maintain the growth 
temperature at 37˚C. 
 
Preparation of conditioned medium: E. coli cells carrying the GFP or the Rv1258 plasmid 
were grown in LB medium containing arabinose (3.2mg/L) for 24 hours at 37°C to a final 
OD600 of 1.65. The supernatant was collected and sterilized by filtration through a 0.2-µm-
pore-size filter. 
 
Antibiotic treatment: To determine the effect of antibiotics, cells were grown in the 
microchemostat in drug-free medium for 24 to 40 hours to establish a steady state cell 
density. Medium containing the test drugs including streptomycin (0.78µg/ml) or gentamicin 






Microchemostat chip design and fabrication: Microchemostat chips were fabricated out of 
silicone elastomer polydimethylsiloxane (Momentive Performance Materials, Columbus, OH, 
RTV 615) using multi-layer soft lithography as described previously. In this chip, the number 
of reactors per chip was increased to 14 as described previously 197,198. 
 
Microscopic cell counting: The total number of cells in each reactor was determined directly 
through automated phase contrast microscopy by counting the number of cells present in a 
growth chamber section of the microchemostat of known volume. Phase-contrast images 
were captured using a cooled charge coupled device camera (XM10, monochrome from 
Olympus). A Nikon Ti Eclipse inverted microscope (Nikon UK Ltd, Surrey, UK) with a 
40×/0.6NA Ph2 objective (Nikon, UK) was used for all measurements. Labview software 
was used to control all chip operation. Typically, a set of eight phase-contrast images was 
taken in each reactor, with mixing of the culture in between each snapshot. Image processing 
algorithms written in Matlab software were used to determine the average number of cells in 
each set of pictures, from which the total cell count was determined as described previously 
197,198.  A motorized stage system on the Nikon Ti-E microscope enabled simultaneous 
documentation of multiple microchemostat experiments that operated in parallel on a single 
chip. Focus was maintained using the perfect focus system (PFS) feature of the Nikon 
microscope.  
 
Regression analysis:  Step 1. Cubic spline interpolation. We employed cubic spline 
interpolation using Matlab's curve fitting tool with a (fit parameter = 0.5) to fit smooth curves 
to cell density and cell length data obtained from the microchemostat cultures. Box 1, panel 1 
shows on the primary axis, the cell density data (grey points) and the cubic spline fit (blue 
curve); and on the secondary axis, the cell length data (orange dots) and the cubic spline fit 
(red curve). Interpolation also served the purpose of denoising the data by removing point-to-
point noise variations, which made it possible to obtain the instantaneous derivatives from the 
smoothed data in Step 4. Step 2. Cell length transformation. To perform the cell length 
transformation, the cell length value in each data point was multiplied by a constant -A and 
then, another constant B was added to the result. This transformation flipped the cell length 
graph about the horizontal axis, shrank it by a factor of A, and then shifted the entire graph 
upward by a value of B. Box 1, panel 2 shows the original cell length trend (L(t); dashed red 
curve) as well as the transformed trend (-A·L(t) + B; solid red curve). Step 3. Cell density 




the time value of each cell density data point, which had the effect of shifting the cell density 
graph to the right by the value, τD. Box 1, panel 3 shows the entire graph of the original cell 
density trend (n(t); dashed blue curve) as well as the transformed trend (n(t-τD); solid blue 
curve). The values A, B and τD were adjusted as necessary until the best fit was obtained for 
the transformed length graph −𝐴 ∙ 𝑳 𝑡 + 𝐵  superimposed over the transformed cell density 
graph [n(t-τD)] in terms of periodicity and amplitude. Step 4. Finite Element Derivatives. At 
each time point, i, the finite element derivative, 𝑑𝑦 𝑑𝑡 !  for the cell density or cell length 








The derivative graphs for cell density (𝑑𝒏 𝑑𝑡, or cell division rate) and cell length (𝑑𝑳 𝑑𝑡, 
or the filamentation rate) were then transformed using the approach outlined in steps 2 and 3. 
Box 1, panel 4 shows the first derivatives of the transformed graphs, 𝑑𝒏 𝑡 − 𝜏! 𝑑𝑡 and 
−𝐴 ∙ 𝑑𝑳 𝑑𝑡. 
 
Results and Discussion 
Effect of Rv1258 expression on E. coli cell morphology. The tap-like efflux pump gene 
designated Rv1258, which encodes a multidrug efflux pump in M. tuberculosis was isolated 
and expressed from a plasmid in transporter-deficient E. coli under control of an arabinose-
inducible promoter (S1A. Fig.). Efflux gene expression dynamics were measured by 
monitoring the E. coli cells using a microchemostat—a miniaturized 10 nl bioreactor that 
enables automated culturing of small populations (102–104) of bacteria for hundreds of hours. 
By continually substituting a fraction of a bacterial culture with sterile nutrients, the 
microchemostat creates a near-constant environment that is ideal for long-term controlled 
studies of microbes and microbial communities. Some cell populations carrying the Rv1258 
plasmid were induced with arabinose (efflux ON) and others were not induced (efflux OFF), 
and yet others contained no plasmid but were cultured with arabinose (Fig. 1A). Efflux OFF 
(reactor 5 and 6) and plasmid-free (reactors 7 and 8) cultures grew exponentially to a steady-
state density of ~2.5 cells/pL. In contrast, growth in efflux ON cultures 1 and 2 exhibited 
damped oscillations whereby the cell density dropped dramatically after the first oscillation 






Fig. 1.  (A) Typical microchemostat growth curves of E. coli cells expressing the efflux 
or GFP plasmids. Graphs are shown for growth with the efflux ON (reactors 1 to 2), efflux 
OFF (reactors 5 to 6), GFP ON (reactor 3), GFP OFF (reactor 4), or plasmid-free (reactors 7 
to 8). (B) Graphs of the average specific cell length corresponding to each of the cell 
populations depicted in (A) measured at each time point. All graphs are smoothed spline 
interpolations of raw data shown in S2 Fig. Bottom panels (a to e) show micrographs of the 
cells in reactor 1 at the corresponding points during the first oscillation (scale bar, 25 µm). 
Cells were grown at 37°C in LB medium at a dilution rate of 0.32 hour−1 and induced with 3.2 
mg/L arabinose. 
 
To ascertain that the damped oscillation in the efflux ON cultures were due to expression of 
the Rv1258 gene, we utilized a control plasmid in which the green fluorescent protein (GFP) 
gene was substituted for the Rv1258 efflux pump gene (S1B Fig.). As shown in Fig. 1A, cells 
in reactor 3 carrying the GFP plasmid that were induced with arabinose (GFP ON) grew 
without oscillation in cell density to a steady-state of ~1 cell/pL. The uninduced GFP culture 
(GFP OFF) in reactor 4 also grew without oscillation in cell density to a steady state of ~2 
cells/pL, which was double that of the GFP ON cultures. Induction with arabinose led to a 
~25% reduction in the steady state cell density of GFP cells but increased the fraction of GFP 
fluorescent cells from ~8% in the GFP OFF population to ~67% in the GFP ON population 
(S3 Fig.). The reduced density of the GFP ON population relative to the GFP OFF culture 
demonstrates the fitness cost associated with expression of plasmid encoded genes. However, 
the variations in steady-state cell density of GFP ON cells were negligible compared to the 
overall population oscillations observed in the efflux ON cultures. Thus, the oscillations 
observed in the efflux ON cultures could neither be accounted for by arabinose induction nor 
the plasmid backbone but were attributable to Rv1258 gene expression.  
 
A deterministic relationship between cell density and cell length during expression of 
Rv1258 by E. coli cells. By monitoring specific cell morphologies in the microchemostat 
cultures, we observed that expression of Rv1258 induced cell filamentation (Fig. 1B). Efflux 
ON cells were on average 2 to 3 times longer than the cells in the non-effluxing populations, 
with specific cell lengths routinely reaching 30µm, which was ~10 times greater than the 




in the efflux ON populations exhibited oscillatory behavior that was not observed in the non-
effluxing populations, but was tightly coupled to the oscillations in cell density. For example, 
Fig. 2A shows the cell density and average cell length of the population depicted in culture 2 
of Fig. 1. The oscillations in cell density were reversed relative to the oscillations in the 
average cell length and phase delayed by ~12 minutes. This deterministic relationship is 
illustrated in Fig. 2B and specified by a phase-shifted linear equation: 
𝒏 𝑡 − 𝜏! ≅ −𝐴 ∙ 𝑳 𝑡 + 𝐵                                                               (1) 
where n is the cell density (cells/pL), L is the cell length (µm), and 𝜏! represents the ~12-
minute time delay between the cell density and length waves. A and B are relationship 
constants that were measured to be 0.45 cells/pL·µm and 2.15 cells/pL respectively.  
 
Fig. 2. (A) Growth curve (blue; primary axis) and cell length (red; secondary axis) with the 
Rv1258 efflux pump ON. (B) Growth curve (blue) shifted forward in time by a time delay 
(τD= 12 minutes) and linear transformation of cell length as per equation 1 (red). (C) Finite 
element derivatives of experimental data showing the cell division rate (blue, primary axis) 
and cell elongation rate (red, secondary axis). (D) Finite element cell division rate (blue) 
shifted forward in time by the time delay (τD = 12 minutes) and the linear transformation of 
the elongation rate as per equation 2 (red). 
 
To probe the interrelation between cell density and length, and the link to Rv1258 gene 
expression, we looked to the first derivative association of the time-variable parameters in 
equation 1:  
𝑑𝒏(𝑡 − 𝜏!)
𝑑𝑡 ≅ −𝐴 ∙
𝑑𝑳 𝑡
𝑑𝑡                                                                     (2) 
where dn/dt is the cell division rate (cells/pL·hour) and dL/dt is the filamentation rate 
(µm/hour). This relationship was consistent with the finite element derivatives obtained from 
the experimental data (Fig. 2C) whereby the oscillations in the filamentation rate were 
reversed relative to the oscillations in the cell division rate and phase-shifted by the time-
delay of ~12 minutes, as illustrated in Fig. 2D. Except for the 12-minute lag in the elongation 
rate signal, the cell division rate varied directly as the elongation rate. Thus, for instance, a 




vice versa, although the changes in the filamentation rate were always delayed by a ~12-
minutes lag, designated τD.  
 
The time-shifted but direct proportionality relationship between the cell division and 
filamentation rates suggest that the filamentous phenotype adopted by efflux ON cells was 
due to cell division arrest, whereby rod-shaped cells ceased to divide into separate daughter 
cells but instead continued to grow in volume and length. Cell filamentation behavior has 
been observed in other bacterial species in response to a variety of stressful environments, 
including nutrient deficiency 210, extensive DNA damage through the SOS response pathway 
211, host innate immune responses 212, and antibiotic treatment 213-215. In addition, the 
filamentation response was not permanent, because periodically, the filamentation rate was 
reversed during periods when the cells gradually reverted back towards a normal rod-shaped 
phenotype (Fig. 2 and S4 Fig.). The transitions between the alternating periods of increasing 
and decreasing filamentation rates in the efflux ON populations were notably abrupt and 
switch-like (Fig. 2C). Population-wide synchronized control of gene expression is necessary 
for such switch-like transitions; from which we can infer that the cyclic cell filamentation 
pattern was a response to fluctuations in a population-wide factor, such as the extracellular 
concentration of a stress factor. We have previously shown that the observed filamentation 
pattern was caused by Rv1258 gene expression, and therefore we attributed the filamentation 
process to the extracellular concentration of a bio-chemical signal extruded from within the 
cells by the Rv1258 efflux pump (referred to as the natural efflux product in the remainder of 
this manuscript). This inference was supported by cell culture experiments performed using 
conditioned medium (i.e., medium containing the suspected growth-inhibiting factors 
extruded by the Rv1258 efflux pump). We observed a 20% reduction in growth of GFP cells 
supported by medium conditioned with E. coli cells expressing the Rv1258 plasmid-encoded 
gene relative to GFP cells supported by medium conditioned with cells expressing the GFP 
gene (S5 Fig.). 
 
An extension of this inference is that the natural product extruded by the Rv1258 efflux pump 
suppresses its own production—a necessary condition for the observed oscillatory behavior. 
Together, our results show that the Rv1258 efflux pump extrudes a natural product, 
synthesized intracellularly that is evidently non-disruptive to cell growth and morphology in 
the intracellular environment—a necessary requirement for the observed switch-like 




in the extracellular environment and at sufficiently high concentrations, effect cell-division 
arrest, resulting in cell filamentation, and a decreased production of the natural efflux 
product. Eventually, when the production rate of the natural efflux product falls below the 
dilution rate, the natural efflux product gets diluted out of the microchemostat culture, which 
reverses the filamentation process, and the population recovers and enters the next cycle. 
 
Consistent observations were made in conventional liquid batch cultures (S6 Fig.). Following 
the lag and exponential growth phases, the non-effluxing cultures entered stationary phase 
after ~8 hours of culturing with a cell density of ~1.6 (OD600). The typical non-effluxing cell 
length decreased from ~10µm during lag phase to ~3µm during stationary phase. By contrast, 
efflux ON cultures prematurely entered stationary phase after only 4 hours of culture with a 
lower cell density of ~0.8 (OD600). The typical efflux ON cell length increased from ~10µm 
during lag phase to ~16µm during stationary phase. In the absence of continuous dilution, 
these stationary phase characteristics persisted throughout the remainder of the culturing 
process, in contrast to the microchemostat cultures that underwent oscillatory behavior. 
 
Rv1258 expression increases tolerance to growth-inhibiting compounds in E. coli cells. 
We next investigated the efflux phenotype due to Rv1258 expression at various 
concentrations of ethidium bromide (EtBr)—a known inhibitor for E. coli cell growth 216,217 
that has previously been documented as a substrate of the Rv1258 pump 218. As shown in the 
top row of Fig. 3A, in the efflux OFF cultures, as the ethidium bromide concentration was 
increased from 0 to 0.25, 0.5 and 1µg/ml, the steady-state cell density decreased from ~2.6 to 
~2.5, ~1.7, and <0.7 cells/pL respectively, illustrating the deleterious effect of EtBr in the 
absence of efflux. As described previously, in the absence of EtBr, the typical efflux ON 
culture displayed damped oscillations in the cell density, attaining a steady-state density of 
~0.7 cells/pL that was ~3× lower than the corresponding efflux OFF culture. However, in 
contrast to the efflux OFF trend, the efflux ON steady state density was maintained at ~0.7 
cells/pL when the EtBr concentration increased to 0.25µg/ml EtBr, and even increased 
slightly to ~0.85 cells/pL at a higher EtBr concentration of 0.5µg/ml. Clearly, EtBr extrusion 
by the Rv1258 efflux pump enabled the efflux ON cells to maintain a high cell density—
comparable to the density in the EtBr-free culture—at EtBr concentrations that affected 
growth in the equivalent efflux OFF cultures (0.25 and 0.5µg/ml). When the EtBr 
concentration was increased further to 1µg/ml, the Rv1258 efflux pump became 




state density. The corresponding dynamics in cell length are shown in the bottom row of Fig. 
3. 
 
Fig. 3.  (A) Top row graphs represent the effects of the ethidium bromide (EtBr) 
concentration on population dynamics of E.coli cells with efflux ON or OFF. In the 
efflux OFF cultures, the steady-state cell density decreased with increasing EtBr 
concentration. The efflux ON cultures maintained their steady state density as the 
concentration of EtBr was increased except for the highest EtBr concentration of 1µg/ml. 
Bottom row graphs represent dynamics in cell length corresponding to the growth curves in 
the top rows. All graphs are smoothed spline interpolations of raw data shown in S7 Fig. 
Cells were grown at 37°C in LB medium at a dilution rate of 0.32 hour−1 and induced with 3.2 
mg/L arabinose. (B) Time delay (τD) between the growth and elongation oscillatory 
dynamics as a function of ethidium bromide concentration (EtBr). As the EtBr dose was 
increased from 0 to 0.25, 0.5 and 1µg/ml, the time-delay τD increased from 12 minutes, to 40 
minutes, 1 hour and 1 hour, respectively. 
 
At higher concentrations of EtBr (12.5 and 25µg/ml), microbial biofilms, which are not 
subject to wash-out through continuous bioreactor operation of the microchemostat, supplied 
most of the bulk culture cells in both the efflux OFF and ON cultures, leading to much higher 
cell densities than were achievable under more ideal chemostat conditions at lower EtBr 
concentrations (S8 Fig.). Exactly why biofilm formation was exacerbated at high 
concentrations of EtBr is unclear. However, as a result of elevated biofilm formation, we 
observed that at 12.5 µg/ml EtBr, the efflux ON and OFF microchemostat populations 
attained cell densities as high as ~2.5 cells/pL, which was at least 3× higher than the densities 
attained at 1ug/ml EtBr, in spite of the growth inhibitory effect of EtBr. At 25µg/ml of EtBr, 
the efflux ON cell density (~ 4 cells/pL) exceeded that of the efflux OFF culture (~3 
cells/pL), further illustrating increased biofilm formation at higher concentrations of EtBr and 
the EtBr extrusion advantage conferred by the Rv1258 efflux pump to the efflux ON cells. 
 
The interference between the efflux extrusion of EtBr and the natural efflux product of the 
Rv1258 pump was observable in the efflux ON cultures at the various concentrations of EtBr. 
As the EtBr dose was increased from 0 to 0.25, 0.5 and 1µg/ml, the frequency of the 




decreased in tandem, and these oscillations essentially disappeared in the 0.5 and 1µg/mL 
EtBr concentration efflux ON graphs (Fig. 3A). Furthermore, the time-delay τD between the 
cell density and cell length oscillations increased from 12 minutes, to 40 minutes, 1 hour and 
1 hour, respectively (Fig. 3B). The response dynamics slowed down as the EtBr 
concentrations was increased. We speculate that this behavior was due to efflux substrate 
displacement whereby the EtBr molecules competed with the natural efflux product 
molecules for extrusion through the Rv1258 pump, which delayed accumulation of the 
natural efflux product in the extracellular environment and the onset of cell filamentation.  
 
We next investigated drug-tolerance under Rv1258 gene expression by introducing 
antibiotics including streptomycin and gentamicin to microchemostat cell populations that 
had reached a steady state density. In a representative set of experiments involving 
streptomycin (Fig. 4A), the efflux pump was turned ON in culture 1; left OFF in culture 2; 
and absent (no plasmid) in culture 3. In the absence of streptomycin (time 0 to 40 hours), the 
non-effluxing cultures grew to a steady-state density of ~2 cells/pL, while the efflux ON cell 
density oscillated to a lower density of ~0.5 cells/pL. When medium containing streptomycin 
(0.78 µg/ml) was introduced at 40 hours, the non-effluxing cultures decayed exponentially 
and were washed out by 90 hours. By contrast, upon introduction of streptomycin, the cell 
density in efflux ON culture 1 initially dropped to ~0.1 cells/pL but recovered at 60 hours to 
the pre-streptomycin steady state of ~0.5 cells/pL that was maintained during the remainder 
of the experiment, which lasted to 130 hours. Similar dynamics were apparent when 
gentamicin (1.56 µg/ml) was introduced to different cell populations under otherwise similar 
conditions (Fig. 4B). Prior to introducing gentamicin, the efflux OFF and plasmid-free 
populations attained steady-state cell densities of ~3 cells/pL, and the efflux ON culture 
~0.5cells/pL. Upon introduction of gentamicin, the non-effluxing cells washed out of the 
microchemostat reactors while the efflux ON culture dropped to a cell density of ~0.1cells/pL 
and did not wash out of the reactor. Altogether these results illustrate that expression of the 
Rv1258 efflux pump increased tolerance to streptomycin and gentamicin. 
 
Fig. 4. (A) Growth of E. coli cells in the presence of streptomycin (0.78µg/ml) including 
a log scale in the inset. Initially, the efflux pump was turned ON in culture 1 and left OFF in 
culture 2. Culture 3, which was plasmid-free and inoculated at time 20 hours (point A) was 
cultivated on a separate chip in a different experiment under the same conditions. At 40 hours 




the non-effluxing cultures 2 and 3 decayed and washed out, whereas that of the effluxing 
culture 1 attained a non-trivial steady-state of 0.5 cells/pL. (B) Growth of E. coli cells in the 
presence of gentamicin (1.56µg/ml) including a log scale in the inset. Initially, the efflux 
pump was turned ON in culture 1, left OFF in culture 2, and absent in culture 3. At 24 hours 
(point B), medium containing gentamicin was introduced to all cultures. Whereas the non-
effluxing cultures washed out, the efflux ON culture attained a lower steady-state density of 
0.1 cells/pL. All graphs are smoothed spline interpolations of raw data shown in S10 Fig. All 




Our data demonstrate that there is a yet unidentified natural efflux product extruded by the 
Rv1258 efflux pump, which suppresses its own production and causes cell-division arrest and 
filamentation at sufficiently high extracellular concentration. In a closed system without 
replenishment of nutrients or other growth factors during the period of incubation, 
constitutive Rv1258 expression led suppressed growth and a filamentous phenotype, 
conditions which persisted indefinitely. In the microchemostat where the cell culture was 
periodically substituted with fresh sterile medium, constitutive expression of the Rv1258 
efflux gene engendered alternating phases of two distinct phenotypes, which we refer to here 
as active and dormant efflux. During active efflux, a natural efflux product was actively 
extruded from within the cells. This phase was characterized by normal-sized, actively 
dividing cells. A decrease in the intracellular concentration of antibiotics extruded by the 
pump during this phase impairs their accessibility to the drug target and can facilitate 
progressive acquisition of chromosomal mutations that confer higher levels of resistance to 
the respective antibiotics. Conversely, the dormant efflux phase was characterized by 
suppressed efflux product extrusion and filamentous cells with arrested cell division, which 
gradually reverted back towards a more normal cell shape, cell division rate and efflux 
product extrusion rate.  Although drug molecule extrusion by the efflux pump may be 
suppressed during this phase, the filamentous shape represents a survival strategy known to 
protect bacteria from antibiotic medicines and allows bacteria to survive engulfment by 
phagocytic cells 206. In addition, because most bactericidal antibiotics rely on bacteria to be 




activity can in theory confer broader phenotypic resistance to drugs that the efflux pumps 
may not directly extrude. 
 
We have demonstrated, using Rv1258 as a test-case, that expression of M. tuberculosis efflux 
pumps in transporter-deficient E. coli cells combined with high resolution measurement of 
cellular properties using the microchemostat platform, can address the challenge of functional 
redundancy and enable researchers to more cleanly pinpoint compound substrates extrudable 
by the pump. The approach we have outlined should serve as a robust and widely applicable 
route to screen the performance of other discrete transporter proteins against a wider range of 
compounds and efflux pump inhibitors, with the ultimate goal of reconstructing the 
functional interplay between the various transporters comprising the M. tuberculosis efflux 
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Legends to supplementary figures. 
S1 Fig.  Implementation of the Rv1258 and GFP plasmid constructs. (A) The tap-like 
efflux gene designated Rv1258, cloned from M. tuberculosis, was inserted into an arabinose 
inducible plasmid pBAD-DEST49 and maintained by Ampicillin. (B) The GFP gene cloned 
into the same arabinose inducible plasmid pBAD-DEST49 is maintained by chloramphenicol. 
AMPR, ampicillin resistance; CMR, chloramphenicol resistance; Para, arabinose promoter. 
 
S2 Fig.  Raw data of E. coli cells cultured in the microchemostat showing the cell density on 
the primary axis (red curve with black dots) or average specific cell length on the secondary 
axis (orange curve with gray dots) as a function of time for the curves depicted in Fig. 1A and 
B. Cells were grown at 37°C in LB medium at a dilution rate of 0.16 hour−1 under conditions 
indicated on the right of each graph. 
 
S3 Fig.  Microchemostat growth curves of E. coli cells carrying the GFP plasmid 
construct schematized in S1B Fig. with an arabinose inducible promoter driving GFP 
gene expression. Cells were grown with arabinose (induced, Left) or without (uninduced, 
Right). The red growth curves represent the overall cell density and the green curves 
represent the density of the fluorescent cells. Cells were grown with a dilution rate of 0.32 
hour−1 at 37°C in LB medium and induced with 3.2 mg/L arabinose. 
 
S4 Fig.  Rv1258 expression engendered two alternating, distinct morphological 
phenotypes in E. coli cells. The first phenotype comprised of normal-sized, rod-shaped, 
actively dividing cells depicted in panel (A). The second was characterized by arrested cell 
division and filamentous cells depicted in panel (B). The cells shown here were grown in a 
microchemostat with a dilution rate of 0.32 hour-1 at 37ºC in LB medium and induced with 
3.2 mg/L arabinose. 
 
S5 Fig.  (A) Growth of E. coli cells expressing the Rv1258 and GFP plasmid-encoded 
genes in liquid media. For each condition, 10 ml of fresh LB medium containing arabinose 
was inoculated with cells containing the Rv1258 or GFP plasmid and incubated with shaking 
at 37ºC for 24 hours. (B) Growth of E. coli cells carrying the GFP plasmid in conditioned 
medium. Conditioned with E. coli cells expressing the Rv1258 or the GFP plasmid. 10 




genes was inoculated with cells containing the GFP plasmid and incubated with shaking at 
37ºC for 24 hours. There was a 20% growth reduction in growth of GFP cells supported by 
the medium conditioned with cells expressing the Rv1258 gene. 
 
S6 Fig.  (A) Growth of E. coli cells in conventional liquid tissue culture flask batch 
cultures with the efflux pump ON (black circles), OFF (blue squares) or absent (red 
diamonds). Following lag and exponential growth phases, the non-effluxing cultures entered 
stationary phase after ~8 hours of culturing with a cell density of ~1.6 (OD600). By contrast, 
efflux ON cultures prematurely entered stationary phase after only 4 hours of culture with a 
lower cell density of ~0.8 (OD600). (B) Micrographs of the cells in corresponding to the 
graphs in A at different time points. The typical non-effluxing cell length decreased from 
~10µm during lag phase to ~3µm during stationary phase. The typical efflux ON cell length 
increased from ~10µm during lag phase to ~16µm during stationary phase. (Scale bar, 25 
µm). Cells were inoculated into 10ml of LB broth and cultivated at 37°C tissue culture flasks 
with shaking at 280 rpm, and induced with 3.2 mg/L arabinose. 
 
S7 Fig.   Raw data of E. coli cells cultured in the microchemostat showing the cell density on 
the primary axis (red curve and black dots) or average specific cell length on the secondary 
axis (orange curve and gray dots) as a function of time for the curves depicted in Fig. 3A. 
Cells were grown at 37°C in LB medium at a dilution rate of 0.16 hour−1 under conditions 
indicated on the right of each graph. 
 
S8 Fig.  Top and bottom row graphs represent the effects of high concentrations of ethidium 
bromide (EtBr) on population dynamics of E.coli cells with efflux ON or OFF. All graphs are 
smoothed spline interpolations of raw data shown in S9 Fig. Cells were grown at 37°C in LB 
medium at a dilution rate of 0.32 hour−1 and induced with 3.2 mg/L arabinose. 
 
S9 Fig.  Raw data of E. coli cells cultured in the microchemostat showing the cell density on 
the primary axis (red curve and black dots) or average specific cell length on the secondary 
axis (orange curve and gray dots) as a function of time for the curves depicted in S8 Fig. 
Cells were grown at 37°C in LB medium at a dilution rate of 0.16 hour−1 under conditions 





S10 Fig.  Raw data of E. coli cells cultured in the microchemostat showing the cell density on 
the primary axis (red curve and black dots) or average specific cell length on the secondary 
axis (orange curve and gray dots) as a function of time for the curves depicted in Fig. 4A and 
B. Cells were grown at 37°C in LB medium at a dilution rate of 0.16 hour−1 under conditions 




































































































7. Materials and Methods 
	
7.1 E. coli Strains.  
 
We have made use of E.coli strains generously provided by Dr. Alissa Myrick from the Eric Ruben 
lab at Harvard University, who is now located at H3D at the University of Cape Town. The wild type 
E coli cells—BW25113 ΔemrE ΔmdfA—lacked two of the transporters responsible for multidrug 
resistance99. The use of these strains ensured no outside interference from native transporters. Cloning 
of the Rv1258 tap-like efflux pump into an arabinose inducible vector, pBAD-DEST49 (Invitrogen 
Corporation, Carlsbad, CA), was performed by standard Gateway cloning by amplifying complete 
genes minus the stop codon with attB and promoter regions modified within the primers (Figure 27A).  
The plasmid was maintained with 100µg/ml of ampicillin (Sigma Aldrich, South Africa). The GFP 
plasmid (Figure 27B) was cloned similarly and was maintained using 100µg/ml of chloramphenicol 
(Merck chemicals, South Africa). Wild type d2 cells lack two of the transporters for multidrug 
resistance (ΔemrE ΔmdfA) but underwent no cloning and therefore contained no efflux pump. Wild 




























Figure 27| Implementation of the Rv1258 and GFP plasmid constructs. (A) The tap-like efflux gene 
designated Rv1258, cloned from M. tuberculosis, was inserted into an arabinose inducible plasmid 
pBAD-DEST49 and maintained with Ampicillin. (B) The GFP gene cloned into the same arabinose 
inducible plasmid pBAD-DEST49 is maintained with chloramphenicol. AMPR, ampicillin resistance; 
CMR, chloramphenicol resistance; Para, arabinose promoter. Origin of replication pUC. 
 
7.2 Microchemostat Chip Design and Fabrication. 
 
The microchemostat design was developed using AutoCAD software (Autodesk, South Africa). 
Microchemostat chips were fabricated in a cleanroom facility to prevent contamination with dust 
particles. All chips were fabricated out of silicone elastomer polydimethylsiloxane (PDMS) 
(Momentive Performance Materials, Columbus, OH, RTV 615) using the process of multi-layer soft 
lithography as described previously154. In this chip, the number of reactors per chip was increased to 
14 as described previously197,198. A more detailed description of the chip fabrication process can be 
found in appendix A.  
 
7.3 Calorimetric Assays 
 
The food dye used in the calorimetric microchemostat characterization assays was obtained from 
McCormick & Co., Hunt Valley, Maryland, USA. The dye concentration in the microchemostat was 




chamber. In order to optimize mixing times and to determine the time it takes to completely replace 
the liquid (green dye) within the reactor with deionized water, the dye concentration within the reactor 
was measured throughout a series of dilutions until the reactor became completely filled with water. A 
standard curve was then generated. This information was used to determine how long it takes to 
completely replace fresh media in the reactor with drug containing media. We also made use of the 
standard curve to determine the drug concentration within the reactor at any given time. The dilution 
process is entirely automated using Labview software (National Instruments, South Africa) that was 
developed in house. 
 
7.4 Microchemostat Cultures, Medium and Growth Conditions.  
 
Luria Bertani (LB) medium (Sigma Aldrich, South Africa) used in the microchemostat cultures 
contained tryptone (10g/L), yeast extract (5g/L), NaCl (5g/L), inert binding agents (2.2g/L) and 
bovine serum albumin (10g/L) as an anti- cell adhesion adjuvant. Pre-cultures for microchemostat 
experiments were prepared by inoculating 10 ml of sterile medium with 100µl of glycerol (Merck 
Chemicals, South Africa) stock cultures (50% glycerol:50% culture) and shaking at 120 rpm for ~4 
hours (or until an optical density (OD600) of 0.8) at 37˚C in a bench top incubator (Scientific Orbital 
Shaking, model 260) (Trilab, South Africa).  
 
The pre-cultures were then used to seed microchemostat reactors (~20 cells/nl per reactor). This was 
performed through the use of a 1ml syringe (Lasec, South Africa) connected to a 10cm piece of tygon 
tubing (Cole-Parmer, South Africa) and a steel pin (New England Small Tube Corporation, New 
Hampshire, United States) that was then connected to an input port of the microchemostat reactor. 
The pBAD-DEST49 plasmid was maintained with 100µg/ml of ampicillin (Sigma-Aldrich, South 
Africa). The heterologous efflux pump, under control of a synthetic promoter, was inducible with 
arabinose (Sigma-Aldrich, South Africa) at concentrations ranging from 0.0002% to 0.0008% (v/V). 
Biofilm formation within the reactors was prevented through sequential dilutions with fresh LB media 
and Bacterial protein extraction reagent (B-PER) obtained from ThermoFischer Scientific, South 
Africa. All microchemostat experiments were performed on a heated stage (IMP, South Africa) to 
maintain the growth temperature at 37˚C. 
 
7.5 Antibiotic Treatment.  
 
To determine the effect of antibiotics, cells were grown in the microchemostat in drug-free medium 
for 24 to 40 hours to establish a steady state cell density. Efflux ON cultures were grown in the 




grown with arabinose. Medium containing the test drugs including streptomycin (0.78µg/ml) (Sigma 
Aldrich, South Africa), gentamicin (1.56 µg/ml) (Sigma Aldrich, South Africa) or ethidium bromide 
(0.25 - 25 µg/ml) was then introduced to the microchemostat cultures for the remainder of the 
experiment. Medium was introduced through the use of tygon tubing connected to a pressurized 
source at one side and an input on the microchemostat chip at the other side (Figure 28).  
 
7.6 Microscopic Cell Counting.  
 
The total number of cells in each reactor was determined directly through automated phase contrast 
microscopy by counting the number of cells present in a growth chamber section of the 
microchemostat of known volume. Phase-contrast images were captured using a cooled charge 
coupled device camera (CCD) (XM10, monochrome from Olympus) (Wirsam Scientific, South 
Africa). Fluorescent images were captured with an Andor Luca – R 604 camera (IMP, South Africa). 
A Nikon Ti Eclipse inverted microscope (Nikon UK Ltd, Surrey) with a 40×/0.6NA Ph2 objective 
(Nikon UK Ltd, Surrey) was used for all measurements. Labview software (National Instruments, 
South Africa) was used to control all chip operations allowing complete automation of experiments. 











Figure 28| The setup of the microfluidic system used to achieve microchemostat results. The entire 
process is completely automated through computer control. Actuation of the valves, shutter control for 
fluorescent experiments, and acquisition of phase contrast and fluorescent images all occur through 
the use of Labview software. Results are also obtained in real-time through the use of Matlab 





Typically, a set of eight phase-contrast images was taken in each reactor, with mixing of the culture in 
between each snapshot. Image processing algorithms (Appendix B) written in Matlab software were 
used to determine the average number of cells in each set of pictures, from which the total cell count 
was determined as described previously 197,198. Briefly, the average number of cells per picoliter (pL) 
was calculated by determining the number of cells in a region of the microchemostat reactor of known 
volume. This was then be used as an estimate for the total number of cells in the reactor.  An example 
of the calculations performed for phase contrast images can be found below.  
 
Step 1:  The volume (in pL) of the imaging section is first calculated: 
 
𝑊𝑖𝑑𝑡ℎ 𝑤  𝑜𝑓 𝑟𝑒𝑎𝑐𝑡𝑜𝑟 𝑖𝑛 𝑖𝑚𝑎𝑔𝑖𝑛𝑔 𝑠𝑒𝑐𝑡𝑖𝑜𝑛 = 100µm 
𝐿𝑒𝑛𝑔𝑡ℎ 𝑙  𝑜𝑓 𝑟𝑒𝑎𝑐𝑡𝑜𝑟 𝑖𝑛 𝑖𝑚𝑎𝑔𝑖𝑛𝑔 𝑠𝑒𝑐𝑡𝑖𝑜𝑛 = 154µm 
𝐻𝑒𝑖𝑔ℎ𝑡 ℎ  𝑜𝑓 𝑟𝑒𝑎𝑐𝑡𝑜𝑟 𝑖𝑛 𝑖𝑚𝑎𝑔𝑖𝑛𝑔 𝑠𝑒𝑐𝑡𝑖𝑜𝑛 = 10µm 
 
Therefore, the volume (V) of this section is equal to: 
 
𝑉 = 𝑤. 𝑙. ℎ 
                                                      𝑉 = 100µ𝑚. 154µ𝑚. 10µ𝑚 
                                                                  𝑉 = 154000µ𝑚! 
 
This volume can now be converted to pL: 
 
                                                                   𝑉 = 154000µ𝑚! ÷ 1000 
                                                                  𝑉 = 154𝑝𝐿 
 
Step 2:  Using this volume we can now calculate the number of cells per pL: 
 














Image processing algorithms written in Matlab software were also used to determine morphological 
changes over time induced by pump activation or drug addition. A motorized stage system (Nikon Ti-




multiple microchemostat experiments that operated in parallel on a single chip. Focus was maintained 
using the perfect focus system (PFS) feature of the Nikon microscope.  
 
7.7 Regression Analysis.   
 
Step 1. Cubic spline interpolation.  
 
We employed cubic spline interpolation using Matlab's curve fitting tool with a fit parameter = 0.5 to 
fit smoothed curves to cell density and cell length data obtained from the microchemostat cultures. 
Figure 29, panel 1 shows on the primary axis the cell density data (grey points) and the cubic spline fit 
(blue curve); and on the secondary axis, the cell length data (orange dots) and the cubic spline fit (red 
curve). Interpolation also served the purpose of denoising the data by removing point-to-point noise 
variations, which made it possible to obtain the instantaneous derivatives from the smoothed data in 
Step 4.  
 
Step 2. Cell length transformation. 
 
To perform the cell length transformation, Microsoft excel (Microsoft Corporation, Redmond, 
Washington, USA) was used. The cell length value in each data point was multiplied by a constant -A 
and then, another constant B was added to the result. This transformation flipped the cell length graph 
about the horizontal axis, shrank it by a factor of A, and then shifted the entire graph upward by a 
value of B. Figure 29, panel 2 shows the original cell length trend (L(t); dashed red curve) as well as 
the transformed trend (-A·L(t) + B; solid red curve) 
 
Step 3. Cell density transformation.  
 
To perform the cell density transformation, a time constant τD was added to the time value of each cell 
density data point, which had the effect of shifting the cell density graph to the right by the value, τD. 
Figure 29, panel 3 shows the entire graph of the original cell density trend (n(t); dashed blue curve) as 
well as the transformed trend (n(t-τD); solid blue curve). The values A, B and τD were adjusted as 
necessary until the best fit was obtained for the transformed length graph −𝐴 ∙ 𝑳 𝑡 + 𝐵  







Step 4. Finite Element Derivatives.  
 
At each time point, i, the finite element derivative, 𝑑𝑦 𝑑𝑡 !  for the cell density or cell length 







The derivative graphs for cell density (𝑑𝒏 𝑑𝑡, or cell division rate) and cell length (𝑑𝑳 𝑑𝑡, 
or the filamentation rate) were then transformed using the approach outlined in steps 2 and 3 Figure 
29, panel 4 shows the first derivatives of the transformed graphs, 𝑑𝒏 𝑡 − 𝜏! 𝑑𝑡 and −𝐴 ∙ 𝑑𝑳 𝑑𝑡. 
 
	
Figure 29| The cell length transformation used to help describe the relationship between cell density 






7.8 Conventional Culture Experiments 
 
Luria Bertani (LB) medium (Sigma Aldrich, South Africa) used in the off-chip cultures contained 
Tryptone (10g/L), yeast extract (5g/L), NaCl (5g/L), inert binding agents (2.2g/L) and bovine serum 
albumin (10g/L) as an anti-cell adhesion adjuvant. Cultures for off-chip experiments were prepared by 
inoculating 10 ml of sterile medium with 100µl of glycerol (Merck Chemicals, South Africa) stock 
cultures and shaking at 120 rpm at 37˚C in a bench top incubator (Scientific Orbital Shaking, model 
260) (Trilab, South Africa).  
 
Conventional culture experiments performed in tissue culture flasks involved recording an OD 
reading at a wavelength of 600nm using 2ml micro cuvettes (Lasec, South Africa) and a Beckman 
Coulter DU730 UV spectrophotometer (California, USA) every hour until the cultures reached 
stationary phase (~10 – 12 hours). Off-chip experiments were conducted as controls for comparison to 
microchemostat experiments. 
 
Conventional culture experiments were also conducted using conditioned medium in order to provide 
support for the hypothesis of a growth inhibiting efflux product. For each condition, 10 ml of fresh LB 
medium containing arabinose was inoculated with cells containing the Rv1258 or GFP plasmid and 
incubated with shaking at 37ºC for 24 hours using a bench top incubator (Scientific Orbital Shaking, 
model 260) (Trilab, South Africa). The growth media from these cultures (Rv1258 and GFP) was then 
filtered using a 0.20µm syringe filter from Lasec South Africa in order to remove all bacteria. This 
conditioned media was then used to culture cells expressing the GFP plasmid in order to confirm the 
presence of suspected growth-inhibiting factors extruded by the Rv1258 efflux pump. Bacteria were 
cultured for ~12 hours, with OD600 readings taken every hour through the use of 2ml micro cuvettes 







8. Results  
	
8.1 Culture Conversion Rate Within the Microchemostat 
 
We have taken a synthetic approach for the study of mycobacterial efflux pumps. As mentioned 
previously, we have made use of E.coli constructs that have the Rv1258 efflux pump cloned into an 
arabinose inducible promoter. Thus, we could control efflux pump gene expression by adding or 
removing arabinose (inducer). We required a way to determine the time it takes to completely 
incorporate the arabinose into the growth media within the microchemostat reactor through the 
continuous dilution process described in chapter 4.  
 
Calorimetric assays were performed to determine the rate of conversion of the media within the 
growth chamber. Green food dye was used to determine the number of dilutions required to 
completely replace the liquid within the growth chamber. The rate at which the liquid is replaced 
depends on the dilution rate that is controlled using labview software. A description of the entire 
process can be found in chapter 7. In the example experiment below (Figure 30), a dilution rate of 200 
seconds resulted in the liquid being completely replaced within ~5 hours.  
 
Once an appropriate pump speed and duration was selected, the experiment was left to run to 


































Figure 30| Screen shots from a microchemostat dye experiment showing the dye concentration (here 
denoted as “D”) within the reactor. At the start of the experiment, the concentration in the reactor was 
at 100% (A). In this particular experiment, after ~2.5 hours, the concentration in the reactor had 
reached 50% (B). However, after ~5 hours, water had completely replaced the green dye in the reactor 
(C).  
 
Throughout the experiment, screen shots were taken following every dilution (Figure 30) and the dye 
concentration determined. A standard curve (Figure 31) was generated to allow us to determine the 




media (e.g. drug or inducer containing media). In this particular experiment, in order to convert 50%, 
75% and 99% of the media within the growth chamber, 9, 16 and 60 dilutions were required 
respectively (Figure 31). This standard curve can also be used to determine the drug concentration 
within the reactor at any given time, making it a useful tool for determining the minimum inhibitory 
concentration of drugs.   
Figure 31| A standard curve generated to show the number of dilutions required at a given dilution 
rate to completely replace the fluid within the reactor. This standard curve can be used to determine 
the concentration of drugs within the reactor at any given time. 
	
8.2 Bacterial Growth in the Microchemostat 
 
The tap-like efflux pump gene designated Rv1258, which encodes a multidrug efflux pump in M. 
tuberculosis was isolated and expressed from a plasmid in transporter-deficient E. coli under control 
of an arabinose-inducible promoter (Figure 27A). By continually substituting a fraction of the 
bacterial culture with sterile nutrients, the microchemostat creates a near-constant environment that is 
ideal for long-term controlled studies of these microbes and efflux gene expression. 
 
Uninduced (efflux OFF) (cultures 1 and 2) and plasmid free (cultures 3 and 4) cell populations 
cultured within the microchemostat grew in the characteristic fashion, containing a lag, exponential 




~2.5 cells/pL. Corresponding cell lengths are represented in Figure 32B. Efflux OFF populations grew 
to an average cell length of ~2 µm compared to plasmid free populations that reached ~1.5 µm. 
 
 
Figure 32| (A) Typical microchemostat growth curves of E. coli cells with efflux OFF (reactors 1 and 
2), or plasmid-free (reactors 3 and 4). (B) Graphs of the average specific cell lengths corresponding to 
each of the cell populations depicted in (A) measured at each time point. All graphs are smoothed 
spline interpolations of raw data shown in appendix C. Cells were grown at 37°C in LB medium at a 






8.2.1 Oscillations Due to Efflux Gene Expression 
 
Cell populations carrying the Rv1258 plasmid were induced with arabinose (efflux ON) (Figure 33). 
This lead to the transcription of the Rv1258 gene and subsequent expression of the efflux pump. 
Growth in efflux ON cultures 1 and 2 exhibited damped oscillations whereby the cell density dropped 
dramatically after the first oscillation cycle and then sustained smaller amplitude oscillations about a 
reduced steady state of ~0.7 cells/pL. This reduced steady state illustrates the fitness cost conferred by 
pump activation. Corresponding cell lengths are represented in Figure 33B. Cell lengths for both 
efflux ON populations oscillated around ~2.9 µm. 
 
These oscillatory dynamics appeared to be a unique characteristic of Rv1258. Two additional 
multidrug efflux pumps (Rv2477 and Rv2846) found in M. tuberculosis were induced with arabinose 
and cultured in the microchemostat to determine whether or not these growth characteristics are 
unique to Rv1258. These efflux pumps reached a similar steady state cell density (~1 cell/pL) to that 















































Figure 33| (A) Typical microchemostat growth curves of E. coli cells with efflux ON (reactors 1 and 
2). (B) Graphs of the average specific cell length corresponding to each of the cell populations 
depicted in (A) measured at each time point. All graphs are smoothed spline interpolations of raw data 
shown in appendix C. Bottom panels (a to e) show micrographs of the cells in reactor 1 at the 
corresponding points during the first oscillation (scale bar, 25 µm). Cells were grown at 37°C in LB 
medium at a dilution rate of 0.32 hour−1 and induced with 3.2 mg/L arabinose. Experiments were 





Figure 34| Cell density and length dynamics of the Rv2477 and Rv2846 efflux pumps. (A) Typical 
microchemostat growth curves of E. coli cells with efflux ON (reactors 1 and 2). (B) Graphs of the 
average specific cell length corresponding to each of the cell populations depicted in (A) measured at 
each time point. Cells were grown at 37°C in LB medium at a dilution rate of 0.16 hour−1 (Rv2477) 
and 0.32 hour−1 (Rv2846) and induced with 3.2 mg/L arabinose. All experiments were repeated twice. 
	
8.2.2 A Deterministic Relationship between Cell Density and Cell Length  
 
By monitoring specific cell morphologies in the microchemostat cultures, we observed that expression 
of Rv1258 induced cell filamentation (Figure 33B). Efflux ON cells were on average 2 to 3 times 
longer than the cells in the non-effluxing populations (Figure 32B), with specific cell lengths routinely 
reaching 30µm, which was ~10 times greater than the typical length of the cells in the non-effluxing 




behaviour that was not observed in the non-effluxing populations, but was tightly coupled to the 
oscillations in cell density (Figure 33). 
 
For example, Figure 35A shows the cell density and average cell length of the population depicted in 
culture 2 of Figure 33. The oscillations in cell density were reversed relative to the oscillations in the 
average cell length and phase delayed by ~12 minutes. This deterministic relationship is illustrated in 
Figure 35B and specified by a phase-shifted linear equation: 
 
𝒏 𝑡 − 𝜏! ≅ −𝐴 ∙ 𝑳 𝑡 + 𝐵,                                                              (7)	
	
where n is the cell density (cells/pL), L is the cell length (µm), and 𝜏! represents the ~12-minute time 
delay between the cell density and length waves. A and B are relationship constants that were 
measured to be 0.45 cells/pL·µm and 2.15 cells/pL respectively.  
 
To probe the interrelation between cell density and length, and the link to Rv1258 gene expression, 
we looked to the first derivative association of the time-variable parameters in equation 7:  
 
𝑑𝒏(𝑡 − 𝜏!)
𝑑𝑡 ≅ −𝐴 ∙
𝑑𝑳 𝑡
𝑑𝑡  ,                                                                   (8)	
	
where dn/dt is the cell division rate (cells/pL·hour-1) and dL/dt is the filamentation rate (µm.hour-1). 
This relationship was consistent with the finite element derivatives obtained from the experimental 
data (Figure 35C) whereby the oscillations in the filamentation rate were reversed relative to the 
oscillations in the cell division rate and phase-shifted by the time-delay of ~12 minutes, as illustrated 
in Figure 35D. Except for the 12-minute lag in the elongation rate signal, the cell division rate varied 
directly as the elongation rate. Thus, for instance, a decrease in the growth rate coincided with a 
proportional increase in the elongation rate, and vice versa, although the changes in the filamentation 





Figure 35| A deterministic relationship between cell density and cell length. (A) Growth curve (blue; 
primary axis) and cell length (red; secondary axis) with the Rv1258 efflux pump ON. (B) Growth 
curve (blue) shifted forward in time by a time delay (τD= 12 minutes) and linear transformation of cell 
length as per equation 1 (red). (C) Finite element derivatives of experimental data showing the cell 
division rate (blue, primary axis) and cell elongation rate (red, secondary axis). (D) Finite element cell 
division rate (blue) shifted forward in time by the time delay (τD = 12 minutes) and the linear 
transformation of the elongation rate as per equation 2 (red). 
	
The time-shifted but direct proportionality relationship between the cell division and filamentation 
rates suggest that the filamentous phenotype adopted by efflux ON cells was due to cell division 
arrest, whereby rod-shaped cells ceased to divide into separate daughter cells but instead continued to 
grow in volume and length. For more information regarding the approach used to develop figure 35, 
please see chapter 7.  
 
Cell filamentation behaviour has been observed in other bacterial species in response to a variety of 
stressful environments, including nutrient deficiency 210, extensive DNA damage through the SOS 
response pathway 211, host innate immune responses 212, and antibiotic treatment 213-215. In addition, the 




during periods when the cells gradually reverted back towards a normal rod-shaped phenotype (Figure 
35 and 36). The transitions between the alternating periods of increasing and decreasing filamentation 
rates in the efflux ON populations were notably abrupt and switch-like (Figure 35C). 
 
Figure 36| Rv1258 expression engendered two alternating, distinct morphological phenotypes in E. 
coli cells. The first phenotype comprised of normal-sized, rod-shaped, actively dividing cells depicted 
in panel (A). The second was characterized by arrested cell division and filamentous cells depicted in 
panel (B). The cells shown here were grown in a microchemostat with a dilution rate of 0.32 hour-1 at 
37ºC in LB medium and induced with 3.2 mg/L arabinose. 
 
Consistent observations were made in conventional liquid batch cultures (Figure 37). Following the 
lag and exponential growth phases, the non-effluxing cultures entered stationary phase after ~8 hours 
of culturing with a cell density of ~1.6 (OD600). The typical non-effluxing cell length decreased from 




prematurely entered stationary phase after only 4 hours of culture with a lower cell density of ~0.8 
(OD600). The typical efflux ON cell length increased from ~10µm during lag phase to ~16µm during 
stationary phase. In the absence of continuous dilution, these stationary phase characteristics persisted 
throughout the remainder of the culturing process, in contrast to the microchemostat cultures that 
underwent oscillatory behaviour. 
Figure 37| (A) Growth of E. coli cells in conventional liquid tissue culture flask batch cultures with 
the efflux pump ON (black circles), OFF (blue squares) or absent (red diamonds). Following lag and 
exponential growth phases, the non-effluxing cultures entered stationary phase after ~8 hours of 
culturing with a cell density of ~1.6 (OD600). By contrast, efflux ON cultures prematurely entered 
stationary phase after only 4 hours of culture with a lower cell density of ~0.8 (OD600). (B) 
Micrographs of the cells corresponding to the graphs in A at different time points. The typical non-
effluxing cell length decreased from ~10µm during lag phase to ~3µm during stationary phase. The 
typical efflux ON cell length increased from ~10µm during lag phase to ~16µm during stationary 
phase. (Scale bar, 25 µm). Cells were inoculated into 10ml of LB broth and cultivated at 37°C with 




Results for Plasmid Free with and without arabinose did not differ. Optical density experiments were 
repeated twice. Each data point represents an average of three separately read optical densities 
 
8.3 Efflux Activity—A Plausible cause of Oscillations in Cell Density and Length  
 
8.3.1 The Removal of Oscillations through Efflux Inhibition  
 
To ascertain that the damped oscillations in cell density and length in the efflux ON microchemostat 
cultures were due to expression of the Rv1258 gene, efflux pump inhibitors were used.  
 
Addition of efflux inhibitors CCCP (carbonyl cyanide m-chlorophenyl hydrazone) and PAβN 
(phenylalanine-arginine beta-naphthylamide) to efflux-ON cultures suppressed the oscillatory 
dynamics, suggesting that the efflux-ON oscillatory behaviour may be due to efflux activity (Figure 
38A and B). However, the steady state cell density in the efflux inhibited cultures was dramatically 
reduced (~0.3 cells/pL) relative to equivalent cultures without the inhibitors (~0.7 cells/pL). This 
reduced cell density can be attributed to the toxicity of the efflux inhibitors, which have been shown 
to permeabilize the outer membrane of gram negative bacteria, thereby reducing the cell 
viability219,220.  It is possible that this low cell density may lead to a reduced total concentration of the 





Figure 38| The effect of efflux pump inhibitors on E. coli growth dynamics. Bacterial cell density 
(blue curve; primary axis) and morphology (orange curve; secondary axis) as a function of time in 




expression of the Rv1258 gene. (A and B) Efflux-ON cells cultured with efflux pump inhibitors 
CCCP (A) or PaβN (B) do not elicit oscillations. Cultures were induced with 3.2 mg/L arabinose. 
Cells were grown at 37°C in LB medium, at a dilution rate of D= 0.32 hour-1. All experiments were 
repeated twice. 
	
8.3.2 Removal of Oscillations through Gene Substitution 
 
To ascertain that the damped oscillations in the efflux ON cultures were due to expression of the 
Rv1258 gene, we also utilized a control plasmid in which the green fluorescent protein (GFP) gene 
was substituted for the Rv1258 efflux pump gene (Figure 27B) 221. As shown in Figure 39A, cells in 
reactor 1 carrying the GFP plasmid that were induced with arabinose (GFP ON) grew without 
oscillation in cell density to a steady-state of ~1 cell/pL. Unlike the cell density achieved by the 
cultures grown with efflux pump inhibitors (~0.3 cells/pL), the cell density achieved by the GFP 
expressing population (~1 cell/pL) was high enough to elicit oscillatory behaviour in the efflux-ON 
cultures. The uninduced GFP culture (GFP OFF) in reactor 2 also grew without oscillation in cell 
density to a steady state of ~2 cells/pL, which was double that of the GFP ON cultures. Corresponding 
cell lengths presented with no oscillations with GFP ON populations reaching 1.5 µm compared to 2 













Figure 39| (A) Typical microchemostat growth curves of E. coli cells with GFP ON (reactor 1), or 
GFP OFF (reactor 2) (B) Graphs of the average specific cell length corresponding to each of the cell 
populations depicted in (A) measured at each time point. All graphs are smoothed spline 
interpolations of raw data shown in appendix C. Cells were grown at 37°C in LB medium at a dilution 








Induction with arabinose led to a ~25% reduction in the steady state cell density of GFP cells but 
increased the fraction of GFP fluorescent cells from ~8% in the GFP OFF population to ~67% in the 
GFP ON population (Figure 40). The reduced density of the GFP ON population relative to the GFP 
OFF culture demonstrates the fitness cost associated with expression of plasmid encoded genes. 
However, the variations in steady-state cell density of GFP ON cells were negligible compared to the 
overall population oscillations observed in the efflux ON cultures (Figure 33). Thus, the oscillations 
observed in the efflux ON cultures could neither be accounted for by arabinose induction nor the 
plasmid backbone but were attributable to Rv1258 gene expression.  
 
Figure 40| Microchemostat growth curves of E. coli cells carrying the GFP plasmid construct 
schematized in Figure 27B with an arabinose inducible promoter driving GFP gene expression. Cells 
were grown with arabinose (induced, Left) or without (uninduced, Right). The red growth curves 
represent the overall cell density and the green curves represent the density of the fluorescent cells. 
Cells were grown with a dilution rate of 0.32 hour−1 at 37°C in LB medium and induced with 3.2 mg/L 
arabinose. 
	
8.4 Oscillatory Dynamics Induced through an Extruded Natural Efflux Product 
 
To conceptualize the mechanisms involved in bacterial efflux, we developed a hypothesis that states 
that “oscillatory dynamics in the efflux ON populations are due to an extruded product that acts on the 
population as a whole to induce cell filamentation and suppress growth.” 
 
Population-wide synchronized control of gene expression is necessary for such switch-like transitions; 
from which we can infer that the cyclic cell filamentation pattern was a response to fluctuations in a 




shown that the observed filamentation pattern was caused by Rv1258 gene expression, and therefore 
we attributed the filamentation process to the extracellular concentration of a bio-chemical signal 
(natural efflux product) extruded from within the cells by the Rv1258 efflux pump.  
 
This inference was supported by cell culture experiments performed using conditioned medium (i.e., 
medium containing the suspected growth-inhibiting factors extruded by the Rv1258 efflux pump). We 
observed a 20% reduction in the growth of GFP cells cultured in conditioned medium containing the 
growth inhibiting factors (obtained from a previous culture of efflux ON cells), relative to GFP cells 
cultured in medium conditioned with cells expressing the GFP gene (Figure 41). 
 
Figure 41| The effect of an extruded natural efflux product on the growth of cells expressing GFP. 
(A) Growth of E. coli cells expressing the Rv1258 and GFP plasmid-encoded genes in liquid media. 
Stationary phase OD600 readings are presented. For each condition, 10 ml of fresh LB medium 
containing arabinose was inoculated with cells containing the Rv1258 or GFP plasmid and incubated 
with shaking at 37ºC for 24 hours. (B) Growth of E. coli cells carrying the GFP plasmid in 
conditioned medium. Medium was conditioned with E. coli cells expressing the Rv1258 (blue bar) or 
the GFP plasmid (green bar). 10 ml of medium conditioned with E. coli cells expressing the Rv1258 
or GFP plasmid-encoded genes was inoculated with cells containing the GFP plasmid and incubated 
with shaking at 37ºC for 24 hours. There was a 20% reduction in growth of GFP cells supported by 




8.4.1 A Qualitative Model of Efflux Gene Expression 
 
An extension of this inference is that the natural product extruded by the Rv1258 efflux pump 
suppresses its own production—a necessary condition for the observed oscillatory behaviour. 
Together, our results show that the Rv1258 efflux pump extrudes a natural product, synthesized 
intracellularly that is evidently non-disruptive to cell growth and morphology in the intracellular 
environment—a necessary requirement for the observed switch-like transitions. However, once 
extruded from the cell, the natural efflux product can accumulate in the extracellular environment and 
at sufficiently high concentrations, effect cell-division arrest, resulting in cell filamentation and a 
decreased production of the natural efflux product. Eventually, when the production rate of the natural 
efflux product falls below the dilution rate, the natural efflux product gets diluted out of the 
microchemostat culture, which reverses the filamentation process, and the population recovers and 



















Figure 42| Schematized view of a model relating the rates of cell division and elongation during 
expression of the Rv1258 efflux pump. The efflux pump extrudes a natural substrate, synthesized 
intracellularly that is non-disruptive to cell growth and morphology in the intracellular environment 
where it is well regulated. However, once extruded by the efflux pump, this substrate can accumulate 




in cell elongation. The model also postulates that the Rv1258 efflux proteins are substantially located 
at the cell poles, such that elongated polyploid cells are less efficient efflux extruders because they 
have a smaller pole surface area ratio relative to normal size cells generated during active cell 
division. This phenomenon has also been observed in Caulobacter crescentus in a study conducted by 
Kirkpatrick and Viollier. Cell elongation results in a decrease in the extrusion of the natural efflux 
substrate, which is gradually diluted out by chemostat operation.  A low extracellular concentration 
desuppresses cell division, which switches off the cell elongation process. Active cell division 
resumes, which in turn increases efflux of the natural substrate and ushers in the next cycle.  
	
8.4.2 A Quantitative Model of Efflux Gene Expression 
 
To further understand the dynamics of the E. coli expression system, we developed a simplified 
quantitative model that captures the essential features of the system.  
 
In conventional liquid batch cultures, wild type, efflux-OFF and efflux-ON cultures initially grew at 
similar exponential growth rates of 1.03 hr-1, 1.06 hr-1 and 1.04 hr-1 respectively (Figure 37A). 
However, although the wild type and efflux-OFF cultures entered stationary phase after ~6 hours at an 
optical density of ~1.6, the efflux-ON cultures prematurely entered a permanent stationary phase after 
~4 hours at an optical density of ~0.8. As discussed previously, one plausible scenario for such an 
outcome is that the efflux-ON cultures were extruding a product that was harmless at low 
concentrations but became toxic above a threshold concentration and halted cell division abruptly. 
Similar observations were made for the microchemostat experiments. We formulated differential 
equations that capture the main aspects of this scenario and compared their numerical solutions to the 
patterns observed in the microchemostat cultures.  
 
When the efflux pump is OFF, cell proliferation in the microchemostat cultures is modeled by the 
canonical chemostat equation 4 (chapter 4), where n, D and µ represent the number of cells, dilution 
rate and specific growth rate respectively.  
 
In order to develop the model, we expressed the specific growth rate as	µ = µ!"# · 𝐻 𝑁  − 𝑛 ,	where 
µmax is the maximum specific growth rate during the exponential phase.	𝐻 𝑁  − 𝑛 	 expressed as	
1 − 1 1 + 𝑒!∙!!∙ !!!! 	 is a smooth approximation of the Heaviside step function modeling the 
change in the growth rate as the microchemostat culture transitions from exponential to stationary 
phase. cn is the sharpness of this transition and N∞ is the maximum number of cells the microchemostat 






= −𝑛 · 𝐷 + 𝑛 · µ!"# · 1 −
1
1+𝑒2·𝑐𝑛·(𝑁 −𝑛)
			 	 	 	 [9]	
When the efflux pump is turned ON, we express the specific growth rate as µ! = µ · 𝐻 𝑝  − 𝑝 , 
where µ is the specific growth rate and p is the concentration of the efflux product. 𝐻 𝑝! − 𝑝  
expressed as 1 − 1 1 + 𝑒!∙!!∙ !!!!   is a smooth approximation of another Heaviside step 
function modeling the change in the growth rate as the efflux product transitions from a harmless 
level above the toxic threshold concentration. cp is the sharpness of this transition and p∞ is the 
threshold concentration above which the efflux product becomes toxic. The rate of production of p is 
expressed as a differential equation where k is the rate of extrusion of efflux products by each cell. 
Thus, the pump ON model consists of two coupled differential equations representing the rate of 




= −𝑛 · 𝐷 + 𝑛 · µ!"# · 1 −
1
1+𝑒2·𝑐𝑛·(𝑁 −𝑛)





= −𝑝 · 𝐷 + 𝑛 · 𝑘		 	 	 	 	 	 	 											[11]	
	
Numerical solutions to the model described in equations 9 to 11 were programmed into a spreadsheet 
using parameter values listed in Table 2, appendix D. The model predicted underdamped oscillations 



































Figure 43| A model predicting underdamped oscillations in the efflux-ON cell population density. 
Model predictions (solid lines) have been plotted with typical data (data points). The model predicts 
damped oscillations in the efflux-ON cell density (1), which eventually reaches a steady-state. The 
behaviour of wild type (2) and efflux-OFF (3) cultures is consistent with typical microchemostat cell 
growth dynamics.  
 
8.5 Efflux-Associated Drug Tolerance  
 
8.5.1 Ethidium Bromide Tolerance  
 
We next investigated the efflux phenotype due to Rv1258 expression at various concentrations of 
ethidium bromide (EtBr)—a known inhibitor for E. coli cell growth 216,217 that has previously been 
documented as a substrate of the Rv1258 pump 218. As shown in the top row of Figure 44A, in the 
efflux OFF cultures, as the ethidium bromide concentration was increased from 0 to 0.25, 0.5 and 
1µg/ml, the steady-state cell density decreased from ~2.6 to ~2.5, ~1.7, and <0.7 cells/pL 
respectively, illustrating the deleterious effect of EtBr in the absence of efflux. As described 




cell density, attaining a steady-state density of ~0.7 cells/pL that was ~3× lower than the 
corresponding efflux OFF culture. However, in contrast to the efflux OFF trend, the efflux ON steady 
state density was maintained at ~0.7 cells/pL when the EtBr concentration increased to 0.25µg/ml 
EtBr, and even increased slightly to ~0.85 cells/pL at a higher EtBr concentration of 0.5µg/ml. 
Clearly, EtBr extrusion by the Rv1258 efflux pump enabled the efflux ON cells to maintain a high 
cell density—comparable to the density in the EtBr-free culture—at EtBr concentrations that affected 
growth in the equivalent efflux OFF cultures (0.25 and 0.5µg/ml). When the EtBr concentration was 
increased further to 1µg/ml, the Rv1258 efflux pump became overwhelmed and the efflux ON culture 
registered a major decrease in growth and steady-state density. The corresponding dynamics in cell 













Figure 44| The effect of EtBr concentrations on population dynamics of E.coli cells (A) Top row 
graphs represent the effects of the ethidium bromide (EtBr) concentration on population dynamics of 
E.coli cells with efflux ON or OFF. In the efflux OFF cultures, the steady-state cell density decreased 
with increasing EtBr concentration. The efflux ON cultures maintained their steady state density as 




row graphs represent dynamics in cell length corresponding to the growth curves in the top rows. All 
graphs are smoothed spline interpolations of raw data shown in appendix C. Cells were grown at 37°C 
in LB medium at a dilution rate of 0.32 hour−1 and induced with 3.2 mg/L arabinose. (B) Time delay 
(τD) between the growth and elongation oscillatory dynamics as a function of ethidium bromide 
concentration (EtBr). As the EtBr dose was increased from 0 to 0.25, 0.5 and 1µg/ml, the time-delay 
τD increased from 12 minutes, to 40 minutes, 1 hour and 1 hour, respectively. Each set of conditions 
were repeated twice. 
 
At higher concentrations of EtBr (12.5 and 25µg/ml), microbial biofilms, which are not subject to 
wash-out through continuous bioreactor operation of the microchemostat, supplied most of the bulk 
culture cells in both the efflux OFF and ON cultures, leading to much higher cell densities than were 
achievable under more ideal chemostat conditions at lower EtBr concentrations (Figure 45). Exactly 
why biofilm formation was exacerbated at high concentrations of EtBr is unclear. However, as a result 
of elevated biofilm formation, we observed that at 12.5 µg/ml EtBr, the efflux ON and OFF 
microchemostat populations attained cell densities as high as ~2.5 cells/pL, which was at least 3× 
higher than the densities attained at 1ug/ml EtBr, in spite of the growth inhibitory effect of EtBr. At 
25µg/ml of EtBr, the efflux ON cell density (~ 4 cells/pL) exceeded that of the efflux OFF culture (~3 
cells/pL), further illustrating increased biofilm formation at higher concentrations of EtBr and the 











































Figure 45| The effect of high concentrations of EtBr on E.coli population dynamics. Top and bottom 
row graphs represent the effects of high concentrations of ethidium bromide (EtBr) on population 
dynamics of E.coli cells with efflux ON or OFF. All graphs are smoothed spline interpolations of raw 
data shown in appendix C. Cells were grown at 37°C in LB medium at a dilution rate of 0.32 hour−1 






The interference between the efflux extrusion of EtBr and the natural efflux product of the Rv1258 
pump was also observable in the efflux ON cultures at the various concentrations of EtBr. As the EtBr 
dose was increased from 0 to 0.25, 0.5 and 1µg/ml, the frequency of the oscillations in the steady-
state cell density and length increased while their amplitude decreased in tandem, and these 
oscillations essentially disappeared in the 0.5 and 1µg/mL EtBr concentration efflux ON graphs 
(Figure 44A). Furthermore, the time-delay τD between the cell density and cell length oscillations 
increased from 12 minutes, to 40 minutes, 1 hour and 1 hour, respectively (Figure 44B). The response 
dynamics slowed down as the EtBr concentrations was increased. We speculate that this behaviour 
was due to efflux substrate displacement whereby the EtBr molecules competed with the natural 
efflux product molecules for extrusion through the Rv1258 pump, which delayed accumulation of the 
















Figure 46| Schematized view of a model relating to the displacement of the natural efflux product by 
ethidium bromide. The efflux pump extrudes a natural substrate, synthesized intracellularly that is 
non-disruptive to cell growth and morphology in the intracellular environment where it is well 
regulated. However, once extruded by the efflux pump, this substrate can accumulate in the 
extracellular environment and at sufficiently high concentrations inhibit cell division, resulting in cell 
elongation. When ethidium bromide (EtBr) (which is also a substrate of the Rv1258 efflux pump) is 
added to the medium, it competes with the natural substrate for efflux extrusion. This minimizes the 
oscillatory dynamics in the cell density and increases the time delay between the cell density and cell 




8.5.2 Streptomycin and Gentamicin Tolerance 
 
We next investigated drug-tolerance under Rv1258 gene expression by introducing antibiotics 
including streptomycin and gentamicin to microchemostat cell populations that had reached a steady 
state density. In a representative set of experiments involving streptomycin (Figure 47A), the efflux 
pump was turned ON in culture 1; left OFF in culture 2; and absent (no plasmid) in culture 3. In the 
absence of streptomycin (time 0 to 40 hours), the non-effluxing cultures grew to a steady-state density 
of ~2 cells/pL, while the efflux ON cell density oscillated to a lower density of ~0.5 cells/pL. When 
medium containing streptomycin (0.78 µg/ml) was introduced at 40 hours, the non-effluxing cultures 
decayed exponentially and were washed out by 90 hours. By contrast, upon introduction of 
streptomycin, the cell density in the efflux ON culture 1 initially dropped to ~0.1 cells/pL but 
recovered at 60 hours to the pre-streptomycin steady state of ~0.5 cells/pL that was maintained during 
the remainder of the experiment, which lasted to 130 hours.  
 
 
Similar dynamics were apparent when gentamicin (1.56 µg/ml) was introduced to different cell 
populations under otherwise similar conditions (Figure 47B). Prior to introducing gentamicin, the 
efflux OFF and plasmid-free populations attained steady-state cell densities of ~3 cells/pL, and the 
efflux ON culture ~0.5cells/pL. Upon introduction of gentamicin, the non-effluxing cells washed out 
of the microchemostat reactors while the efflux ON culture dropped to a cell density of ~0.1cells/pL 
and did not wash out of the reactor. The differences observed following streptomycin and gentomicin 
addition were consistent with previous experiments. These data suggest that streptomycin is a better 
substrate for the Rv1258 efflux pump compared to gentamicin. Altogether, these results illustrate that 




Figure 47| Efflux pump activation induces tolerance to streptomycin and gentamicin. (A) Growth of 
E. coli cells in the presence of streptomycin (0.78µg/ml) including a log scale in the inset. Initially, 
the efflux pump was turned ON in culture 1 and left OFF in culture 2. Culture 3, which was plasmid-
free and inoculated at time 20 hours (point A) was cultivated on a separate chip in a different 
experiment under the same conditions. At 40 hours (point B), medium containing streptomycin was 
introduced to all cultures. The cell density in the non-effluxing cultures 2 and 3 decayed and washed 




Growth of E. coli cells in the presence of gentamicin (1.56µg/ml) including a log scale in the inset. 
Initially, the efflux pump was turned ON in culture 1, left OFF in culture 2, and absent in culture 3. At 
24 hours (point B), medium containing gentamicin was introduced to all cultures. Whereas the non-
effluxing cultures washed out, the efflux ON culture attained a lower steady-state density of 0.1 
cells/pL. All graphs are smoothed spline interpolations of raw data shown in appendix C. All cells 
were grown at 37°C in LB medium at a dilution rate of 0.16 hour−1 and induced with 3.2 mg/L 
arabinose. All streptomycin experiments were repeated five times. Efflux ON and Plasmid-Free 
gentamicin experiments were repeated three times. Efflux OFF gentamicin experiments were repeated 
twice. 
 
8.6 Loss of Efflux Gene Function 
 
Throughout the project, we observed some interesting growth dynamics when cultures were grown in 
the microchemostat. Occasionally, some efflux-ON cultures escaped heterologous efflux pump 
regulation (Figure 48). In this case, the cells adopted a phenotype equivalent to cells that are not 
expressing the circuit (efflux OFF), with the cell density rapidly increasing whilst the cell size 
decreased.  Conversely, growth in some Rv1258-bearing but uninduced cultures (efflux OFF) was 
halted briefly resulting in a dramatic decrease in cell density (Figure 49).  This scenario resulted in the 
cells adopting an efflux ON phenotype, with the cell number decreasing whilst the length increased. A 
possible cause of this behaviour may be due to basal level expression of the Rv1258 gene in 
uninduced cultures which led to a slow but gradual increase in the efflux products reaching their toxic 
threshold concentration. These cell cultures recovered after a brief period once the efflux products 

























Figure 48| Interesting growth dynamics whereby Efflux-ON populations escaped heterologous efflux 
pump regulation. Microchemostat growth curves illustrating the cell density (blue curve; primary 
axis) and morphology (orange curve; secondary axis) of cells with the Rv1258 efflux pump turned 
ON. Although the culture is induced during the entire experiment, the cells escape regulation of the 
Rv1258 circuit at ~60 hrs. Cells were grown at 37°C in LB medium at a dilution rate of 0.32 hour−1 

























Figure 49| Basal level expression of Rv1258 in efflux OFF cultures. Microchemostat growth curves 
illustrating the cell density (blue curve; primary axis) and morphology (orange curve; secondary axis) 
of cells with the Rv1258 efflux pump OFF. Although the culture is uninduced during the entire 
experiment, the cell density on occasion plummets possibly due to basal level expression of the 
Rv1258 gene. Cells were grown at 37°C in LB medium, at a dilution rate of 0.32 hour-1.  
 
8.7 Mycobacterium Smegmatis Culture in the Microchemostat 
 
Prior to the use of the E.coli expression system, we experimented with the use of the microchemostat 
to continuously culture Mycobacterium smegmatis as a model for future culture of M. tuberculosis 
using the microchemostat.  
 
This organism is used as a laboratory model for the study of M. tuberculosis, and like tuberculosis, 
readily forms biofilms. As described previously, biofilm formation can interfere with microchemostat 
operation if uncontrolled. Conventionally, a lyses buffer (BPER) is used to slow down biofilm growth 
and prevent clogging of channels. This approach works well for organisms such as E.coli that grow in 
biofilms and as planktonic cells; however, M. smegmatis  predominantly grows in biofilms, with its 
unique cell wall posing a major obstacle  to lysis and subsequent removal from chamber walls. If left 
uncontrolled M. Smegmatis is able to form biofilms that can completely fill the reactor, thereby 













Figure 50| Optical micrographs showing M. smegmatis biofilms blocking the microchemostat growth 
chamber (A), and preventing peristaltic mixing (B). 
 
Despite these challenges, we were able optimize the lysis time and slow down biofilm growth to allow 
for the continuous culture of M. smegmatis over ~10 days reaching a steady state cell density of ~0.1 
pixels (Figure 51). This culture grew as a mixed population containing both small biofilms and 
planktonic cells (Figure 52). However, these biofilms were not allowed to grow to such an extent that 









Figure 51| A microchemostat growth curve of M. smegmatis growing in a mixed population of 
biofilms and planktonic cells. The experiment was run for a period of ~10 days, reaching a steady 
state cell density of ~0.1pixels. Cells were grown at 37°C in 7H9 medium at a dilution rate of 0.036 





























Figure 52| An optical micrograph of a mixed population of M. smegmatis cells containing both small 
biofilms and planktonic cells. 
 
M. smegmatis cell density was determined by enumerating the number of pixels occupied by the cells 
at different time points within the growth chamber. This process was performed using algorithms 
written in Matlab. Individual cells were not counted as described previously for the E.coli constructs 
due to the presence of smegmatis biofilms that can impede the ability to achieve an accurate cell 
count.  
 
Despite successfully culturing M. smegmatis in the microchemostat system, the presence of difficult-
to-remove biofilms presented too many confounding factors. For this reason, we utilized the E. coli 
constructs created by Dr. Alissa Myrick for the study of M. tuberculosis efflux pumps. We believe the 
study of mycobacteria by culture is more suited to the Microdialyser system described previously 
(chapter 3). Unlike the microchemostat, the microdialyser system does not rely on continuous mixing 
for its operation. As a result, biofilm growth does not pose a major obstacle to the functioning of the 
device. The microchemostat is more suited to the study of fast growing organisms such as E.coli that 










The tap-like efflux pump gene designated Rv1258, which encodes a multidrug efflux pump in M. 
tuberculosis was isolated and expressed from a plasmid in transporter-deficient E. coli under control 
of an arabinose-inducible promoter (Figure 27A). Efflux gene expression dynamics were measured by 
monitoring the E. coli cells using a microchemostat—a miniaturized 10 nl bioreactor that enables 
automated culturing of small populations (102–104) of bacteria for hundreds of hours. By continually 
substituting a fraction of a bacterial culture with sterile nutrients, the microchemostat creates a near-
constant environment that is ideal for long-term controlled studies of microbes and microbial 
communities. The E. coli expression system and the microchemostat have allowed us to fully 
interrogate a mycobacterial efflux pump (Rv1258) previously shown to be involved in the 
development of drug resistance to M. tuberculosis87,93,112,113. 
 
9.1 Oscillations through Efflux Gene Expression 
 
Using these systems, we have been able to observe oscillations in the cell density of efflux ON 
populations. Efflux inhibitors CCCP and PaβN were able to completely remove these oscillatory 
dynamics, suggesting that this behaviour is due to efflux activity (Figure 38A and B). These results 
were confirmed using a control plasmid in which the green fluorescent protein (GFP) gene was 
substituted for the Rv1258 efflux pump gene (Figure 27B). GFP cells induced with arabinose grew 
without oscillation in cell density, thereby confirming the efflux inhibitor results. Thus, the 
oscillations observed in the efflux ON cultures could neither be accounted for by arabinose induction 
nor the plasmid backbone but were attributable to Rv1258 gene expression. Experimentation with 
other efflux constructs did not yield oscillations, suggesting that these characteristics are unique to 
Rv1258. 
 
9.2 Oscillations Due to an Extruded Natural Efflux Product 
 
Our data suggest that these oscillations occur due to the extrusion of a yet unidentified natural efflux 
product, which suppresses its own production and causes cell-division arrest and filamentation at 





Although the natural efflux product has not been identified, a number of studies have shown that 
bacterial efflux pumps can extrude products that may act extracellularly to suppress growth. For 
example, Bacillus subtilis is able to extrude spermidine, a polyamine that has been shown to be vital 
for cell survival. Bile salts have also been shown to be extruded by E.coli and are able to regulate 
growth through altering the extracullular pH85,86. 
 
During conventional cell culture experiments performed using tissue culture flasks, nutrients and 
growth factors were not replenished during the period of incubation. As a result, constitutive Rv1258 
expression and subsequent extrusion of the natural efflux product led to suppressed growth and a 
filamentous phenotype, conditions that persisted indefinitely (Figure 37).  
 
In the microchemostat where the cell culture was periodically substituted with fresh sterile medium, 
constitutive expression of the Rv1258 efflux gene and extrusion of the natural efflux product 
engendered alternating phases of two distinct phenotypes, which we refer to here as active and 
dormant efflux (Figure 42). These alternating phases appeared as oscillations in the growth curve and 
were only observable through the use of the microchemostat, illustrating the potential benefits this 
device offers for the study of cell biology.  
 
The active efflux phenotype was characterized by normal-sized, actively dividing cells that were 
actively extruding a natural efflux product (Figure 36A). A decrease in the intracellular concentration 
of antibiotics extruded by the pump during this phase impairs their accessibility to the drug target and 
can facilitate progressive acquisition of chromosomal mutations that confer higher levels of resistance 
to the respective antibiotics79. 
 
Once extruded from the cell, the natural efflux product can accumulate in the extracellular 
environment and at sufficiently high concentrations induce a dormant phenotype on the bacteria. The 
dormant efflux phase was characterized by suppressed efflux product extrusion and the formation of 
filamentous cells with arrested cell division (Figure 36B). These filamentous cells gradually revert 
back towards a more normal cell shape, cell division rate and efflux product extrusion rate, thereby 
ushering in the next cycle (Figure 36A). Although drug molecule extrusion by the efflux pump may 
be suppressed during this phase, the filamentous shape represents a survival strategy known to protect 
bacteria from antibiotic medicines and allows bacteria to survive engulfment by phagocytic cells 206. 
In addition, because most bactericidal antibiotics rely on bacteria to be actively dividing to achieve 
rapid killing, a dormant, filamentous phenotype engendered by efflux activity can in theory confer 
broader phenotypic resistance to drugs that the efflux pumps may not directly extrude. This dormant 
phenotype represents a novel method of resistance induced through efflux activation that, to the best 




9.3 Efflux-Associated Drug Tolerance 
 
Many drugs currently used for the treatment of drug susceptible and drug resistant TB target actively 
growing mycobacteria. For example, Isoniazid, one of the most effective and commonly used anti-TB 
drugs,  has a high level of early bactericidal activity but only limited sterilizing activity39. As a result, 
there is limited activity against non-replicating bacteria43. Ethambutol, another first-line TB drug, has 
also been shown to be effective against actively growing bacilli through targeting cell wall 
biosynthesis53. In particular, it inhibits the synthesis of arabinogalactan55. This dormant phenotype 
engendered by Rv1258 efflux activation would therefore pose a significant challenge to the activity of 
these drugs that mainly target actively growing mycobacteria. 
 
Two of the antibiotics tested in this study, streptomycin and gentamycin, are aminoglycosides that 
bind to the 30S subunit of the bacterial ribosome, thereby interrupting protein synthesis222,223. As a 
result, they both rely on active bacterial growth in order to remain effective. Active extrusion of these 
drugs, as well as the ability of the bacterial population to enter a dormant state may explain the 
significant bacterial tolerance observed in efflux ON populations in the presence of these drugs 
(Figure 47). 
 
9.4 The Role of the Microchemostat 
 
Although the microchemostat is not necessarily essential for the study of efflux pumps, its ability to 
allow for long-term growth of bacteria with single cell resolved measurements proved crucial to the 
characterization of Rv1258. This fully automated system enabled us to obtain cell density and 
morphology information every few minutes in real time, thereby allowing us to observe oscillatory 
dynamics induced through efflux activation that would not have been possible with conventional 
batch cultures (Figure 33). The scalability of microfluidic technologies provides the opportunity for 
high throughput screening of these transporters. In this particular study the microchemostat allowed 
us to conduct 14 independent experiments in parallel (Figure 25). However, this device can be scaled 
up to allow even 100 independent reactors on a single device.  
 
9.5 Future Studies 
 
Using the microchemostat, we have demonstrated that the RV1258 efflux pump has two distinct 
methods of resistance that may be clinically relevant. The active efflux phase is characterized by the 
extrusion of a natural efflux product that ushers in the dormant efflux phase. In order to better 




the natural efflux product. This may yield useful information for the development of drugs in the 
future.  
 
We have demonstrated, using Rv1258 as a test-case, that expression of M. tuberculosis efflux pumps 
in transporter-deficient E. coli cells combined with high resolution measurement of cellular properties 
using the microchemostat platform, can address the challenge of functional redundancy and enable 
researchers to more cleanly pinpoint compound substrates extrudable by the pump. In addition to this, 
we intend to use this approach to screen the performance of other discrete transporter proteins against 
a wider range of compounds and efflux pump inhibitors. This will be performed with the ultimate goal 
of reconstructing the functional interplay between the various transporters comprising the M. 
tuberculosis efflux system, their potential contribution to multidrug resistance and role in the basic 
biology of the species. Detailed knowledge of the molecular basis of M. tuberculosis efflux pumps is 
required for the development of new antibiotics that are not extruded or of inhibitors that block efflux 







Appendix A: Microfabrication Protocols for the Microchemostat 
	
Mold Fabrication:  
Push up Control Molds (Negative Photoresist) 
Spin SU8 2015:    1500rpm x 1 min, Acceleration = 270rpm  
Film thickness = 25 microns 
Pre-exposure Bake:   Contact bake on hotplate 
3 min x 65°C / 5 min x 95°C 
Expose wafer:   2 - 5 seconds at 7 Mw/ cm2 using a mask-aligner  
Post-exposure Bake:   5 min x 65°C / 15 min x 95°C  
Develop:  Develop using 100% Shipley SU8 Nanodeveloper for 1-2 
minutes. Rinse with fresh developer and dry with house air. 
Push Down Control Molds (Negative Photoresist) 
Spin SU8 2015:    1500rpm x 1 min, Acceleration = 270rpm  
      Film thickness = 24 microns 
Pre-exposure Bake:    Contact bake on hotplate 
      3 min x 65°C / 5 min x 95°C 
Expose wafer:     2 – 5 seconds at 7 Mw/ cm2 using a mask aligner 
Post-exposure Bake:    5 min x 65°C / 15 min x 95°C  
Develop:  Develop using 100% Shipley SU8 Nanodeveloper for 1-2 




Flow Hybrid Mold 
Step 1 (Negative Photoresist): 
 
Spin SU8 2005:    4000 rpm x 1 min, Acceleration = 270rpm/sec  
      Film thickness = ~3 - 4 microns 
Pre-Exposure Bake:    Contact bake hotplate 
      1 min x 65 C / 2min x 95 C 
Expose wafer:     1 - 5 seconds at 7 Mw/ cm2 using a mask aligner 
Develop:  Develop using 100% Shipley SU8 Nanodeveloper for 1-2 
minutes. Rinse with fresh developer and dry with house air.  
Hard bake:    200°C for 1 -2 hours  
Step 2 (Negative Photoresist).  On the same mold, 
Spin SU8 2010:    3000rpm x 1 min, Acceleration =130rpm/sec  
      Film thickness = 10 microns 
Pre-exposure Bake:    Contact bake hotplate 
      1 min x 65°C / 2 min x 95°C  
Expose wafer:    5 seconds at 7 Mw/ cm2using a mask aligner 
Post-exposure Bake:    1 min x 65°C / 3 min x 95°C  
Develop:  Develop using 100% Shipley SU8 Nanodeveloper for 1-2 
minutes. Rinse with fresh developer and dry with house air. 




Step 3 (Positive Photoresist). On the same mold, 
Priming:     HDMS vapor 2 min in plastic container 
Spin ma-p1275 positive tone resist:  1200 rpm x 1 min, Acceleration = 133rpm/sec ramp up Film 
thickness = 10 microns 
Soft bake:     Contact bake hotplate 
      90 sec x 95°C 
Expose wafer:     15 seconds at 7Mw / cm2using a mask aligner 
Develop: Develop using 100% ma-D 531 developer. Rinse with 
deionized water and then dry under house dry air. 
Reflow:     contact hotplate 
      65°C x 3 min / 115°C x 15 min  
Cooling:    Allow cooling to room temperature 
 
Fabrication of the Microchemostat using Microfluidic Soft Lithography: 
Priming: All molds are primed by placing them in a plastic container 
(STP) with TMCS vapor for 3 min  
 
Push Down Control Layer 
Spin control layer    Combine 5:1 GE 615 TRV (35 g A: 7 g B)  
      Mix in hybrid mixer (5 min mix / 5 min degas) 
Molding: Dispense 33 g onto push down control layer mold (placed in 
a 80mm petri dish lined with Aluminum foil) 
Degas flow layer: Performed by placing mold in a bell jar and creating a 




Cure layer:    Binder® oven 80°C x 40 min  
 
Push Up Control Layer 
Spin control layer    Combine 20:1 GE 615 RTV (20 g A: 1 g B)  
      Mix in hybrid mixer (5 min mix / 5 min degas) 
Molding:    Dispense 5ml onto push up control layer mold 
Spin:   1800 rpm x 60 sec, Acceleration = 500rpm/sec ramp 
Cure layer:     Binder® oven 80°C x 40 min  
 
Flow Layer 
Spin flow layer     Combine 20:1 GE 615 RTV (20 g A: 1 g B)  
      Mix in hybrid mixer (5 min mix / 5 min degas) 
Molding:    Dispense 5ml onto flow layer mold 
Spin:   2300 rpm x 60 sec, Acceleration = 500rpm/sec ramp  
Cure layer:     Binder® oven 80°C x 40 min  
Bonding 
Push down peeling: Push down layer is peeled from the mold 
Cutting: Next, cut the layer into shape using a blade 
Hole punching:  All input and output ports are punched on the push down 
layer 
Push down/Flow bonding: Align push down control layer to flow layer using the 
Olympus SZX16 microscope. 




Cutting: Cut around periphery of thick layer avoiding damage to the 
mold  
Peel: Peel bonded layers from the flow mold 
 Punch all input and output ports 
Bonding to push up layer: Align bonded layer to the push up control layer using the 
Olympus SZX16 microscope. 
Bake in convection oven at 80°C x 40 min to bond layers 
Cutting: Once bonded, cut around periphery of thick layer avoiding 
damage to the mold  
Peel: Peel bonded layers from the flow mold 
 Punch all input and output ports 
Blank Layer 
 
Spin blank layer:   Combine 30:1 GE 615 RTV (30 g A: 1 g B)  
      Mix in hybrid mixer (5 min mix / 5 min degas) 
Molding: Dispense 5ml onto a clean glass substrate (slide or coverslip) 
Spin:   1800 rpm x 60 sec, Acceleration = 500rpm/sec ramp 
Cure layer:     Binder® oven 80°C x 40 min  
Blank/combined layer bonding: Place push up/flow/push down hybrid on blank layer. Inspect 
with the Olympus SZX16 microscope to ensure no air 
bubbles are present and no valves have collapsed.  







Appendix B: Matlab Data Processing Code 
Matlab Algorithm for Detecting Cells in Phase Contrast Images 
%%Authors: Jared_Mackenzie and Frederick_Balagaddé  
%%K-Rith Bioengineering 
  
%Select directory to process 
format long; 
Data_Start = 150; 
data_pts = 'F:\Shots\DIL_800_23Jul2014_02_48PM\R2C5\DataSet150'; 
data_filename = 'F:\Shots\DIL_800_23Jul2014_02_48PM\R2C5\Data_150.xls'; 
data_filename_length = 'F:\Shots\DIL_800_23Jul2014_02_48PM\R2C5\Data_length_150.xls'; 
data_filename_area = 'F:\Shots\DIL_800_23Jul2014_02_48PM\R2C5\Data_area_150.xls'; 
Pictroot = 'Pict_F3_'; 
imageInfor2 = dir(data_pts ); 
imDate=imageInfor2.date; 
  
%Create excel file for data 
fid = fopen(data_filename, 'w'); 
fid2 = fopen(data_filename_length, 'w'); 
fid3 = fopen(data_filename_area, 'w'); 
  
for cint = 1:100 
    cint2 = cint-1; 
    stryng = num2str(cint2); 
    fprintf(fid, stryng); 
    fprintf(fid, ' \t'); 
end 
  
for cint = 1:100 
    cint2 = cint-1; 
    stryng = num2str(cint2); 
    fprintf(fid2, stryng); 
    fprintf(fid2, ' \t'); 
end 
  
for cint = 1:100 
    cint2 = cint-1; 
    stryng = num2str(cint2); 
    fprintf(fid3, stryng); 
    fprintf(fid3, ' \t'); 
end 
  
fprintf(fid, '\n Count \t Time numeric \t Time (Hrs) \t Description \t Cells 1 \t Cells 2 \t Cells 3 \t Cells 
4 \t Cells 5 \t Cells 6\t Cells 7 \t Cells 8 \t Cells Ave \t\t\t'); 
fprintf(fid2, '\n Count \t Length 1 \t Length 2 \t Length 3 \t Length 4 \t Length 5 \t Length 6\t Length 7 
\t Length 8 \t Length \t\t\t'); 
fprintf(fid3, '\n Count \t Area 1 \t Area 2 \t Area 3 \t Area 4 \t Area 5 \t Area 6\t Area 7 \t Area 8 \t 
Area \t\t\t'); 
  
for cint = 1:8 
    stryng = strcat('Cells',num2str(cint)); 
    fprintf(fid, stryng); 






fprintf(fid, ' \t'); 
for cint = 1:8 
    stryng = strcat('Length ',num2str(cint)); 
    fprintf(fid, stryng); 
    fprintf(fid, ' \t'); 
end 
  
fprintf(fid, ' \t'); 
fprintf(fid, 'Ave Length \t'); 
  
fprintf(fid, ' \t'); 
fprintf(fid, ' \t'); 
for cint = 1:8 
    stryng = strcat('Area ',num2str(cint)); 
    fprintf(fid, stryng); 
    fprintf(fid, ' \t'); 
end 
  
fprintf(fid, ' \t'); 
fprintf(fid, 'Ave Area \t\t\t'); 
  
for cint = 1:8 
    stryng = strcat('Sort Len  ',num2str(cint)); 
    fprintf(fid, stryng); 
    fprintf(fid, ' \t'); 
end 
  
fprintf(fid, ' \t'); 
  
fprintf(fid, 'SortLen Ave \t\t\t'); 
  
  
for cint = 1:8 
    stryng = strcat('Sort Area  ',num2str(cint)); 
    fprintf(fid, stryng); 
    fprintf(fid, ' \t'); 
end 
  
fprintf(fid, ' \t'); 
fprintf(fid, 'SortArea Ave \t\t\n'); 
fprintf(fid2, ' \n'); 




filename    =   strcat(data_pts,'\',Pictroot,'1.png'); 
  
%Select region of interest 
I = imread(filename); 
Active = I; 
GreenPlane = I; 











fprintf(fid, '%g \t', Data_Start+1); 
fprintf(fid2, '%g \t', Data_Start+1); 
fprintf(fid3, '%g \t', Data_Start+1); 
%this_time = (new_time(k) - (min(time_dirs)))*1000000; 
  
fprintf(fid, ' \t \t \t'); 
Sum_H = 0; 




for j = 2 : 9 
     
     filename = strcat(data_pts,'\',Pictroot,num2str(j),'.png'); 
    I = imread(filename); 
    %XX = rgb2gray(I); 
    XX = I; 
    %impix(j) = sum(sum(I2.*positionBG0)); 
     
    impix(j-1) =  sum(sum(XX.*uint16(positionB0)));            
end 
  
for j2 = 1:8 
    im_div_min(j2) = round(2*impix(j2)/min(impix))/2; 
end 
  
impixmod = mode(im_div_min); 
im_div_mod = impix/impixmod; 
immultfact2 = im_div_min / impixmod; 
  
for j = 2 : 9 
     
    filename = strcat(data_pts,'\',Pictroot,num2str(j),'.png'); 
    I = imread(filename); 
    %XX = rgb2gray(I); 
    XX = I; 
    A(:,:,j-1) =  imdivide(XX.*uint16(positionB0), immultfact2(j-1)); 






for jk = 1:4 
    B(:,:,jk) = imlincomb(0.5,A(:,:,jk), 0.5, A(:,:,jk+4)); 
end 
  
for jh = 1:2 






D = imlincomb(0.5,C(:,:,1), 0.5, C(:,:,2)); 
%adjust the image to allow for the detection of all cells 
for ji = 1:8 
    E = imsubtract(D, A(:,:,ji)); 
     
    %%%Changes 
    F(:,:,ji) = immultiply(E,15); %15  %%%Changes 
    H = filter2(fspecial('average', 6),F(:,:,ji))/65535; %6 
    J = imadjust(H, [0.15 1], [0 1]);  %0.15 (0.1 on the 10_04_2014, 0.1 is too sensitive when few or no 
cells present) 
    K=graythresh(J); 
    L(:,:,ji) = im2bw(J,K); 
    [labelled,nn2(ji)] = bwlabel(L(:,:,ji),8); %8 
     
    bw = bwareaopen(L(:,:,ji), 10); 
    cc = bwconncomp(bw, 8); 
    number_ob_per_pic(ji) = cc.NumObjects; 
     
    fprintf(fid, '%g \t', cc.NumObjects); 
     
    SUM_OB = SUM_OB + number_ob_per_pic(ji); 
    SUM_temp = SUM_temp + mean2(L); 
     
    %*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%* 
    numbobs = cc.NumObjects; 
    STATS = regionprops(bw, 'MajorAxisLength'); 
    ave_length = 0; 
    for obc=1:numbobs 
        ave_length = ave_length + STATS(obc).MajorAxisLength; 
        fprintf(fid2, '%g \t', STATS(obc).MajorAxisLength); 
    end 
    avelen(ji) = ave_length/numbobs; 
     
     
    STATS2 = regionprops(bw, 'Area'); 
    ave_area = 0; 
    for obc2=1:numbobs 
        ave_area = ave_area + STATS2(obc2).Area; 
        fprintf(fid3, '%g \t', STATS2(obc2).Area); 
    end 
    aveare(ji) = ave_area/numbobs; 
    %Save processed images 
    %*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%* 
    imwrite(A(:,:,ji), strcat(data_pts,'\or_Pict',num2str(ji),'.png')); 















%Average the number of cells 
average_number_ob =  SUM_OB/8; 
myAve = SUM_OB/8; 
%Write to the excel file created previously 
fprintf(fid, '%g \t', myAve); 
fprintf(fid, '%g \t', 0); fprintf(fid, '%g \t', 0); 
  
sort_obs = sort(number_ob_per_pic); 
  
for myiny = 1:7 
    fprintf(fid, '%g \t', sort_obs(myiny)); 
end 
  
fprintf(fid, '%g \t', sort_obs(8)); 
  
%*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%* 
fprintf(fid, ' \t'); 
  
for tis2 = 1:8 
    fprintf(fid, '%g \t', avelen(tis2)); 
end 
  
fprintf(fid, ' \t'); 
fprintf(fid, '%g \t ', mean(avelen)); 
fprintf(fid, ' \t'); 
  
%%%%%%%%%%%%%%%%%%%%% 
fprintf(fid, ' \t'); 
  
for tis3 = 1:8 
    fprintf(fid, '%g \t', aveare(tis3)); 
end 
  
fprintf(fid, ' \t'); 




fprintf(fid, ' \t \t'); 
sort_lens = sort(avelen); 
  
for myiny = 1:8 













for myiny = 1:8 
    fprintf(fid, '%g \t', sort_aveare(myiny)); 
end 
fprintf(fid, '\t'); 




fprintf(fid, ' \n'); 
fprintf(fid2, ' \n'); 










Matlab Algorithm for Detecting Fluorescent Cells  
%%Authors: Jared_Mackenzie and Frederick_Balagaddé  
%%K-Rith Bioengineering 
  
%Select directory to process 
format long; 
Pictroot = 'Pict_F2_';  
Data_Start = 30; 
data_pts = 'F:\Shots\DIL_800_11Nov2015_03_19PM\R1C6\DataSet30'; 
data_filename = 'F:\Shots\DIL_800_11Nov2015_03_19PM\R1C6\DataSet20.xls'; 
data_filename_area = 'F:\Shots\DIL_800_11Nov2015_03_19PM\R1C6\Data_f_ area_20.xls'; 
data_filename_Brightness = 'F:\Shots\DIL_800_11Nov2015_03_19PM\R1C6\Data_f_bright_20.xls'; 
%Specify max and min brightness, as well as bin size 
EdMax = 30000; 
edMin = 5000; 
BinSize = 5000; 
  
imageInfor2 = dir(data_pts ); 
imDate=imageInfor2.date; 
  
%Create excel file for data 
fid = fopen(data_filename, 'w'); 
fid2 = fopen(data_filename_area, 'w'); 
fid3 = fopen(data_filename_Brightness, 'w'); 
  
for cint = 1:125 
    cint2 = cint-1; 
    stryng = num2str(cint2); 
    fprintf(fid, stryng); 
    fprintf(fid, ' \t'); 
end 
  
for cint = 1:125 
    cint2 = cint-1; 
    stryng = num2str(cint2); 
    fprintf(fid2, stryng); 
    fprintf(fid2, ' \t'); 
end 
  
for cint = 1:125 
    cint2 = cint-1; 
    stryng = num2str(cint2); 
    fprintf(fid3, stryng); 
    fprintf(fid3, ' \t'); 
end 
fprintf(fid, '\n Count \t Time numeric \t Time (Hrs) \t Description \t Cells 1 \t Cells 2 \t Cells 3 \t Cells 
4 \t \t Cells Ave \t\t\t'); 
fprintf(fid2, '\n Count \t area \t area \t area \t area 1 \t area 2 \t area 3 \t area 4 \t \t area Ave \t\t\t'); 
fprintf(fid3, '\n Count \t brightness \t brightness \t brightness \t brightness 1 \t brightness 2 \t 
brightness 3 \t brightness 4 \t \t brightness \t\t\t'); 
  
for cint = 1:4 
    stryng = strcat('SortCells',num2str(cint)); 




    fprintf(fid, ' \t'); 
end 
  
fprintf(fid, ' \t'); 
for cint = 1:4 
    stryng = strcat('Length ',num2str(cint)); 
    fprintf(fid, stryng); 
    fprintf(fid, ' \t'); 
end 
  
fprintf(fid, ' \t'); 
fprintf(fid, 'Ave Length \t'); 
  
fprintf(fid, ' \t'); 
fprintf(fid, ' \t'); 
for cint = 1:4 
    stryng = strcat('Area ',num2str(cint)); 
    fprintf(fid, stryng); 
    fprintf(fid, ' \t'); 
end 
  
fprintf(fid, ' \t'); 
fprintf(fid, 'Ave Area \t\t\t'); 
  
for cint = 1:4 
    stryng = strcat('Sort Len  ',num2str(cint)); 
    fprintf(fid, stryng); 
    fprintf(fid, ' \t'); 
end 
  
fprintf(fid, ' \t'); 
  
fprintf(fid, 'SortLen Ave \t\t\t'); 
  
for cint = 1:4 
    stryng = strcat('Sort Area  ',num2str(cint)); 
    fprintf(fid, stryng); 
    fprintf(fid, ' \t'); 
end 
  
fprintf(fid, ' \t'); 
fprintf(fid, 'SortArea Ave \t\t'); 
  
fprintf(fid, ' \t'); 
fprintf(fid, 'MaxBrightBin \t'); 
fprintf(fid, 'MaxBBCt \t\t'); 
  
nBins = (EdMax - edMin)/BinSize; 
  
for nb = 1:nBins 
    fprintf(fid, strcat('b',num2str(nb),'cells \t')); 
end 
fprintf(fid, ' \t \t'); 
for nb = 1:nBins 





















fprintf(fid, ' \t\t'); 
  
  
for cint = 1:4 
    stryng = strcat('Inter-Brghtness ',num2str(cint)); 
    fprintf(fid, stryng); 
    fprintf(fid, ' \t'); 
end 
  
fprintf(fid, ' \n'); 
fprintf(fid2, ' \n'); 




%Select region of interest 
%original code to replace when inserting into labview 
 filename    =   strcat(data_pts,'\',Pictroot,'1.lvm'); 
I = dlmread(filename, '\t');  
I2 = uint16(I); 
I3 = immultiply(I2, 25); 
 Image20 = imadjust(I3); 
figure, imshow(Image20); 
positionB0 = uint16(roipoly( Image20)); 
  
close all; 
fprintf(fid, '%g \t', Data_Start+1); 
fprintf(fid, ' \t \t \t'); 
fprintf(fid2, '%g \t', Data_Start+1); 
fprintf(fid3, '%g \t', Data_Start+1); 
  
Sum_H = 0; 
SUM_temp = 0; 
SUM_OB =0; 
  
for j = 1 : 4 
    filename = strcat(data_pts,'\',Pictroot,num2str(j),'.lvm'); 




    I2 = uint16(I); 
    I3 = immultiply(I2, 25); %25 
    A(:,:,j) =  I3.*uint16(positionB0); 
end 
for jk = 1:2 
    B(:,:,jk) = imlincomb(0.5,A(:,:,jk), 0.5, A(:,:,jk+2)); 
end 
D = imlincomb(0.5,B(:,:,1), 0.5, B(:,:,2)); 
obinum = 0; 
areaBrightAve_bright(1,3) = 0; 
  
%adjust the image to allow for the detection of all fluorescent cells 
for ji = 1:4 
    E = imsubtract(A(:,:,ji), D); 
    %%%Changes 
    F(:,:,ji) = immultiply(E,15); %15  %%%Changes 
    ft2 = imadjust(F(:,:,ji)); 
    H = filter2(fspecial('average', 4),ft2)/65535; %4 
    J = imadjust(H, [0.4 1], [0 1]);  %0.5 (0.1 on the 10_04_2014, 0.1 is too sensitive when few or no 
cells present) 
    K=graythresh(J); 
    L(:,:,ji) = im2bw(J,K); 
    [labelled,nn2(ji)] = bwlabel(L(:,:,ji),8); %8 
    bw = bwareaopen(L(:,:,ji), 10); %10 
    cc = bwconncomp(bw, 8); 
     
    imwrite(A(:,:,ji), strcat(data_pts,'\or_Pict',num2str(ji),'.png')); 
    imwrite(F(:,:,ji), strcat(data_pts,'\pre_processed_Pict',num2str(ji),'.png')); 
    %imwrite(grain3, strcat(data_pts,'\fin_Pict',num2str(ji),'.png')); 
    imwrite(bw, strcat(data_pts,'\processed_Pict',num2str(ji),'.png')); 
     
     
    number_ob_per_pic(ji) = cc.NumObjects; %number of cells 
    fprintf(fid, '%g \t', cc.NumObjects); 
    SUM_OB = SUM_OB + number_ob_per_pic(ji); 
    SUM_temp = SUM_temp + mean2(L); 
    %*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%* 
    numbobs = cc.NumObjects; 
    STATS = regionprops(bw, 'MajorAxisLength'); 
    ave_length = 0; 
    for obc=1:numbobs 
        ave_length = ave_length + STATS(obc).MajorAxisLength; 
    end 
    avelen(ji) = ave_length/numbobs; 
    STATS2 = regionprops(bw, 'Area'); 
    ave_area = 0; 
    for obc2=1:numbobs 
        ave_area = ave_area + STATS2(obc2).Area; 
    end 
    aveare(ji) = ave_area/numbobs; 
    %*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%*%* 
    %Determines the number of fluorescent cells 
    for obnum = 1:numbobs 
        obinum = obinum+1; 




        grain(cc.PixelIdxList{obnum}) = true; 
         
        grain2 = uint16(grain); 
        grain3 = A(:,:,ji).*grain2; 
        %determines the brightness of each individual cell 
        areaBrightAve_bright(obinum,1) = sum(sum(grain)); %number of pixels 
        areaBrightAve_bright(obinum,2) = sum(sum(grain3)); %original brightness 
        areaBrightAve_bright(obinum,3) = sum(sum(grain3))/sum(sum(grain)); %average brightness = 
original brightness / number of pixels 
         
        fprintf(fid2, '%g \t', areaBrightAve_bright(obinum,1)); 
        fprintf(fid3, '%g \t', areaBrightAve_bright(obinum,2)); 
         
        Fn = ((obinum*9)/8); 
         
        
%               
%                 fprintf(fid, num2str(obinum)); fprintf(fid, '\t'); 
%                 fprintf(fid, '%g \t', areaBrightAve_bright(obinum,1)); 
%                 fprintf(fid, '%g \t', areaBrightAve_bright(obinum,2)); 
%                 fprintf(fid, '%g \n', areaBrightAve_bright(obinum,3)); 
    end 
end 
grain = false(size(bw)); 
grain2 = uint16(grain); 
grain3 = A(:,:,ji).*grain2; 
%Determines the average number of fluorescent cells 
Fn = ((obinum*9)/8); 
mean_Fn = mean(Fn(:,1)); 
sum_original_brightness = sum(areaBrightAve_bright(:,2)); 
sum_size_normalized_brightness = sum(areaBrightAve_bright(:,3)); 
  
mean_size = mean(areaBrightAve_bright(:,1)); 
mean_original_brightness = mean(areaBrightAve_bright(:,2)); 
mean_size_normalized_brightness = mean(areaBrightAve_bright(:,3)); 
  %Display processed images       










%Write to created excel file 
myAve = SUM_OB/4; 
fprintf(fid, '\t'); 
fprintf(fid, '%g \t', myAve); 
fprintf(fid, '%g \t', 0); fprintf(fid, '%g \t', 0); 
sort_obs = sort(number_ob_per_pic); 
for myiny = 1:4 






fprintf(fid, ' \t'); 
for tis2 = 1:4 
    fprintf(fid, '%g \t', avelen(tis2)); 
end 
  
fprintf(fid, ' \t'); 
fprintf(fid, '%g \t ', mean(avelen)); 
fprintf(fid, ' \t'); 
%%%%%%%%%%%%%%%%%%%%% 
fprintf(fid, ' \t'); 
  
for tis3 = 1:4 
    fprintf(fid, '%g \t', aveare(tis3)); 
end 
  
fprintf(fid, ' \t'); 
fprintf(fid, '%g \t ', mean(aveare)); 
%%%%%%%%%%%%%%% 
fprintf(fid, ' \t \t'); 
sort_lens = sort(avelen); 
  
for myiny = 1:4 
    fprintf(fid, '%g \t', sort_lens(myiny)); 
end 
fprintf(fid, '\t'); 
fprintf(fid, '%g \t\t', mean(sort_lens(1:4))); 
fprintf(fid, '\t'); 
sort_aveare = sort(aveare); 
for myiny = 1:4 
    fprintf(fid, '%g \t', sort_aveare(myiny)); 
end 
fprintf(fid, '\t'); 
fprintf(fid, '%g \t\t', mean(sort_aveare(1:4))); 
fprintf(fid, ' \t'); 
edges1 = [edMin:BinSize:EdMax]; 
h = hist(areaBrightAve_bright(:,3), edges1); 
[MyMax,peakBin] = max(h); 
hVals = h; 
bar(h); 
xlabel('Fluorescence'); % x-axis label 
ylabel('#Cells/bin'); % y-axis label 
saveas(gcf,strcat(data_pts,'\histogram.png')) ; 
  
fprintf(fid, '%g \t', peakBin); 
fprintf(fid, '%g \t\t', MyMax); 
fprintf(fid, '%g \t', hVals); 
fprintf(fid, ' \t\t'); 
fprintf(fid, '%g \t', edges1); 
% fprintf(fid, '%g\t\t', obinum); 
fprintf(fid, '%g \t\t',obinum); 
fprintf(fid, '%g \t',Fn); 
fprintf(fid, '%g \t',mean_Fn); 
fprintf(fid, '%g \t',sum_original_brightness); 




fprintf(fid, '%g \t',mean_size); 
fprintf(fid, '%g \t',mean_original_brightness); 




sumbright = 0; 
fprintf(fid, ' \t'); 
for myiny = 1:4 
    fprintf(fid, '%g \t', sum(sum(F(:,:,myiny)))); 
     
    sumbright = sumbright + sum(sum(F(:,:,myiny))); 
end 
  
 sumbright =  sumbright/4; 
  
 fprintf(fid, '%g \t\t', sumbright); 
  
  
fprintf(fid, ' \n'); 
fprintf(fid2, ' \n'); 




% fprintf(fid, '\n\n'); 
% fprintf(fid, '\n'); 
% fprintf(fid, 'c count'); fprintf(fid, '\t\t'); 
% fprintf(fid, 'size'); fprintf(fid, '\t'); 
% fprintf(fid, 'original brightness'); fprintf(fid, '\t'); 
% fprintf(fid, 'size normalized brightness'); fprintf(fid, '\t'); 
  
% % 
% for ccount = 1:obinum 
%     fprintf(fid, '\n'); 
%     fprintf(fid, '%g \t\t', ccount); 
%     fprintf(fid, '%g \t',areaBrightAve_bright(ccount,1)); 
%     fprintf(fid, '%g \t',areaBrightAve_bright(ccount,2)); 
%     fprintf(fid, '%g \t',areaBrightAve_bright(ccount,3)); 















Appendix C: Raw Data of E. coli Cells Cultured in the Microchemostat 
	
These results show the cell density on the primary axis (red curve with black dots) and average 
specific cell length on the secondary axis (orange curve with gray dots) as a function of time. Cells 
were grown at 37°C in LB medium under conditions indicated on the right of each graph. 
	


















































Appendix D: Transgenic Efflux Pump Model Parameter Values 
 
Dilution rate D: The dilution rate D (hr-1) was calculated analytically using the expression 𝐷 =
−ln [1 − 𝐹] 𝑇  where F is the fraction of microchemostat culture replaced with fresh medium during 
each dilution event and T is the time interval between consecutive dilution events: for example, D = 
0.2 hr-1 for 25% discrete dilution (F = 1/4) every hour (T = 1 hour). 
 
Maximum growth rate µmax : The specific growth rate is determined from the exponential growth 
constant µ of the microchemostat cultures using the expression µmax = µ+D.   
 
Efflux pump-OFF parameters cn, n∞ : Efflux pump-OFF parameters including cn and n∞ were 
determined by adjusting trial initial values of these parameters until the simulated growth curves 
matched the pump-OFF growth curves obtained from actual microchemostat data. 
 
Efflux pump-ON parameters k, cp, p∞ : Efflux pump-ON parameters including k, cn and n∞, were 
determined by adjusting trial initial values of these parameters until the simulated growth curves 




















Table 2| Numerical values of the key parameters in Equations 9-11 
# Parameter Description Value 
1 D  Microchemostat dilution rate  0.32 ℎ𝑟!! 
2 µmax Maximum specific growth rate of pump-OFF cultures 1.03 ℎ𝑟!! 
3 cn Heaviside function parameter representing the sharpness 
of the transition in cell density from exponential to 
stationary phase. 
0.008 𝑐𝑒𝑙𝑙𝑠!! 
4 n∞ Heaviside function parameter representing the 
maximum number of cells the microchemostat reactor 
can sustain indefinitely in the absence of culture 
dilution. 
2.81 𝑐𝑒𝑙𝑙𝑠 𝑝𝑙 





6 cp Heaviside function parameter representing the sharpness 
of the transition in efflux product concentration from 




7 p∞ Heaviside function parameter representing the threshold 
concentration above which the efflux product becomes 
toxic. 
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